辛伐他汀联合山莨菪碱在冠脉介入治疗中的心肾保护作用
|
摘要
经皮冠状动脉介入治疗是冠心病治疗的重大进展,每年有大量的冠心病患者从中获益。和世界各国一样,我国的冠心病介入治疗病例逐年增多,据统计,我国2002年的经皮冠状动脉介入治疗例数为3万例,2005年为7万5千例,到2009年,我国的冠心病介入治疗例数已经突破24万例,目前还在快速上升期。
冠状动脉介入治疗后缓复流(无复流)现象和急性对比剂肾损伤是影响经皮冠状动脉介入治疗近远期效果的主要因素。虽然目前其发病机制尚未明确,但是,微循环功能障碍、炎症以及氧化应激反应等被认为是发生无复流和对比剂肾病的共同病理基础。
他汀类药物和山莨菪碱均具有改善微循环、抗炎、抗氧化应激、改善血管内皮功能等作用。已有研究表明,常规剂量的他汀类药物可显著改善心肌灌注,降低对比剂肾病的发生,我们以前的研究也已经证明了山莨菪碱对冠脉无复流的防治作用。目前,关于强化剂量的他汀类药物能否进一步改善冠脉灌注、山莨菪碱对急性对比剂肾损伤的防治作用以及二者联合使用的效果等尚无研究。本研究在既往工作的基础上,进一步探索强化辛伐他汀治疗以及辛伐他汀联合山莨菪碱对冠脉介入治疗中心肌灌注的影响以及对急性肾损伤的保护作用并探讨起可能机制。
本研究分为以下五部分:
第一部分强化降脂治疗对急性冠脉综合征患者经皮冠状动脉介入治疗中心肌灌注的保护作用
目的:探讨强化他汀治疗对急性冠脉综合征患者经皮冠状动脉介入治疗过程中心肌灌注的保护作用,并探讨其可能机制。
方法:行择期PCI的急性冠脉综合征患者228例,随机分为标准他汀组(n=115)和强化他汀组(n=113)。于PCI术前7天,纪录PCI后的TIMI血流、纠正的TIMI计桢数(CTFC)以及TIMI心肌灌注分级(TMPG)等。于PCI前后测量肌酸磷酸激酶(CPK)、CPK同工酶MB(CPK-MB)、肌钙蛋白(ITnI)、高敏C反应蛋白(hs-CRP)、P选择素和细胞间粘附分子(ICAM)水平。
结果:强化他汀组支架植入后TIMI血流0-1级显著少于标准他汀组,3级显著多于标准他汀组(P<0.05)。强化他汀组无复流发生率显著低于标准他汀组(P<0.001)。CTFC在强化他汀组显著低于标准他汀组(P<0.001)。强化他汀组的TMPG也显著优于标准他汀组(P=0.001)。PCI术后24小时,CPK-MB和TnI在强化他汀组显著低于标准他汀组(CPK-MB:18.74±8.41对21.78±10.64 P=0.018;TnI:0.99±1.07对1.47±1.54 P=0.006)。标准治疗组CK-MB升高者占27.8% (32/115),强化他汀组则只有15.9%(18/113)(P=0.030)。标准他汀组TnI升高者显著多于强化他汀组[36.5% (42/115)对19.5%(22/113),P=0.04],其中,标准他汀组的心肌坏死发生率为13%(15/115),而在强化他汀组仅为4.4%(5/113)(P=0.021)。PCI术后24小时,强化他汀组的hs-CRP、P选择素及ICAM-1水平均显著低于标准他汀组(P<0.001)。
结论:PCI术前使用强化他汀治疗比标准他汀治疗能更有效改善急性冠脉综合征患者的心肌灌注、减轻心肌损伤。同时伴有hs-CRP、P选择素和ICAM-1水平的显著降低。
第二部分辛伐他汀联合山莨菪碱治疗对约克猪冠状动脉介入治疗后心肌灌注的保护作用
目的:缓复流/无复流不但增加冠脉介入治疗过程中的手术风险,还严重影响术后患者的长期预后。研究无复流的发生机制、寻找有效的预防和治疗的手段,是目前冠心病介入治疗领域的研究热点之一。山莨菪碱具有改善微循环,抗氧化、保护心肌细胞的良好作用。他汀类药物具有改善血管内皮细胞功能、抗凝、抗血小板、抗氧化、抗炎、改善血流动力学效应等多重效应。目前尚未发现有二者联合使用改善冠脉介入治疗中心肌灌注效果的研究报告。为此,我们在既往实验性微型猪冠脉介入治疗后无复流模型的基础上,进一步评价了强化的辛伐他汀联合山莨菪碱对冠脉介入治疗过程中心肌微循环灌注的保护作用。并通过测定炎症因子高敏C反应蛋白(hs-CRP)、超氧化物歧化酶(SOD)、丙二醛(MDA)和一氧化氮(NO)的水平,探讨其可能机制。
方法:健康约克猪16头,体重30-40kg,被随机分为山莨菪碱组和辛伐他汀+山莨菪碱治疗组。联合治疗组预先饲喂辛伐他汀1mg/kg,山莨菪碱组则给予安慰剂,7天后开始实验。利用微导管超选择LAD,将多普勒导丝置于LAD中段,纪录LAD中段血流速度的变化,并监测LCA开口处压力。于LAD中段注射PMBS混悬液,5ml/次,每十分钟一次,共四次,每次注射PMBS前2分钟LAD内注射山莨菪碱5000ug,PMBS注射后5分钟行冠脉造影,纪录LAD的TIMI血流、TMPG和CTFC,评价心肌灌注情况。于试验结束时处死动物,取坏死和正常交界处缺血心肌分别测定超氧化物歧化酶(SOD)、丙二醛(MDA)、一氧化氮(NO),并行病理学检查。于实验前、实验后采静脉血测定CKMB、TnI以及血清C反应蛋白(CRP)水平。利用染色法计算梗死心肌占左室重量之百分比。
结果:联合治疗组的TIMI血流显著优于山莨菪碱组,TFCs显著低于山莨菪碱组(均P<0.05)。早期LAD内注射PMBS后两组心率均较基础值显著上升(P<0.05),但两组之间无显著差别(P=0.47,P=0.85)。以后山莨菪碱组的心率进一步显著升高(P=0.005),而联合治疗组则仍保持原水平。
早期LAD内给与PMBS注射后两组的冠脉灌注压均显著上升(P<0.01)。以后山莨菪碱组的冠脉灌注压开始降低(P<0.05),联合治疗组则仍维持较高的冠脉灌注压力(P=0.042)。晚期联合治疗组冠脉灌注压力仍维持无显著降低,而山莨菪碱组则显著降低。早期冠脉注射PMBS后,两组的bAPV均有增高,但山莨菪碱组更明显;hAPV在山莨菪碱组降低,而在联合治疗组则维持高水平(P=0.000)。第三次PMBS注射后hAPV两组均较基础值显著降低(P<0.01),但联合治疗组仍显著高于山莨菪碱组(P=0.000)。至第四次PMBS注射后,两组的hAPV进一步降低,两组比较无显著差别。在第一、二次冠脉注射PMBS后,联合治疗组CFR无显著降低,而山莨菪碱组的CFR则持续显著降低(P=0.006)。第三、四次注射PMBS后两组的CFR均连续显著降低(P<0.05),但联合治疗组始终优于山莨菪碱组(P=0.025)。第一、二次注射PMBS后山莨菪碱组的h-MR均显著增高(P=0.032),而联合治疗组则无显著增高。在第三次冠脉LAD内注射PMBS后,两组的h-MR均显著增高(P=0.030),两组间比较联合治疗组的h-MR仍显著低于山莨菪碱组(P=0.010)。在第四次冠脉LAD内注射PMBS后,两组的h-MR进一步显著增高(P=0.024),两组间比较h-MR已无显著差别。
试验前山莨菪碱组血清总胆固醇水平为4.44±0.47mmol/L,联合治疗组的血清胆固醇水平为3.93±0.53mmol/L(P=0.063)。实验后60分钟,肌酸激酶同工酶MB、TnI、hs-CRP、MDA均显著增高,但山莨菪碱组显著高于联合治疗组;NO水平均显著增高(P=0.000),但联合治疗组的NO水平显著高于山莨菪碱组(P=0.006)。SOD水平显著降低(P=0.000),但联合治疗组的SOD水平高于山莨菪碱组(P=0.000)。山莨菪碱组心肌坏死平均坏质量占左心室总质量的18.5±3.1%,联合治疗组为11.3±2.9%。(P<0.05)。光镜下改变联合治疗组的心肌坏死显著轻于山莨菪碱组。
结论:联合应用山莨菪碱和辛伐他汀治疗可显著改善冠脉介入治疗中的冠脉血流,增加心肌灌注,保护心肌。改善冠脉血流动力学、抗炎、抗氧化可能是其潜在机制。
第三部分强化他汀治疗对经皮冠状动脉介入治疗后肾损伤的保护作用目的:研究强化他汀治疗对PCI后肾功能的保护作用和预防对比剂肾病的效果,探讨其可能机制。
方法:228例接受择期PCI的急性冠脉综合征,随机分为标准他汀治疗组(SSG n=115)和强化他汀治疗组(ISG n=113)。于PCI术前7天开始,SSG组患者口服20mg/天辛伐他汀,ISG组患者则口服80mg/天辛伐他汀。于PCI术前、术后24、48小时分别测定血清肌酐水平,按Cochcroft-Gault公式计算肌酐清除率。于PCI术前、术后24小时分别测定血清高敏C反应蛋白(hs-CRP)、P选择素和细胞间粘附分子1(ICAM-1)水平。
结果:PCI后血肌酐水平显著升高,并于术后24小时达高峰,然后逐渐下降。PCI术后48小时,ISG组血肌酐水平显著回降(和术后24小时比P<0.001)并恢复到术前水平(和术前比P=0.94),而SSG组PCI术后48小时血肌酐水平未显著回降(和术后24小时比,P=0.11)。PCI术后24、48小时,ISG组的血肌酐水平均显著低于SSG组(术后24小时,P<0.05;术后48小时P<0.001)。PCI术后,两组肌酐清除率均显著降低,最低值出现在术后24小时,然后逐渐回升。术后48小时,SSG组肌酐清除率显著回升(和术后24小时相比,P=0.03),但仍低于术前水平(和术前相比,P<0.001),而ISG组术后48小时显著回升(和术后24小时相比,P<0.001)并恢复到术前水平(和术前相比,P=0.87),在术后24、48小时,ISG组肌酐清除率的回升程度均显著高于SSG组(均P<0.001)。虽然PCI术后血清hs-CRP、P选择素和ICAM-1水平均显著升高(均P<0.001),但ISG组低于SSG组(均P<0.001)。
结论:和标准剂量他汀治疗相比,PCI前使用强化剂量他汀治疗可进一步保护PCI术后肾脏功能,降低CIN的发生率。这种益处伴随有血清hs-CRP、P选择素和ICAM-1水平的显著降低。
第四部分急性对比剂肾损伤动物模型的建立
目的:随着血管内使用对比剂日益增多,对比剂急性肾脏损伤已经成为当前医院内获得性急性肾损伤的第三位原因。急性对比剂肾损伤的发生机制及预防措施,是当前心血管介入领域研究的焦点问题。但是迄今为止,还没有研究急性对比剂肾损伤的动物模型。本研究的目的是探讨利用大鼠复制急性对比剂肾损伤动物模型的效果。
方法:健康SD大鼠24只,随机分为A组(实验组)和B组(安慰剂对照组)。A、B两组再分别随机分为12小时组和24小时组。大鼠正常饲养7天,待适应环境后开始模型制作。禁水三天后,A组经舌下静脉注射复方泛影葡胺8ml/Kg,B组则注射等量生理盐水,然后给予自然饮水至试验结束,A、B两组分别于注射对比剂后12小时、24小时处死动物。分别于试验前、禁水三天后、注射对比剂后3小时、6小时、12小时、24小时(B组)行肾脏超声检查,观察肾脏形态结构变化。并测量左侧肾脏长径、宽径和厚径以及左侧肾动脉直径、收缩期峰值血流速度(PSV)、舒张期峰值血流速度(EDV)、收缩/舒张期血流速度比值(S/D)、阻力指数(RI)、左肾血流量积分指数(VTI)容量及心率。于实验前、禁水三天后、术后12小时(A组)、24小时(B组)采血测量血肌酐水平。分别于术后12小时(A组)、24小时(B组)处死大鼠,取肾脏进行光镜和透射电镜检查。
结果:试验前、禁水三天后两组肾脏大小无显著差别,术后3小时、6小时、12小时和24小时实验组的肾脏体积逐渐增大,回声均匀减低,但未见集合系统分离现象,此种表现在6-12小时最为明显,到术后24小时仍未恢复正常。
肾动脉直径两组之间无显著差异。但收缩期峰值血流速度(PSV)、舒张期峰值血流速度(EDV)、收缩/舒张期血流速度比值(S/D)、左肾血流量积分指数(VTI)容量在术后6小时最低,以后逐渐恢复,至术后24小时基本恢复到术前水平;阻力指数(RI)术后逐渐升高,在术后6小时最低,到术后24小时恢复到术前水平,禁水三天后心率显著增快,但术后心率无显著改变。禁水三天后术后血清肌酐水平显著升高,以术后12小时为最高,至术后24小时随有明显恢复,当仍未恢复到术前水平。
光镜检查发现使用对比剂后12小时肾髓质区可见片状肾小管结构消失,广泛充血、淤血,可见肾小管上皮细胞高度退变,并有较多的成纤维细胞增生及单核细胞浸润。24小时仍可见肾髓质区呈局灶性肾小管结构消失,充血、淤血,有少量成纤维细胞增生及数个单核细胞浸润,但均较12小时明显减轻。光镜下未见显著的肾小球病理学改变。电镜检查发现,使用对比剂后肾小管上皮细胞微绒毛脱落、稀疏,线粒体嵴合膜融合、消失,部分线粒体肿胀、破碎,质膜内褶消失,部分阻塞小管腔,基底膜水肿等改变。另外也可见肾小球毛细血管上皮细胞肿胀、吞噬现象,基底膜及组织间隙水肿,以术后12小时最明显。
结论:结合脱水和对比剂静脉注射可造成的显著的急性肾功能损害,其肾脏组织形态学、血流动力学以及肾功能改变均符合人类对比剂肾病的特点。因此,本模型是研究人类对比剂肾病的理想模型。
第五部分辛伐他汀联合山莨菪碱对大鼠急性对比剂肾损伤的保护作用
目的:随着血管内使用对比剂日益增多,急性对比剂肾损伤发病率急剧增加,研究急性对比剂肾损伤的发生机制及预防措施,是当前心血管介入领域研究的焦点问题。他汀类药物具有独立于降脂作用以外的多重肾脏保护作用,山莨菪碱也具有抗休克、改善组织微循环灌注、抗自由基等的良好作用。但是,目前尚没有关于山莨菪碱对冠脉介入治疗后急性对比剂肾损伤的防治作用的研究,也缺乏关于他汀类药物和山莨菪碱联合使用对使用对比剂后肾脏保护方面的研究。本研究利用大鼠急性对比剂肾损伤动物模型,研究辛伐他汀、山莨菪碱及其联合使用对急性对比剂肾损伤的保护作用,并探讨其可能机制。
方法:健康SD大鼠48只,随机分为对照组(C,n=12只)、山莨菪碱组(A,n=12只)、辛伐他汀组(S,n=12只)、辛伐他汀联合山莨菪碱组(A+S,n=12只)。四组再分别随机分为12小时组和24小时组,每组各6只。辛伐他汀组及联合治疗组大鼠给予辛伐他汀灌胃(0.1mg/100g)。对照组和山莨菪碱组则以等量生理盐水灌饲,连续7天。于给药的第四天开始禁水,连续三天后,静脉注射对比剂(0.8ml/100g),然后给予自然饮水。
于注射对比剂前15分钟,山莨菪碱组和联合治疗组分别给予山莨菪碱100ug/100g腹腔注射,对照组和辛伐他汀组则给予等量生理盐水腹腔注射。山莨菪碱组和联合治疗组于注射对比剂后4小时内每小时腹腔注射山莨菪碱100ug/100g一次,至第4-12小时每4小时重复腹腔注射山莨菪碱100ug/100g,而对照组和辛伐他汀组则于相应时间腹腔注射等量生理盐水。
别于试验前、禁水三天后、注射对比剂后3小时、6小时分别行肾脏超声检查,观察肾脏形态结构变化。并测量左侧肾脏长径、宽径和厚径以及左侧肾动脉直径、收缩期峰值血流速度(PSV)、舒张期峰值血流速度(EDV)、阻力指数(RI)、左肾血流量积分指数(VTI)容量及心率。分别于试验前、禁水三天后、注射对比剂后12(12小时组)、24小时(24小时组)取血测定血肌酐、高敏C反应蛋白水平。于术后第12小时和24小时处死动物,分离左侧肾脏,做光镜和电镜检查。并取肾脏组织测定抗氧化指标超氧化物岐化酶、丙二醛、一氧化氮合成酶、一氧化氮、谷胱苷肽氧化酶水平。
结果:注射对比剂后6小时起对照组肾脏的各径线均显著增大,而联合治疗组的肾脏各径线则均无显著变化。山莨菪碱组和辛伐他汀组则部分肾脏径线出现显著增大。对照组皮质髓质回声较3小时均匀减低,山莨菪碱组和辛伐他汀组回声仅有轻微减低,而联合治疗组则未见明显回声减低表现,各组均未见集合系统分离现象。
术后3小时,联合治疗组的收缩期峰值血流速度(PSV)、舒张期峰值血流速度(EDV)、左肾血流量积分指数(VTI)均显著高于其它各组同期水平,并且不低于甚至高于术前水平。而对照组上述指标则显著低于其它各组,并且低于术前水平。山莨菪碱组和辛伐他汀组则无显著差别。在术后6小时,联合治疗组的收缩期峰值血流速度(PSV)、舒张期峰值血流速度(EDV)、左肾血流量积分指数(VTI)仍然显著高于其它各组同期水平,并且均比3小时显著增高。对照组上述指标则仍显著低于其它各组,并未恢复到术前水平,甚至进一步减低。而辛伐他汀组显著高于山莨菪碱组。
术前S/D联合治疗组显著低于其它三组,对照组显著高于其它三组,辛伐他汀组和山莨菪碱组无显著差别。术后3、6小时,在继续保持这种差异的同时,S/D总体趋于恢复到基线水平,但联合治疗组在术后6小时已经和基线时无显著差别,而对照组仍显著高于基线水平。在术后3、6小时,联合治疗组的阻力指数显著低于对照组,而辛伐他汀组和山莨菪碱组则无显著差别。禁水三天后心率显著增快(284±25次/分),但术后3小时和6小时山莨菪碱组和联合治疗组的心率均显著高于对照组和辛伐他汀组,辛伐他汀组3、6小时无差别,而山莨菪碱组6小时的心率高于3小时。
血清肌酐水平在禁水三天后、术后12小时及24小时显著升高,以术后12小时为最高,至术后24小时虽有明显恢复,但只有联合治疗组和辛伐他汀组恢复到术前水平,而山莨菪碱组和对照组均未恢复到术前水平,其中对照组恢复最慢。从肌酐升高的水平来看,术后12小时对照组最高,而联合治疗组最低,山莨菪碱组和辛伐他汀组位列第二和第三,四组均有显著性差异。
使用对比剂后12小时光镜观察发现:对照组在肾髓质区可见片状肾小管结构消失,广泛充血、淤血,可见多个高度退变的肾小管样上皮细胞残留,有较多的成纤维细胞增生及单核细胞浸润。山莨菪碱组肾髓质区可见局灶性区域肾小管结构消失,广泛充血、淤血,有数个散在的肾小管上皮残留,并可见少量成纤维细胞增生及数个单核细胞浸润。辛伐他汀组肾髓质区可见局灶性区域肾小管结构消失,广泛充血、淤血,可见少量成纤维细胞增生及数个单核细胞浸润。联合治疗组肾髓质区可见点状肾小管结构紊乱,有极少量成纤维细胞和数个单核细胞浸润,轻度充血。术后24小时,对照组仍可见肾髓质区呈局灶性肾小管结构消失,充血、淤血,可见有少量成纤维细胞增生及数个单核细胞浸润,山莨菪碱组也可发现上述改变,但均较12小时时明显减轻,而辛伐他汀组和联合治疗组的肾脏结构基本恢复正常。光镜下12小时和24小时均未见显著的肾小球病理学改变。
电镜检查发现,使用对比剂后肾小管上皮细胞微绒毛脱落、稀疏,线粒体嵴合膜融合、消失,部分线粒体肿胀、破碎,质膜内褶消失,部分阻塞小管腔,并有基底膜及组织间隙水肿等改变,另外也可见肾小球毛细血管上皮细胞肿胀、吞噬现象,基底膜及组织间隙水肿,以术后12小时最明显。四组比较以对照组最明显,而联合治疗组最轻。
四组动物的高敏C反应蛋白(hs-CRP)术前则显著增高,但联合治疗组和辛伐他汀组显著低于其它两组。术后12小时,hs-CRP水平达到最高水平,四组之间均有显著差别,其中联合治疗组最低,对照组最高,辛伐他汀组低于山莨菪碱组。至术后24小时,四组的hs-CRP水平均比12小时显著降低,但仍均显著高于术前水平。其中仍以联合治疗组最低,对照组最高,辛伐他汀组显著低于山莨菪碱组。
术后12小时,四组的SOD水平均显著降低,其中对照组SOD降低最显著,而联合治疗组最高,山莨菪碱组和辛伐他汀组无显著差别,但均显著高于对照组。术后24小时,对照组和山莨菪碱组的SOD水平进一步显著降低,而辛伐他汀组和联合治疗组则显著回升,其中联合治疗组已经恢复到基础水平。
术后12小时四组MDA水平均显著增高,其中对照组最高,联合治疗组最低,虽然山莨菪碱组和辛伐他汀组显著低于对照组,但辛伐他汀组显著低于山莨菪碱组。术后24小时的MDA水平在四组均显著降低,其中联合治疗组的MDA水平已经接近术前水平,而其它三组仍显著高于术前水平。
术后12小时,GSH-Px水平以对照组为最低,联合治疗组最高,山莨菪碱组和辛伐他汀组均显著高于对照组,辛伐他汀组高于山莨菪碱组。术后24小时,四组的GSH-Px水平较12小时均显著回升,其中联合治疗组已经恢复到术前水平,而其它三组仍低于术前水平。
术后12小时,对照组和山莨菪碱组的NOS水平显著降低,而辛伐他汀组则无显著改变,而联合治疗组则显著升高。术后24小时,对照组的NOS水平进一步降低,山莨菪碱组无显著差别,而辛伐他汀组和联合治疗组则进一步升高,其中联合治疗组升高最明显,后二者均显著高于基础水平。
术后12小时,iNOS水平显著增高(P<0.01),其中以对照组最高,显著高于其它三组(P<0.05),而山莨菪碱组、辛伐他汀组和联合治疗组无显著差别。术后24小时,仍以对照组为最高,联合治疗组最低,山莨菪碱组和辛伐他汀组无显著差别。和12小时比较,术后24小时iNOS水平在对照组、山莨菪碱组和辛伐他汀组均无显著差别,但联合治疗组的iNOS水平则显著低于术后12小时。
在对照组,术后12小时NO水平较低,24小时有轻微但显著上升;山莨菪碱组12小时NO较高,但术后24小时的显著降低;辛伐他汀组术后12小时的NO含量比较高,术后24小时则继续上升;联合治疗组在术后12小时的NO最高,虽在术后24小时有所下降,但仍呈显著升高状态。
结论:山莨菪碱和辛伐他汀的联合治疗可有效预防对比剂急性肾损伤的发生,其可能机制涉及改善肾脏的血流动力学、抗炎、抗氧化等。
More and more patients of coronary artery disease have benefit from percutaneous coronary intervention (PCI). About 30 000 cases of PCI were performed in 2002 in China. It rises to 75 000 in 2005. By the end of 2009, the PCI cases has been over 240 000. Now, the number is still increasing.
No/slow reflow phenomenon and contrast induced nephropathy are the main complications that limited the short and long-term efficacy of PCI. Although the exact mechanism remains uncertain, it was accepted that dysfunction of microcirculation, inflamation and oxidant stress were among the common pathophysiological basis.
Both statins and anisodamine possess these characteristics such as anti-inflammation, antioxidation, improving the function of the endothelium. It has been confirmed that common dose statins improve myocardial perfusion and prevent the incidence of CIN. Data in our laboratory also support the use of anisodamine in the setting of NRP. So far, the effect of intensive statin dose on myocardial perfusion, the preventive effect of anisodamine on CIN and the effect of their combination have not been carried out. Based on our previous work, this study was designed to evaluate the effect of intensive simvastatin, anisodamine and their combination on myocardila perfusion and CIN. The possible mechanisms were also probed.
Part I Intensive cholesterol lowering with simvastatin improves the outcomes of percutaneous coronary intervention in patients with acute coronary syndrome
Objective: The incidence of no reflow penomenon limits the clinical outcomes of percutaneous coronary intervention (PCI). We designed a randomized controlled study to evaluate the immediate protective effects of intensive statin pretreatment on myocardial perfusion and myocardial ischemic injury during PCI.
Methods: A total of 228 acute coronary syndrome (ACS) patients were randomly divided into standard statin group (SSG, n=115) and intensive statin group (ISG, n=113). Patients in SSG received 20 mg simvastatin and patients in ISG received 80 mg simvastatin for 7 days before PCI. TIMI grade flow (TGF), corrected TIMI frame count (CTFC) and TIMI myocardial perfusion grade (TMPG) of the intervened vessel were recorded before and after stent deployment. CPK isoenzyme MB, troponin I and plasma level of hs-CRP, P-selectin and ICAM were measured before and 24 hours after the procedure.
Results: The TFG after stent deployment was significantly improved with less TIMI 0-1 patients and more TIMI 3 blood flow in ISG than in SSG (all p<0.05). Patients with no reflow phenomenon were less in ISG (P<0.001). The CTFC was lower in ISG than SSG (P<0.001). TMPG was also improved in ISG than SSG (P=0.001). Twenty-four hours after the procedure, although PCI caused significantly increase in CK-MB, the elevated CK-MB value was lower in ISG than SSG (18.74±8.41 vs 21.78±10.64 P=0.018). Similar changes were also found with regard to Troponin I (0.99±1.07 in ISG vs 1.47±1.54 in SSG P=0.006). CK-MB elevation occurred in 27.8% (32/115) in SSG versus 15.9% (18/113) in ISG (P=0.030). Among them, myocardial necrosis was detected in 4.4% (5/115) of the patients in SSG, whereas 0.9% (1/113) in ISG (P=0.341). No myocardial infarction was found. Similarly, the patients with increased troponin I were much more in SSG (36.5% 42/115) than ISG (19.5% 22/113) (P=0.04). Among them, myocardial necrosis was detected in 13% (15/115) of the patients in SSG, while 4.4% (5/113) in ISG (P=0.021). Myocardial infarction was found in 4.4% (5/115) in the patients in SSG and 0.9% (1/113) in ISG (P=0.213).
Conclusion: Intensive statin pretreatment for 7 days before PCI can further improve myocardial blood perfusion, protect myocardium from ischemic injury. This benefit is associated with the lowering of hs-CRP, P-selectin and ICAM level.
Part II Protective effect of simvastatin in combined with anisodamine on myocardial perfusion in swine no reflow model.
Objectives: Slow reflow or no reflow phenomenon not only increase the risk during percutaneous coronary intervention, but also limit the long prognosis of this therapy. Study of its mechanism and find out the prevention measures remain the main focus of this field. Anisodamine can improve the state of mircrocirculation, antioxidant and protect the myocardium from ischemic injury, while statins posses the ability of improving the function of endothelium, anticoagulation, antiplatelet, antioxidation, antiinflammation and improving blood hemodynamics. So far, data on the combination of the two drugs on the prevention of SRP/NRP is absent. So, based on our previous study of experimental SRP/NRP model on minipig, we evaluated the preventive effect of their combination. We also probed the possible mechanism by measuring the level of hs-CRP, SOD, MDA and NO.
Method: Totally 16 minipin of 30-40 Kg were randomly divided into anisodamine groups (A, n=8) and anisodamine plus simvastatin group (A+S, n=8). Pigs of A+S group were prtreated with oral simvastatin (1 mg/Kg) for 7 days, while pigs in S groups were given oral placebo.Seven days later, after coronary angiography were performed, a minicatheter was superselected into middle LAD,and the dopper wire was placed at the midle LAD, 3 cm far from the catheter in order to record the changes of blood velocity. The pressure of aorta was monitored all the time. PMBS was injected (5ml each time) for 4 times with an interval of 10 minutes. Anisodamine (5000u) was injected into the LAD 2 minutes before PBMS was injected. CAG was reperformed 5 minutes after the PMBS was injected to record the TIMI blood flow, TMPG and CTFC to evaluate the myocardial perfusion. Then the animal was killed and the smple of myocardium was take at the joint area of ischemic and normal myocardium in order to measure the tissue level of SOD,MDA and NO and to perform pathological examination.Blood sample was take before and after the expeiment to measure the level of CK-MB,InI and hs-CRP. The percent of necrostic myocardium was calculated by myocardium stain method.
Results: The TIMI blood flow was better in S group and TFCs was lower in A group (P<0.05). At the early stage of PMBS injection, the heart rate was increased in both the groups than their baseline (P<0.05). There was no difference between the two groups. There after, the HR was further increased in A group, while the HR in A+S group remain unchanged.
The Pa was increased in both the two groups after PMBS injection at the early stage (P<0.01). Then it begain to decrease in A group (P<0.05), while it remain its high level in A+S group (P=0.042). In the late stage, the Pa did not decrease in A+S group, however, it was further decreased in A group.
In the early stage after PMBS injection, the bAPV was increased in both groups, which was more obvious in the S group.The hAPV was decreased in S group while it remain its high level in A+S group (P=0.000). After the third injection of PMBS, comparing with the baseline, the hAPV was sinificantly decreased in both groups (P<0.01), but it was still higher than that in S groups (P=0.000). After the forth injection, the hAPV was further decreased with no difference between the two groups.
After the first and second injection of PMBS, the CFR in A+S group was not changed, while it was decreased continously in S group (P=0.006).The CFR was continously deceased after the third and the fourth injection (p<0.05), but it was higher in A+S group (P=0.025).
The h-MR in S group was elevated in S group after the first and the second injection of PMBS (P=0.032), while it not changed in A+S group.After the third injection, the h-MR increased in both group (P=0.030) with the higher level in A+S group (P=0.010). After the fourth injection, the h-MR was further increased (P=0.024), with no difference between two groups.
The level of serum cholesterol 7 days later was 4.44±0.47mmol/L and 3.93±0.53mmol/L in S group and A+S group (P=0.063). The CK-MB, TnI, hs-CRP and MDA were increased 60 minutes after the experiment, but they were higher in S group. Level of NO was also increased (P=0.000), with the higher level in A+S group (P=0.006). SOD was decreased (P=0.000) in both groups, but it was lower in A group (P=0.000).The infarcted myocardium in S grous was 18.5±3.1%, while it was 11.3±2.9% in A+S group (P<0.05).
Conclusion: Simvastatin combined with anisodamine treatment can significantly improves myocardial blood perfusion and porotect the myocardium against ischemic injury during percutaneous coronary intervention. The possible mechanism involves improving of coronary hemodynamics, antiinflammation and antioxidation.
Part III Protective effects of intensive statin pretreatment on renal function in patients with acute coronary syndrome undergoing percutaneous intervention
Objectives: To evaluate the protective effects of higher dose statin on renal function and the incidence of CIN and to probe its possible mechanisms.
Methods: Two hundreds and twenty eight patients with acute coronary syndrome undergoing delayed percutaneous coronary intervention were randomly divided into standard statin group (SSG n=115) and intensive statin group (ISG n=113). Patients in SSG group were given simvastatin 20 mg/day and patients in ISG were given simvastatin 80 mg/day for at least 7 days befor PCI, Serum creatinine was measured at admission, 24 hours and 48 hours after PCI. Creatinine clearance was calculated by Cochcroft-Gault formula. The changes of high sensitive C reaction protein (hs-CRP), intercellular cell adhesion molecule 1 (ICAM-1) and P-selectin level before and after the procedure were also measured.
Results: Serum creatinine underwent significant increase after PCI, the peak value occurred at 24 hours, and then began to decrease. At 48 hours after PCI, the creatinine level significantly decreased (P<0.001 compared with the level at 24 hours) to baseline level (P=0.94 compared with the level at baseline) in ISG, whereas in SSG the creatinine level failed to decrease significantly (P=0.11) at 48 hours. Serum creatinine at admission was not significantly different between the two groups. But at 24 and 48 hours after PCI, it was lower in ISG than SSG (P<0.05 at 24 hours and P<0.001 at 48 hours). The creatinine clearance significantly decreased after PCI, the lowest value occurred at 24 hours, and then it began to increase. In SSG, the creatinine clearance increased significantly (P=0.03 compared with the level at 24 hours) at 48 hours, but still significantly lower than baseline level (P<0.001 compared with the level at baseline). In ISG, the creatinine clearance increased significantly (P<0.001 compared with level at 24 hours) at 48 hours and recover to the level at baseline (P=0.87 compared with level of baseline). Creatinine clearance improved much more in ISG at 24 and 48 hours than that in SSG (P<0.001 at 24 hours and at 48 hours). After PCI, the serum level of hs-CRP, P-selectin and ICAM-1in ISG were significantly lower than SSG (all P<0.001). Although procedure caused significant increase in hs-CRP, P-selectin and ICAM-1 (P<0.001), the increase in ISG was smaller than SSG (P<0.001).
Conclusion: Pretreatment with intensive statin dosage before PCI can further decrease the occurrence of postprocedural contrast induced nephropathy compared with standand statin therapy. This benefit is associated with the lowering of hs-CRP, P-selectin and ICAM levels.
Part IV: Establishment of contrast induced nephropathy model in rats
Objectives: with the widespread application of intravascular contrast, contrast induced nephropathy (CIN) has became to the third rank cause of intra-hospital-attained acute kidney injury. Study of the mechanism and its prevention has become the hot research point in the field of interventional cardiology. So far, the accepted animal model of CIN has not been established.The purpose of this stuy was to establish an rat model of CIN and to evaluate its efficacy.
Methods: Totally 24 SD rats of 250-270 grams were randomly allocated into experimental group (group A, n=12) and control group (group B, n=12). Rats in the two groups were further divided into group of 12 hours and group of 24 hours. All the rats were normally raised for 7 days in order to accommodate to the new environment.
After dehydration of three days, rats in group A were given intravenous Meglumine Diatrizoate and Diatrizoate Sodium (MDDS), while rats in group B were given intraveous normal saline (NS). Then, all rats get normal water-drinking to the end of this study. Animals were killed at 12 hours (group of 12 hours) and 24 hours (group of 24 hours).
Renal ultrasonic examination was performed before this study, after dehydration and 3, 6, 12 and 24 hours after contrast media injection to observe the morphologic changes and the changes of renal dimensions (length,width and thickness), diameters of renal artery, peak systolic velocity (PSV), end diastolic velocity (EDV), ratio of PSV/EDV (S/D) and velocity-time index of left kidney. The heart rate was also recorded at the corresponding time points.
Blood samples were taken before the study, after dehydration and 12 hours (Group A) , 24 hours (Group B) to meseaure the level of serum creatinine. Animals were killed at 12 hours (group A) and 24 hours (group B) and the tissue of kidney were incised for microscope and electron microscope study.
Results: The dimensions of the two groups before and after dehydration were not different. It gradually enlarged at 3, 6, 12 and 24 hours after CM injection. These changes were the most obvious at 6 and 12 hours, which did not recover at 24 hours.
The renal diameters of the two groups were not different. The PSV, EDV, S/D and VTI were lowerest at 6 hours and then recover to normal level at 24 hours. RI was increased after CN injection, the lowest occurred at 6 hours, and recover to normal level at 24 hours. The heart rate was obviously increased after hehydration, but it remained unchanged during the following time period. Serum creatinine was signicicantly elevated after dehydration, the highest level occurred at 12 hours and then begain to recover at 24 hours.
Microscope examination to renal sample at 12 hours found patch disapperence of tubular structure, widely congestion at medullar area. High degeneration of the tubular endothelium, infiltration of fibromyocyte and mononuclear cells were also found. At 24 hours, the obove changes were still present, but become much mild. No pathological glomerular changes were found under microscope. Electron microscope examination found desquamation, sparseness of microvillous of tubular endothelium, membrane confusion, disapperence, swelling, fragmentation of the MIT, with obstrcted tubular lumen and basal membrane sweling. Swelling, licking up, edema of basal membrane and interstitium of the endothelium of glomerular capillary were also found. It was most obvious a 12 hours.
Conclusion: Combined with dehydration, intravenous injection of contrast lead to obvious acute kidney injury, with the changes of kidney tissue pathology, hemodynamics and kidney functions much similar to the characteristics of contrast induced nephropathy in humanbings. Thus, we established an eligible animl model of contrast induced nephropathy which mimiced the time course of contrast induced nephropathy in humanbeings.
Part V: Renal protective effects of intensive statin in combined with anisodamine against contrast induced nephropathy.
Objectives: With the widespread use of intravascular contrast, acute kidney injury was more and more found in clinical practice. Study on its mechanism and prevention has aroused great interest in the field of interventional cardiology. Statins possess pleiotrophic effects against renal injury, which are independent of its cholesterol lowering effects. Also, anisodamine have benefit features again renal injury such as antishock, improving microcirculation and antioxidation. But study of anisodamine in the prevention of CIN after percutaneous coronary intervention has not been carried out. Also, data about their combination for the prevention of CIN after percutaneous coronary intervention was absent. This study, based on the CIN rat model we established, was performed to evaluate the protective effect of simvastatin, anisodamine and their combination in the prevention of CIN and to probe the possible mechanism.
Methods: Totally, 48 of SD rats were randomly divided into control group (control, C, n=12), anisodamine group (anisodamine, A, n=12), simvastatin group (simvastatin, S, n=12) and anisodamine+simvastatin, A+S group, n=12). Then, rats in the four group were futher divided into 12hrs subgroup and 24hrs subgroup (n=6 in each subgroup). Rats in S group and A+S group were given oral simvastatin 0.1mg/100g, while rats in group C and group A+S were given oral placebo for 7 days. After dehydration for 3 days, intravenous Meglumine Diatrizoate and Diatrizoate Sodium (MDDS) was given (0.8mg/100g), then normal water drinking was recovered.
At 15 minutes before contrast injection, anisodamine (100ug/100g) was abdominally injected in group A and group A+S, while normal saline in the other two groups. During the 4 hours after contrast injection, anisodamine abdominal injection was performed every 1 hours in group A and group A+S, while normal saline was injected abdominally at the corresponding time point.During the time between 4 and 12 hours after contrast injection, anisodamine (100ug/100g) and normal saline was repeated every 4 fours as mentioned above.
Kidney untrasound examination was performed at baseline, after dehydration, 3 hours, 6 hours after contrast injection to observe the mophorlogical changes, the renal dimensions and hemodynamic parameters such as diameter of renal artery, peak systolic velocity (PSV), end-diastolic velocity (EDV), resistant index (RI), velocity time index (VTI) and heart rate (HR). Serum creatinine, high sensitive C reactive protein (hs-CRP) were measured at baseline, after dehydration, 12 (12hrs subgroup), 24 (24hrs subgroup) hours after contrast injection. Animals were killed at 12 (12hrs subgroup) and 24 (24hrs subgroup) hours respectively. Renal samples were incised to measure level of superoxide dimutase (SOD), MDA, NOS, NO and GSH-Px.
Results: All the dimensions in group C increased 6 hours afer contrast injection, but is remain unchanged in group A+S. Partial of the dimensions in group A and S increased. The echo decreased at 6 hours compared with 3 hous in group C, while it was abscent in group A+S. The echo changes in group A and S was mild. No dilation of collective system concentrating system was found in all the groups.
At 3 hours, the PSV, EDV and VTI in group A+S were higher than the other groups, and were not less than that after dehydration. However, these parameters were much lower in group C, and lower that that after dehydration of the same group.These parameters was not changed in group A and S. At 6 hours, the PSV, EDV and VTI remain the highest among the four groups and were higher than that at 3 hours. However, these parameters in group C were still lower than the other groups and not recovered to the level after dehydration,Those parameters in group S were higher than that in group A.
S/D was the lowest in group A+S and the higest in group C, while no difference was found between group S and A. At 3 and 6 hours after contrast injection, although these differences of S/D keep existed, it tends to recorver. At 6 hours, it has recovered to baseline in group A+S while it keeps higher in group C. The RI in group A+S at 3 and 6 hours was lower than that in group C, while there was no difference between group S and A. The HR increased in all groups after dehydration with the higher level in group A and A+S. The HR in group S was not different between 3 and 6 hours, while it was higher at 6 hours than 3 hours in group S.
Serum creatinine increased after dehydration, 12 and 24 hours after contrast injection with the highest level occurred at 12 hours. Although it recovered significantly at 24 hours, only that in group A+S and S recovered to baseline level and group C remain the highest. At 12 hours, the higest level occurred in group C and the lowest level at group A+S, group A ranked the second and group S ranked the third.
Microscope examination to renal sample at 12 hours found that in group C, there were patch disapperence of tubular structure, widely congestion at medullar area. High degeneration of the tubular endothelium, infiltration of fibromyocyte and mononuclear cells were also found. In group A, local changes of above mentioned, scattered tubular endothelium and a few fibromyocyte and mononuclear cells were found. In group S, the changes were much similar to group A. In group A+S, there were only spotted changes of above mentioned, few fibromyocyte and mononuclear cells and mild congestion. At 24 hours, the obove changes were still present in group C and group A, but it become much mild in group S. It recovered completely to normal apperence in group A+S. No pathological glomerular changes were found under microscope.
Electron microscope examination found desquamation, sparseness of microvillous of tubular endothelium, membrane confusion, disapperence, swelling, fragmentation of the MIT, with obstructed tubular lumen and basal membrane sweling. Swelling, licking up, edema of basal membrane and interstitium of the endothelium of glomerular capillary were also found. It was most obvious a 12 hours. Among the four groups, group C was the most obvious and group A+S was the mildest.
Although the level of hs-CRP increased in all the groups after dehydration, it was lower in group A+S and S. At 12 hours, hs-CRP reached its highest level. Among the four groups, group A+S was the lowest and group C was the highest. At 24 hours, the hs-CRP was lower than that of 12 hours in all the groups, but still higer than that after dehydration, among which, the lowerest occurred in group A+S, the highest in group C. It was lower in group S than that in group A.
At 12 hours, the level of SOD was decreased in all the four groups, among which, the lowest in group C,the highest in group A+S. Although there was no difference between group A and S, they were all higher than that in group C. AT 24 hours, SOD was further decreased in group C and A, while it increased in group S and A+S. It has recovered to baseline level in group A+S.
At 12 hours, level of MDA increased significantly. The highest occurred in group C and the lowest in group A+S. The level of SOD ranked the second in group A and the third in group S. At 24 hours, MDA was further decreased in all the groups, among which, the MDA in group has recovered to baseline, however, it was still higher the other three groups.
At 12 hours, level of GSH-Px was the lowest in group C, the higest in group A+S.Group S rank the second and group A the third. At 24 hours, GSH-Px began to increase in all the four groups, among which, group A+S has recovered to baseline level and the other three groups remained lower than baseline.
At 12 hours, the NOS deceased in group C and A, while group A+S increased. Group S did not change. At 24 hours, NOS in group C further decreased, NOS in group S and A+S further increased. Group A did not change. The most increasing occurred in group A+S.
At 12 hours, iNOS increased significantly, with the highest in group C. At 24 hours, group C remain the highest and group A+S the lowest. There was no different between group A and S. Compared with 12 hours, level of iNOS at 24 hours in group C,A and S were not different, while level of iNOS in group A+S decreased.
In group C, level of NO was lower at 12 hours and elevated at 24 hours. In group A, NO level was slightly but significantly higher, but decreased at 24 hours. In group S, NO level was significantly higher among the four groups at 12 hours, and further increased at 24 hours. In group A+S, NO level was the highest among the four groups at 12 hours.Althought there was a slight decrease at 24 hours, it was still higher than that at 12 hours, and further increased at 24 hours.
Conclusion: Anisodamine combined with simvastatin can effectively prevent the contrast induced acute kidney injury. Improvement of renal hemodynamics, antiinflammation and antioxidation are the underlying mechanism.
冠状动脉介入治疗后缓复流(无复流)现象和急性对比剂肾损伤是影响经皮冠状动脉介入治疗近远期效果的主要因素。虽然目前其发病机制尚未明确,但是,微循环功能障碍、炎症以及氧化应激反应等被认为是发生无复流和对比剂肾病的共同病理基础。
他汀类药物和山莨菪碱均具有改善微循环、抗炎、抗氧化应激、改善血管内皮功能等作用。已有研究表明,常规剂量的他汀类药物可显著改善心肌灌注,降低对比剂肾病的发生,我们以前的研究也已经证明了山莨菪碱对冠脉无复流的防治作用。目前,关于强化剂量的他汀类药物能否进一步改善冠脉灌注、山莨菪碱对急性对比剂肾损伤的防治作用以及二者联合使用的效果等尚无研究。本研究在既往工作的基础上,进一步探索强化辛伐他汀治疗以及辛伐他汀联合山莨菪碱对冠脉介入治疗中心肌灌注的影响以及对急性肾损伤的保护作用并探讨起可能机制。
本研究分为以下五部分:
第一部分强化降脂治疗对急性冠脉综合征患者经皮冠状动脉介入治疗中心肌灌注的保护作用
目的:探讨强化他汀治疗对急性冠脉综合征患者经皮冠状动脉介入治疗过程中心肌灌注的保护作用,并探讨其可能机制。
方法:行择期PCI的急性冠脉综合征患者228例,随机分为标准他汀组(n=115)和强化他汀组(n=113)。于PCI术前7天,纪录PCI后的TIMI血流、纠正的TIMI计桢数(CTFC)以及TIMI心肌灌注分级(TMPG)等。于PCI前后测量肌酸磷酸激酶(CPK)、CPK同工酶MB(CPK-MB)、肌钙蛋白(ITnI)、高敏C反应蛋白(hs-CRP)、P选择素和细胞间粘附分子(ICAM)水平。
结果:强化他汀组支架植入后TIMI血流0-1级显著少于标准他汀组,3级显著多于标准他汀组(P<0.05)。强化他汀组无复流发生率显著低于标准他汀组(P<0.001)。CTFC在强化他汀组显著低于标准他汀组(P<0.001)。强化他汀组的TMPG也显著优于标准他汀组(P=0.001)。PCI术后24小时,CPK-MB和TnI在强化他汀组显著低于标准他汀组(CPK-MB:18.74±8.41对21.78±10.64 P=0.018;TnI:0.99±1.07对1.47±1.54 P=0.006)。标准治疗组CK-MB升高者占27.8% (32/115),强化他汀组则只有15.9%(18/113)(P=0.030)。标准他汀组TnI升高者显著多于强化他汀组[36.5% (42/115)对19.5%(22/113),P=0.04],其中,标准他汀组的心肌坏死发生率为13%(15/115),而在强化他汀组仅为4.4%(5/113)(P=0.021)。PCI术后24小时,强化他汀组的hs-CRP、P选择素及ICAM-1水平均显著低于标准他汀组(P<0.001)。
结论:PCI术前使用强化他汀治疗比标准他汀治疗能更有效改善急性冠脉综合征患者的心肌灌注、减轻心肌损伤。同时伴有hs-CRP、P选择素和ICAM-1水平的显著降低。
第二部分辛伐他汀联合山莨菪碱治疗对约克猪冠状动脉介入治疗后心肌灌注的保护作用
目的:缓复流/无复流不但增加冠脉介入治疗过程中的手术风险,还严重影响术后患者的长期预后。研究无复流的发生机制、寻找有效的预防和治疗的手段,是目前冠心病介入治疗领域的研究热点之一。山莨菪碱具有改善微循环,抗氧化、保护心肌细胞的良好作用。他汀类药物具有改善血管内皮细胞功能、抗凝、抗血小板、抗氧化、抗炎、改善血流动力学效应等多重效应。目前尚未发现有二者联合使用改善冠脉介入治疗中心肌灌注效果的研究报告。为此,我们在既往实验性微型猪冠脉介入治疗后无复流模型的基础上,进一步评价了强化的辛伐他汀联合山莨菪碱对冠脉介入治疗过程中心肌微循环灌注的保护作用。并通过测定炎症因子高敏C反应蛋白(hs-CRP)、超氧化物歧化酶(SOD)、丙二醛(MDA)和一氧化氮(NO)的水平,探讨其可能机制。
方法:健康约克猪16头,体重30-40kg,被随机分为山莨菪碱组和辛伐他汀+山莨菪碱治疗组。联合治疗组预先饲喂辛伐他汀1mg/kg,山莨菪碱组则给予安慰剂,7天后开始实验。利用微导管超选择LAD,将多普勒导丝置于LAD中段,纪录LAD中段血流速度的变化,并监测LCA开口处压力。于LAD中段注射PMBS混悬液,5ml/次,每十分钟一次,共四次,每次注射PMBS前2分钟LAD内注射山莨菪碱5000ug,PMBS注射后5分钟行冠脉造影,纪录LAD的TIMI血流、TMPG和CTFC,评价心肌灌注情况。于试验结束时处死动物,取坏死和正常交界处缺血心肌分别测定超氧化物歧化酶(SOD)、丙二醛(MDA)、一氧化氮(NO),并行病理学检查。于实验前、实验后采静脉血测定CKMB、TnI以及血清C反应蛋白(CRP)水平。利用染色法计算梗死心肌占左室重量之百分比。
结果:联合治疗组的TIMI血流显著优于山莨菪碱组,TFCs显著低于山莨菪碱组(均P<0.05)。早期LAD内注射PMBS后两组心率均较基础值显著上升(P<0.05),但两组之间无显著差别(P=0.47,P=0.85)。以后山莨菪碱组的心率进一步显著升高(P=0.005),而联合治疗组则仍保持原水平。
早期LAD内给与PMBS注射后两组的冠脉灌注压均显著上升(P<0.01)。以后山莨菪碱组的冠脉灌注压开始降低(P<0.05),联合治疗组则仍维持较高的冠脉灌注压力(P=0.042)。晚期联合治疗组冠脉灌注压力仍维持无显著降低,而山莨菪碱组则显著降低。早期冠脉注射PMBS后,两组的bAPV均有增高,但山莨菪碱组更明显;hAPV在山莨菪碱组降低,而在联合治疗组则维持高水平(P=0.000)。第三次PMBS注射后hAPV两组均较基础值显著降低(P<0.01),但联合治疗组仍显著高于山莨菪碱组(P=0.000)。至第四次PMBS注射后,两组的hAPV进一步降低,两组比较无显著差别。在第一、二次冠脉注射PMBS后,联合治疗组CFR无显著降低,而山莨菪碱组的CFR则持续显著降低(P=0.006)。第三、四次注射PMBS后两组的CFR均连续显著降低(P<0.05),但联合治疗组始终优于山莨菪碱组(P=0.025)。第一、二次注射PMBS后山莨菪碱组的h-MR均显著增高(P=0.032),而联合治疗组则无显著增高。在第三次冠脉LAD内注射PMBS后,两组的h-MR均显著增高(P=0.030),两组间比较联合治疗组的h-MR仍显著低于山莨菪碱组(P=0.010)。在第四次冠脉LAD内注射PMBS后,两组的h-MR进一步显著增高(P=0.024),两组间比较h-MR已无显著差别。
试验前山莨菪碱组血清总胆固醇水平为4.44±0.47mmol/L,联合治疗组的血清胆固醇水平为3.93±0.53mmol/L(P=0.063)。实验后60分钟,肌酸激酶同工酶MB、TnI、hs-CRP、MDA均显著增高,但山莨菪碱组显著高于联合治疗组;NO水平均显著增高(P=0.000),但联合治疗组的NO水平显著高于山莨菪碱组(P=0.006)。SOD水平显著降低(P=0.000),但联合治疗组的SOD水平高于山莨菪碱组(P=0.000)。山莨菪碱组心肌坏死平均坏质量占左心室总质量的18.5±3.1%,联合治疗组为11.3±2.9%。(P<0.05)。光镜下改变联合治疗组的心肌坏死显著轻于山莨菪碱组。
结论:联合应用山莨菪碱和辛伐他汀治疗可显著改善冠脉介入治疗中的冠脉血流,增加心肌灌注,保护心肌。改善冠脉血流动力学、抗炎、抗氧化可能是其潜在机制。
第三部分强化他汀治疗对经皮冠状动脉介入治疗后肾损伤的保护作用目的:研究强化他汀治疗对PCI后肾功能的保护作用和预防对比剂肾病的效果,探讨其可能机制。
方法:228例接受择期PCI的急性冠脉综合征,随机分为标准他汀治疗组(SSG n=115)和强化他汀治疗组(ISG n=113)。于PCI术前7天开始,SSG组患者口服20mg/天辛伐他汀,ISG组患者则口服80mg/天辛伐他汀。于PCI术前、术后24、48小时分别测定血清肌酐水平,按Cochcroft-Gault公式计算肌酐清除率。于PCI术前、术后24小时分别测定血清高敏C反应蛋白(hs-CRP)、P选择素和细胞间粘附分子1(ICAM-1)水平。
结果:PCI后血肌酐水平显著升高,并于术后24小时达高峰,然后逐渐下降。PCI术后48小时,ISG组血肌酐水平显著回降(和术后24小时比P<0.001)并恢复到术前水平(和术前比P=0.94),而SSG组PCI术后48小时血肌酐水平未显著回降(和术后24小时比,P=0.11)。PCI术后24、48小时,ISG组的血肌酐水平均显著低于SSG组(术后24小时,P<0.05;术后48小时P<0.001)。PCI术后,两组肌酐清除率均显著降低,最低值出现在术后24小时,然后逐渐回升。术后48小时,SSG组肌酐清除率显著回升(和术后24小时相比,P=0.03),但仍低于术前水平(和术前相比,P<0.001),而ISG组术后48小时显著回升(和术后24小时相比,P<0.001)并恢复到术前水平(和术前相比,P=0.87),在术后24、48小时,ISG组肌酐清除率的回升程度均显著高于SSG组(均P<0.001)。虽然PCI术后血清hs-CRP、P选择素和ICAM-1水平均显著升高(均P<0.001),但ISG组低于SSG组(均P<0.001)。
结论:和标准剂量他汀治疗相比,PCI前使用强化剂量他汀治疗可进一步保护PCI术后肾脏功能,降低CIN的发生率。这种益处伴随有血清hs-CRP、P选择素和ICAM-1水平的显著降低。
第四部分急性对比剂肾损伤动物模型的建立
目的:随着血管内使用对比剂日益增多,对比剂急性肾脏损伤已经成为当前医院内获得性急性肾损伤的第三位原因。急性对比剂肾损伤的发生机制及预防措施,是当前心血管介入领域研究的焦点问题。但是迄今为止,还没有研究急性对比剂肾损伤的动物模型。本研究的目的是探讨利用大鼠复制急性对比剂肾损伤动物模型的效果。
方法:健康SD大鼠24只,随机分为A组(实验组)和B组(安慰剂对照组)。A、B两组再分别随机分为12小时组和24小时组。大鼠正常饲养7天,待适应环境后开始模型制作。禁水三天后,A组经舌下静脉注射复方泛影葡胺8ml/Kg,B组则注射等量生理盐水,然后给予自然饮水至试验结束,A、B两组分别于注射对比剂后12小时、24小时处死动物。分别于试验前、禁水三天后、注射对比剂后3小时、6小时、12小时、24小时(B组)行肾脏超声检查,观察肾脏形态结构变化。并测量左侧肾脏长径、宽径和厚径以及左侧肾动脉直径、收缩期峰值血流速度(PSV)、舒张期峰值血流速度(EDV)、收缩/舒张期血流速度比值(S/D)、阻力指数(RI)、左肾血流量积分指数(VTI)容量及心率。于实验前、禁水三天后、术后12小时(A组)、24小时(B组)采血测量血肌酐水平。分别于术后12小时(A组)、24小时(B组)处死大鼠,取肾脏进行光镜和透射电镜检查。
结果:试验前、禁水三天后两组肾脏大小无显著差别,术后3小时、6小时、12小时和24小时实验组的肾脏体积逐渐增大,回声均匀减低,但未见集合系统分离现象,此种表现在6-12小时最为明显,到术后24小时仍未恢复正常。
肾动脉直径两组之间无显著差异。但收缩期峰值血流速度(PSV)、舒张期峰值血流速度(EDV)、收缩/舒张期血流速度比值(S/D)、左肾血流量积分指数(VTI)容量在术后6小时最低,以后逐渐恢复,至术后24小时基本恢复到术前水平;阻力指数(RI)术后逐渐升高,在术后6小时最低,到术后24小时恢复到术前水平,禁水三天后心率显著增快,但术后心率无显著改变。禁水三天后术后血清肌酐水平显著升高,以术后12小时为最高,至术后24小时随有明显恢复,当仍未恢复到术前水平。
光镜检查发现使用对比剂后12小时肾髓质区可见片状肾小管结构消失,广泛充血、淤血,可见肾小管上皮细胞高度退变,并有较多的成纤维细胞增生及单核细胞浸润。24小时仍可见肾髓质区呈局灶性肾小管结构消失,充血、淤血,有少量成纤维细胞增生及数个单核细胞浸润,但均较12小时明显减轻。光镜下未见显著的肾小球病理学改变。电镜检查发现,使用对比剂后肾小管上皮细胞微绒毛脱落、稀疏,线粒体嵴合膜融合、消失,部分线粒体肿胀、破碎,质膜内褶消失,部分阻塞小管腔,基底膜水肿等改变。另外也可见肾小球毛细血管上皮细胞肿胀、吞噬现象,基底膜及组织间隙水肿,以术后12小时最明显。
结论:结合脱水和对比剂静脉注射可造成的显著的急性肾功能损害,其肾脏组织形态学、血流动力学以及肾功能改变均符合人类对比剂肾病的特点。因此,本模型是研究人类对比剂肾病的理想模型。
第五部分辛伐他汀联合山莨菪碱对大鼠急性对比剂肾损伤的保护作用
目的:随着血管内使用对比剂日益增多,急性对比剂肾损伤发病率急剧增加,研究急性对比剂肾损伤的发生机制及预防措施,是当前心血管介入领域研究的焦点问题。他汀类药物具有独立于降脂作用以外的多重肾脏保护作用,山莨菪碱也具有抗休克、改善组织微循环灌注、抗自由基等的良好作用。但是,目前尚没有关于山莨菪碱对冠脉介入治疗后急性对比剂肾损伤的防治作用的研究,也缺乏关于他汀类药物和山莨菪碱联合使用对使用对比剂后肾脏保护方面的研究。本研究利用大鼠急性对比剂肾损伤动物模型,研究辛伐他汀、山莨菪碱及其联合使用对急性对比剂肾损伤的保护作用,并探讨其可能机制。
方法:健康SD大鼠48只,随机分为对照组(C,n=12只)、山莨菪碱组(A,n=12只)、辛伐他汀组(S,n=12只)、辛伐他汀联合山莨菪碱组(A+S,n=12只)。四组再分别随机分为12小时组和24小时组,每组各6只。辛伐他汀组及联合治疗组大鼠给予辛伐他汀灌胃(0.1mg/100g)。对照组和山莨菪碱组则以等量生理盐水灌饲,连续7天。于给药的第四天开始禁水,连续三天后,静脉注射对比剂(0.8ml/100g),然后给予自然饮水。
于注射对比剂前15分钟,山莨菪碱组和联合治疗组分别给予山莨菪碱100ug/100g腹腔注射,对照组和辛伐他汀组则给予等量生理盐水腹腔注射。山莨菪碱组和联合治疗组于注射对比剂后4小时内每小时腹腔注射山莨菪碱100ug/100g一次,至第4-12小时每4小时重复腹腔注射山莨菪碱100ug/100g,而对照组和辛伐他汀组则于相应时间腹腔注射等量生理盐水。
别于试验前、禁水三天后、注射对比剂后3小时、6小时分别行肾脏超声检查,观察肾脏形态结构变化。并测量左侧肾脏长径、宽径和厚径以及左侧肾动脉直径、收缩期峰值血流速度(PSV)、舒张期峰值血流速度(EDV)、阻力指数(RI)、左肾血流量积分指数(VTI)容量及心率。分别于试验前、禁水三天后、注射对比剂后12(12小时组)、24小时(24小时组)取血测定血肌酐、高敏C反应蛋白水平。于术后第12小时和24小时处死动物,分离左侧肾脏,做光镜和电镜检查。并取肾脏组织测定抗氧化指标超氧化物岐化酶、丙二醛、一氧化氮合成酶、一氧化氮、谷胱苷肽氧化酶水平。
结果:注射对比剂后6小时起对照组肾脏的各径线均显著增大,而联合治疗组的肾脏各径线则均无显著变化。山莨菪碱组和辛伐他汀组则部分肾脏径线出现显著增大。对照组皮质髓质回声较3小时均匀减低,山莨菪碱组和辛伐他汀组回声仅有轻微减低,而联合治疗组则未见明显回声减低表现,各组均未见集合系统分离现象。
术后3小时,联合治疗组的收缩期峰值血流速度(PSV)、舒张期峰值血流速度(EDV)、左肾血流量积分指数(VTI)均显著高于其它各组同期水平,并且不低于甚至高于术前水平。而对照组上述指标则显著低于其它各组,并且低于术前水平。山莨菪碱组和辛伐他汀组则无显著差别。在术后6小时,联合治疗组的收缩期峰值血流速度(PSV)、舒张期峰值血流速度(EDV)、左肾血流量积分指数(VTI)仍然显著高于其它各组同期水平,并且均比3小时显著增高。对照组上述指标则仍显著低于其它各组,并未恢复到术前水平,甚至进一步减低。而辛伐他汀组显著高于山莨菪碱组。
术前S/D联合治疗组显著低于其它三组,对照组显著高于其它三组,辛伐他汀组和山莨菪碱组无显著差别。术后3、6小时,在继续保持这种差异的同时,S/D总体趋于恢复到基线水平,但联合治疗组在术后6小时已经和基线时无显著差别,而对照组仍显著高于基线水平。在术后3、6小时,联合治疗组的阻力指数显著低于对照组,而辛伐他汀组和山莨菪碱组则无显著差别。禁水三天后心率显著增快(284±25次/分),但术后3小时和6小时山莨菪碱组和联合治疗组的心率均显著高于对照组和辛伐他汀组,辛伐他汀组3、6小时无差别,而山莨菪碱组6小时的心率高于3小时。
血清肌酐水平在禁水三天后、术后12小时及24小时显著升高,以术后12小时为最高,至术后24小时虽有明显恢复,但只有联合治疗组和辛伐他汀组恢复到术前水平,而山莨菪碱组和对照组均未恢复到术前水平,其中对照组恢复最慢。从肌酐升高的水平来看,术后12小时对照组最高,而联合治疗组最低,山莨菪碱组和辛伐他汀组位列第二和第三,四组均有显著性差异。
使用对比剂后12小时光镜观察发现:对照组在肾髓质区可见片状肾小管结构消失,广泛充血、淤血,可见多个高度退变的肾小管样上皮细胞残留,有较多的成纤维细胞增生及单核细胞浸润。山莨菪碱组肾髓质区可见局灶性区域肾小管结构消失,广泛充血、淤血,有数个散在的肾小管上皮残留,并可见少量成纤维细胞增生及数个单核细胞浸润。辛伐他汀组肾髓质区可见局灶性区域肾小管结构消失,广泛充血、淤血,可见少量成纤维细胞增生及数个单核细胞浸润。联合治疗组肾髓质区可见点状肾小管结构紊乱,有极少量成纤维细胞和数个单核细胞浸润,轻度充血。术后24小时,对照组仍可见肾髓质区呈局灶性肾小管结构消失,充血、淤血,可见有少量成纤维细胞增生及数个单核细胞浸润,山莨菪碱组也可发现上述改变,但均较12小时时明显减轻,而辛伐他汀组和联合治疗组的肾脏结构基本恢复正常。光镜下12小时和24小时均未见显著的肾小球病理学改变。
电镜检查发现,使用对比剂后肾小管上皮细胞微绒毛脱落、稀疏,线粒体嵴合膜融合、消失,部分线粒体肿胀、破碎,质膜内褶消失,部分阻塞小管腔,并有基底膜及组织间隙水肿等改变,另外也可见肾小球毛细血管上皮细胞肿胀、吞噬现象,基底膜及组织间隙水肿,以术后12小时最明显。四组比较以对照组最明显,而联合治疗组最轻。
四组动物的高敏C反应蛋白(hs-CRP)术前则显著增高,但联合治疗组和辛伐他汀组显著低于其它两组。术后12小时,hs-CRP水平达到最高水平,四组之间均有显著差别,其中联合治疗组最低,对照组最高,辛伐他汀组低于山莨菪碱组。至术后24小时,四组的hs-CRP水平均比12小时显著降低,但仍均显著高于术前水平。其中仍以联合治疗组最低,对照组最高,辛伐他汀组显著低于山莨菪碱组。
术后12小时,四组的SOD水平均显著降低,其中对照组SOD降低最显著,而联合治疗组最高,山莨菪碱组和辛伐他汀组无显著差别,但均显著高于对照组。术后24小时,对照组和山莨菪碱组的SOD水平进一步显著降低,而辛伐他汀组和联合治疗组则显著回升,其中联合治疗组已经恢复到基础水平。
术后12小时四组MDA水平均显著增高,其中对照组最高,联合治疗组最低,虽然山莨菪碱组和辛伐他汀组显著低于对照组,但辛伐他汀组显著低于山莨菪碱组。术后24小时的MDA水平在四组均显著降低,其中联合治疗组的MDA水平已经接近术前水平,而其它三组仍显著高于术前水平。
术后12小时,GSH-Px水平以对照组为最低,联合治疗组最高,山莨菪碱组和辛伐他汀组均显著高于对照组,辛伐他汀组高于山莨菪碱组。术后24小时,四组的GSH-Px水平较12小时均显著回升,其中联合治疗组已经恢复到术前水平,而其它三组仍低于术前水平。
术后12小时,对照组和山莨菪碱组的NOS水平显著降低,而辛伐他汀组则无显著改变,而联合治疗组则显著升高。术后24小时,对照组的NOS水平进一步降低,山莨菪碱组无显著差别,而辛伐他汀组和联合治疗组则进一步升高,其中联合治疗组升高最明显,后二者均显著高于基础水平。
术后12小时,iNOS水平显著增高(P<0.01),其中以对照组最高,显著高于其它三组(P<0.05),而山莨菪碱组、辛伐他汀组和联合治疗组无显著差别。术后24小时,仍以对照组为最高,联合治疗组最低,山莨菪碱组和辛伐他汀组无显著差别。和12小时比较,术后24小时iNOS水平在对照组、山莨菪碱组和辛伐他汀组均无显著差别,但联合治疗组的iNOS水平则显著低于术后12小时。
在对照组,术后12小时NO水平较低,24小时有轻微但显著上升;山莨菪碱组12小时NO较高,但术后24小时的显著降低;辛伐他汀组术后12小时的NO含量比较高,术后24小时则继续上升;联合治疗组在术后12小时的NO最高,虽在术后24小时有所下降,但仍呈显著升高状态。
结论:山莨菪碱和辛伐他汀的联合治疗可有效预防对比剂急性肾损伤的发生,其可能机制涉及改善肾脏的血流动力学、抗炎、抗氧化等。
More and more patients of coronary artery disease have benefit from percutaneous coronary intervention (PCI). About 30 000 cases of PCI were performed in 2002 in China. It rises to 75 000 in 2005. By the end of 2009, the PCI cases has been over 240 000. Now, the number is still increasing.
No/slow reflow phenomenon and contrast induced nephropathy are the main complications that limited the short and long-term efficacy of PCI. Although the exact mechanism remains uncertain, it was accepted that dysfunction of microcirculation, inflamation and oxidant stress were among the common pathophysiological basis.
Both statins and anisodamine possess these characteristics such as anti-inflammation, antioxidation, improving the function of the endothelium. It has been confirmed that common dose statins improve myocardial perfusion and prevent the incidence of CIN. Data in our laboratory also support the use of anisodamine in the setting of NRP. So far, the effect of intensive statin dose on myocardial perfusion, the preventive effect of anisodamine on CIN and the effect of their combination have not been carried out. Based on our previous work, this study was designed to evaluate the effect of intensive simvastatin, anisodamine and their combination on myocardila perfusion and CIN. The possible mechanisms were also probed.
Part I Intensive cholesterol lowering with simvastatin improves the outcomes of percutaneous coronary intervention in patients with acute coronary syndrome
Objective: The incidence of no reflow penomenon limits the clinical outcomes of percutaneous coronary intervention (PCI). We designed a randomized controlled study to evaluate the immediate protective effects of intensive statin pretreatment on myocardial perfusion and myocardial ischemic injury during PCI.
Methods: A total of 228 acute coronary syndrome (ACS) patients were randomly divided into standard statin group (SSG, n=115) and intensive statin group (ISG, n=113). Patients in SSG received 20 mg simvastatin and patients in ISG received 80 mg simvastatin for 7 days before PCI. TIMI grade flow (TGF), corrected TIMI frame count (CTFC) and TIMI myocardial perfusion grade (TMPG) of the intervened vessel were recorded before and after stent deployment. CPK isoenzyme MB, troponin I and plasma level of hs-CRP, P-selectin and ICAM were measured before and 24 hours after the procedure.
Results: The TFG after stent deployment was significantly improved with less TIMI 0-1 patients and more TIMI 3 blood flow in ISG than in SSG (all p<0.05). Patients with no reflow phenomenon were less in ISG (P<0.001). The CTFC was lower in ISG than SSG (P<0.001). TMPG was also improved in ISG than SSG (P=0.001). Twenty-four hours after the procedure, although PCI caused significantly increase in CK-MB, the elevated CK-MB value was lower in ISG than SSG (18.74±8.41 vs 21.78±10.64 P=0.018). Similar changes were also found with regard to Troponin I (0.99±1.07 in ISG vs 1.47±1.54 in SSG P=0.006). CK-MB elevation occurred in 27.8% (32/115) in SSG versus 15.9% (18/113) in ISG (P=0.030). Among them, myocardial necrosis was detected in 4.4% (5/115) of the patients in SSG, whereas 0.9% (1/113) in ISG (P=0.341). No myocardial infarction was found. Similarly, the patients with increased troponin I were much more in SSG (36.5% 42/115) than ISG (19.5% 22/113) (P=0.04). Among them, myocardial necrosis was detected in 13% (15/115) of the patients in SSG, while 4.4% (5/113) in ISG (P=0.021). Myocardial infarction was found in 4.4% (5/115) in the patients in SSG and 0.9% (1/113) in ISG (P=0.213).
Conclusion: Intensive statin pretreatment for 7 days before PCI can further improve myocardial blood perfusion, protect myocardium from ischemic injury. This benefit is associated with the lowering of hs-CRP, P-selectin and ICAM level.
Part II Protective effect of simvastatin in combined with anisodamine on myocardial perfusion in swine no reflow model.
Objectives: Slow reflow or no reflow phenomenon not only increase the risk during percutaneous coronary intervention, but also limit the long prognosis of this therapy. Study of its mechanism and find out the prevention measures remain the main focus of this field. Anisodamine can improve the state of mircrocirculation, antioxidant and protect the myocardium from ischemic injury, while statins posses the ability of improving the function of endothelium, anticoagulation, antiplatelet, antioxidation, antiinflammation and improving blood hemodynamics. So far, data on the combination of the two drugs on the prevention of SRP/NRP is absent. So, based on our previous study of experimental SRP/NRP model on minipig, we evaluated the preventive effect of their combination. We also probed the possible mechanism by measuring the level of hs-CRP, SOD, MDA and NO.
Method: Totally 16 minipin of 30-40 Kg were randomly divided into anisodamine groups (A, n=8) and anisodamine plus simvastatin group (A+S, n=8). Pigs of A+S group were prtreated with oral simvastatin (1 mg/Kg) for 7 days, while pigs in S groups were given oral placebo.Seven days later, after coronary angiography were performed, a minicatheter was superselected into middle LAD,and the dopper wire was placed at the midle LAD, 3 cm far from the catheter in order to record the changes of blood velocity. The pressure of aorta was monitored all the time. PMBS was injected (5ml each time) for 4 times with an interval of 10 minutes. Anisodamine (5000u) was injected into the LAD 2 minutes before PBMS was injected. CAG was reperformed 5 minutes after the PMBS was injected to record the TIMI blood flow, TMPG and CTFC to evaluate the myocardial perfusion. Then the animal was killed and the smple of myocardium was take at the joint area of ischemic and normal myocardium in order to measure the tissue level of SOD,MDA and NO and to perform pathological examination.Blood sample was take before and after the expeiment to measure the level of CK-MB,InI and hs-CRP. The percent of necrostic myocardium was calculated by myocardium stain method.
Results: The TIMI blood flow was better in S group and TFCs was lower in A group (P<0.05). At the early stage of PMBS injection, the heart rate was increased in both the groups than their baseline (P<0.05). There was no difference between the two groups. There after, the HR was further increased in A group, while the HR in A+S group remain unchanged.
The Pa was increased in both the two groups after PMBS injection at the early stage (P<0.01). Then it begain to decrease in A group (P<0.05), while it remain its high level in A+S group (P=0.042). In the late stage, the Pa did not decrease in A+S group, however, it was further decreased in A group.
In the early stage after PMBS injection, the bAPV was increased in both groups, which was more obvious in the S group.The hAPV was decreased in S group while it remain its high level in A+S group (P=0.000). After the third injection of PMBS, comparing with the baseline, the hAPV was sinificantly decreased in both groups (P<0.01), but it was still higher than that in S groups (P=0.000). After the forth injection, the hAPV was further decreased with no difference between the two groups.
After the first and second injection of PMBS, the CFR in A+S group was not changed, while it was decreased continously in S group (P=0.006).The CFR was continously deceased after the third and the fourth injection (p<0.05), but it was higher in A+S group (P=0.025).
The h-MR in S group was elevated in S group after the first and the second injection of PMBS (P=0.032), while it not changed in A+S group.After the third injection, the h-MR increased in both group (P=0.030) with the higher level in A+S group (P=0.010). After the fourth injection, the h-MR was further increased (P=0.024), with no difference between two groups.
The level of serum cholesterol 7 days later was 4.44±0.47mmol/L and 3.93±0.53mmol/L in S group and A+S group (P=0.063). The CK-MB, TnI, hs-CRP and MDA were increased 60 minutes after the experiment, but they were higher in S group. Level of NO was also increased (P=0.000), with the higher level in A+S group (P=0.006). SOD was decreased (P=0.000) in both groups, but it was lower in A group (P=0.000).The infarcted myocardium in S grous was 18.5±3.1%, while it was 11.3±2.9% in A+S group (P<0.05).
Conclusion: Simvastatin combined with anisodamine treatment can significantly improves myocardial blood perfusion and porotect the myocardium against ischemic injury during percutaneous coronary intervention. The possible mechanism involves improving of coronary hemodynamics, antiinflammation and antioxidation.
Part III Protective effects of intensive statin pretreatment on renal function in patients with acute coronary syndrome undergoing percutaneous intervention
Objectives: To evaluate the protective effects of higher dose statin on renal function and the incidence of CIN and to probe its possible mechanisms.
Methods: Two hundreds and twenty eight patients with acute coronary syndrome undergoing delayed percutaneous coronary intervention were randomly divided into standard statin group (SSG n=115) and intensive statin group (ISG n=113). Patients in SSG group were given simvastatin 20 mg/day and patients in ISG were given simvastatin 80 mg/day for at least 7 days befor PCI, Serum creatinine was measured at admission, 24 hours and 48 hours after PCI. Creatinine clearance was calculated by Cochcroft-Gault formula. The changes of high sensitive C reaction protein (hs-CRP), intercellular cell adhesion molecule 1 (ICAM-1) and P-selectin level before and after the procedure were also measured.
Results: Serum creatinine underwent significant increase after PCI, the peak value occurred at 24 hours, and then began to decrease. At 48 hours after PCI, the creatinine level significantly decreased (P<0.001 compared with the level at 24 hours) to baseline level (P=0.94 compared with the level at baseline) in ISG, whereas in SSG the creatinine level failed to decrease significantly (P=0.11) at 48 hours. Serum creatinine at admission was not significantly different between the two groups. But at 24 and 48 hours after PCI, it was lower in ISG than SSG (P<0.05 at 24 hours and P<0.001 at 48 hours). The creatinine clearance significantly decreased after PCI, the lowest value occurred at 24 hours, and then it began to increase. In SSG, the creatinine clearance increased significantly (P=0.03 compared with the level at 24 hours) at 48 hours, but still significantly lower than baseline level (P<0.001 compared with the level at baseline). In ISG, the creatinine clearance increased significantly (P<0.001 compared with level at 24 hours) at 48 hours and recover to the level at baseline (P=0.87 compared with level of baseline). Creatinine clearance improved much more in ISG at 24 and 48 hours than that in SSG (P<0.001 at 24 hours and at 48 hours). After PCI, the serum level of hs-CRP, P-selectin and ICAM-1in ISG were significantly lower than SSG (all P<0.001). Although procedure caused significant increase in hs-CRP, P-selectin and ICAM-1 (P<0.001), the increase in ISG was smaller than SSG (P<0.001).
Conclusion: Pretreatment with intensive statin dosage before PCI can further decrease the occurrence of postprocedural contrast induced nephropathy compared with standand statin therapy. This benefit is associated with the lowering of hs-CRP, P-selectin and ICAM levels.
Part IV: Establishment of contrast induced nephropathy model in rats
Objectives: with the widespread application of intravascular contrast, contrast induced nephropathy (CIN) has became to the third rank cause of intra-hospital-attained acute kidney injury. Study of the mechanism and its prevention has become the hot research point in the field of interventional cardiology. So far, the accepted animal model of CIN has not been established.The purpose of this stuy was to establish an rat model of CIN and to evaluate its efficacy.
Methods: Totally 24 SD rats of 250-270 grams were randomly allocated into experimental group (group A, n=12) and control group (group B, n=12). Rats in the two groups were further divided into group of 12 hours and group of 24 hours. All the rats were normally raised for 7 days in order to accommodate to the new environment.
After dehydration of three days, rats in group A were given intravenous Meglumine Diatrizoate and Diatrizoate Sodium (MDDS), while rats in group B were given intraveous normal saline (NS). Then, all rats get normal water-drinking to the end of this study. Animals were killed at 12 hours (group of 12 hours) and 24 hours (group of 24 hours).
Renal ultrasonic examination was performed before this study, after dehydration and 3, 6, 12 and 24 hours after contrast media injection to observe the morphologic changes and the changes of renal dimensions (length,width and thickness), diameters of renal artery, peak systolic velocity (PSV), end diastolic velocity (EDV), ratio of PSV/EDV (S/D) and velocity-time index of left kidney. The heart rate was also recorded at the corresponding time points.
Blood samples were taken before the study, after dehydration and 12 hours (Group A) , 24 hours (Group B) to meseaure the level of serum creatinine. Animals were killed at 12 hours (group A) and 24 hours (group B) and the tissue of kidney were incised for microscope and electron microscope study.
Results: The dimensions of the two groups before and after dehydration were not different. It gradually enlarged at 3, 6, 12 and 24 hours after CM injection. These changes were the most obvious at 6 and 12 hours, which did not recover at 24 hours.
The renal diameters of the two groups were not different. The PSV, EDV, S/D and VTI were lowerest at 6 hours and then recover to normal level at 24 hours. RI was increased after CN injection, the lowest occurred at 6 hours, and recover to normal level at 24 hours. The heart rate was obviously increased after hehydration, but it remained unchanged during the following time period. Serum creatinine was signicicantly elevated after dehydration, the highest level occurred at 12 hours and then begain to recover at 24 hours.
Microscope examination to renal sample at 12 hours found patch disapperence of tubular structure, widely congestion at medullar area. High degeneration of the tubular endothelium, infiltration of fibromyocyte and mononuclear cells were also found. At 24 hours, the obove changes were still present, but become much mild. No pathological glomerular changes were found under microscope. Electron microscope examination found desquamation, sparseness of microvillous of tubular endothelium, membrane confusion, disapperence, swelling, fragmentation of the MIT, with obstrcted tubular lumen and basal membrane sweling. Swelling, licking up, edema of basal membrane and interstitium of the endothelium of glomerular capillary were also found. It was most obvious a 12 hours.
Conclusion: Combined with dehydration, intravenous injection of contrast lead to obvious acute kidney injury, with the changes of kidney tissue pathology, hemodynamics and kidney functions much similar to the characteristics of contrast induced nephropathy in humanbings. Thus, we established an eligible animl model of contrast induced nephropathy which mimiced the time course of contrast induced nephropathy in humanbeings.
Part V: Renal protective effects of intensive statin in combined with anisodamine against contrast induced nephropathy.
Objectives: With the widespread use of intravascular contrast, acute kidney injury was more and more found in clinical practice. Study on its mechanism and prevention has aroused great interest in the field of interventional cardiology. Statins possess pleiotrophic effects against renal injury, which are independent of its cholesterol lowering effects. Also, anisodamine have benefit features again renal injury such as antishock, improving microcirculation and antioxidation. But study of anisodamine in the prevention of CIN after percutaneous coronary intervention has not been carried out. Also, data about their combination for the prevention of CIN after percutaneous coronary intervention was absent. This study, based on the CIN rat model we established, was performed to evaluate the protective effect of simvastatin, anisodamine and their combination in the prevention of CIN and to probe the possible mechanism.
Methods: Totally, 48 of SD rats were randomly divided into control group (control, C, n=12), anisodamine group (anisodamine, A, n=12), simvastatin group (simvastatin, S, n=12) and anisodamine+simvastatin, A+S group, n=12). Then, rats in the four group were futher divided into 12hrs subgroup and 24hrs subgroup (n=6 in each subgroup). Rats in S group and A+S group were given oral simvastatin 0.1mg/100g, while rats in group C and group A+S were given oral placebo for 7 days. After dehydration for 3 days, intravenous Meglumine Diatrizoate and Diatrizoate Sodium (MDDS) was given (0.8mg/100g), then normal water drinking was recovered.
At 15 minutes before contrast injection, anisodamine (100ug/100g) was abdominally injected in group A and group A+S, while normal saline in the other two groups. During the 4 hours after contrast injection, anisodamine abdominal injection was performed every 1 hours in group A and group A+S, while normal saline was injected abdominally at the corresponding time point.During the time between 4 and 12 hours after contrast injection, anisodamine (100ug/100g) and normal saline was repeated every 4 fours as mentioned above.
Kidney untrasound examination was performed at baseline, after dehydration, 3 hours, 6 hours after contrast injection to observe the mophorlogical changes, the renal dimensions and hemodynamic parameters such as diameter of renal artery, peak systolic velocity (PSV), end-diastolic velocity (EDV), resistant index (RI), velocity time index (VTI) and heart rate (HR). Serum creatinine, high sensitive C reactive protein (hs-CRP) were measured at baseline, after dehydration, 12 (12hrs subgroup), 24 (24hrs subgroup) hours after contrast injection. Animals were killed at 12 (12hrs subgroup) and 24 (24hrs subgroup) hours respectively. Renal samples were incised to measure level of superoxide dimutase (SOD), MDA, NOS, NO and GSH-Px.
Results: All the dimensions in group C increased 6 hours afer contrast injection, but is remain unchanged in group A+S. Partial of the dimensions in group A and S increased. The echo decreased at 6 hours compared with 3 hous in group C, while it was abscent in group A+S. The echo changes in group A and S was mild. No dilation of collective system concentrating system was found in all the groups.
At 3 hours, the PSV, EDV and VTI in group A+S were higher than the other groups, and were not less than that after dehydration. However, these parameters were much lower in group C, and lower that that after dehydration of the same group.These parameters was not changed in group A and S. At 6 hours, the PSV, EDV and VTI remain the highest among the four groups and were higher than that at 3 hours. However, these parameters in group C were still lower than the other groups and not recovered to the level after dehydration,Those parameters in group S were higher than that in group A.
S/D was the lowest in group A+S and the higest in group C, while no difference was found between group S and A. At 3 and 6 hours after contrast injection, although these differences of S/D keep existed, it tends to recorver. At 6 hours, it has recovered to baseline in group A+S while it keeps higher in group C. The RI in group A+S at 3 and 6 hours was lower than that in group C, while there was no difference between group S and A. The HR increased in all groups after dehydration with the higher level in group A and A+S. The HR in group S was not different between 3 and 6 hours, while it was higher at 6 hours than 3 hours in group S.
Serum creatinine increased after dehydration, 12 and 24 hours after contrast injection with the highest level occurred at 12 hours. Although it recovered significantly at 24 hours, only that in group A+S and S recovered to baseline level and group C remain the highest. At 12 hours, the higest level occurred in group C and the lowest level at group A+S, group A ranked the second and group S ranked the third.
Microscope examination to renal sample at 12 hours found that in group C, there were patch disapperence of tubular structure, widely congestion at medullar area. High degeneration of the tubular endothelium, infiltration of fibromyocyte and mononuclear cells were also found. In group A, local changes of above mentioned, scattered tubular endothelium and a few fibromyocyte and mononuclear cells were found. In group S, the changes were much similar to group A. In group A+S, there were only spotted changes of above mentioned, few fibromyocyte and mononuclear cells and mild congestion. At 24 hours, the obove changes were still present in group C and group A, but it become much mild in group S. It recovered completely to normal apperence in group A+S. No pathological glomerular changes were found under microscope.
Electron microscope examination found desquamation, sparseness of microvillous of tubular endothelium, membrane confusion, disapperence, swelling, fragmentation of the MIT, with obstructed tubular lumen and basal membrane sweling. Swelling, licking up, edema of basal membrane and interstitium of the endothelium of glomerular capillary were also found. It was most obvious a 12 hours. Among the four groups, group C was the most obvious and group A+S was the mildest.
Although the level of hs-CRP increased in all the groups after dehydration, it was lower in group A+S and S. At 12 hours, hs-CRP reached its highest level. Among the four groups, group A+S was the lowest and group C was the highest. At 24 hours, the hs-CRP was lower than that of 12 hours in all the groups, but still higer than that after dehydration, among which, the lowerest occurred in group A+S, the highest in group C. It was lower in group S than that in group A.
At 12 hours, the level of SOD was decreased in all the four groups, among which, the lowest in group C,the highest in group A+S. Although there was no difference between group A and S, they were all higher than that in group C. AT 24 hours, SOD was further decreased in group C and A, while it increased in group S and A+S. It has recovered to baseline level in group A+S.
At 12 hours, level of MDA increased significantly. The highest occurred in group C and the lowest in group A+S. The level of SOD ranked the second in group A and the third in group S. At 24 hours, MDA was further decreased in all the groups, among which, the MDA in group has recovered to baseline, however, it was still higher the other three groups.
At 12 hours, level of GSH-Px was the lowest in group C, the higest in group A+S.Group S rank the second and group A the third. At 24 hours, GSH-Px began to increase in all the four groups, among which, group A+S has recovered to baseline level and the other three groups remained lower than baseline.
At 12 hours, the NOS deceased in group C and A, while group A+S increased. Group S did not change. At 24 hours, NOS in group C further decreased, NOS in group S and A+S further increased. Group A did not change. The most increasing occurred in group A+S.
At 12 hours, iNOS increased significantly, with the highest in group C. At 24 hours, group C remain the highest and group A+S the lowest. There was no different between group A and S. Compared with 12 hours, level of iNOS at 24 hours in group C,A and S were not different, while level of iNOS in group A+S decreased.
In group C, level of NO was lower at 12 hours and elevated at 24 hours. In group A, NO level was slightly but significantly higher, but decreased at 24 hours. In group S, NO level was significantly higher among the four groups at 12 hours, and further increased at 24 hours. In group A+S, NO level was the highest among the four groups at 12 hours.Althought there was a slight decrease at 24 hours, it was still higher than that at 12 hours, and further increased at 24 hours.
Conclusion: Anisodamine combined with simvastatin can effectively prevent the contrast induced acute kidney injury. Improvement of renal hemodynamics, antiinflammation and antioxidation are the underlying mechanism.
引文
1 Abbate A, Kontos MC, Biondi-Zoccai GG. No-reflow: the next challenge in treatment of ST-elvevation acute myocardial infarction. Eur Heart J. 2008;29:1795-1797
2 Flaker GC, Warnica JW, Sacks FM, et al. Pravastatin prevents clinical events in revascularized patients with average cholesterol concentrations. Cholesterol and Recurrent Events CARE Investigators. J Am Coll Cardiol. 1999 Jul;34(1):106-12
3 Schwartz GG, Olsson AG, Ezikowitz MD, et al. Myocardial Ischemia Reduction with Aggressive Cholesterol-lowering (MIRACL) StudyInvestigators: Effects of atovastatin on early recurrent ischemic events in acute coronary syndrome: the MIRACL study. JAMA 2001;285:1711-1718
4 Pedersen TR, Faergeman O, Kastelein JJ, et al. Incremental Decrease in End Points Through Aggressive Lipid Lowering (IDEAL) Study Group. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. JAMA 2005; 294:2437-2445
5 Patti G, Pasceri A, Colonna G, et al. Atorvastatin pretreatment improves outcomes in patients with acute coronary syndromes undergoing early percutaneous coronary intervention: results of the ARMYDA-ACS randomized trial. J Am Coll Cardiol.2007;49:1272-1278
6 Pasceri V, Patti G, Nusca A, et al. Randomized trial of atorvastatin for reduction of myocardial damage during coronary intervention, Results from the ARMYDA (Atorvastatin for Reduction of Myocardial Damage during Angioplasty) study. Circulation 2004;110:674-678
7 National Cholesterol Education Program (ECEP) Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adults Treatment Panel III). Third Report of the National Cholesterol Education Program (NECP) Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation, 2002;106:3143-3421
8 Melberg T, Burman R, Dickstein K, et al. The impact of the 2007 ESC-ACC-AHA-WHF Universal definition on the incidence and classification of acute myocardial infarction: A retrospective cohort study. Int J Cardiol. 2008 Nov 21
9 Brener SJ, Ellis SG, Schneider J, et al. Frequency and long-term impact of myonecrosis after coronary stenting. Eur Heart J, 2002;23:869-876
10 Nallamothu BK, Bates ER. Periprocedural myocardial infarction and mortality: causality versus association. J Am Coll Cardiol. 2003;42:1412-1414
11 Ioannidis JPA, Karvouni E, Katritis DG. Mortality risk conferred by smallelevations of creatine kinase-MB isoenzyme after percutaneous intervenion. J Am Coll Cardiol. 2003;42:1406-1411
12 Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet, 1994;344:1383-1389
13 Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia: West of Scotland Coronary Prevention Study Group. N Engl J Med. 1995;333:1301-1307
14 Serruys PW, De Feyter P, Macaya C, et al. Lescol Intervention Prevention Study (LIPS) Investigators. Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention: a randomized controlled trial. JAMA, 2002;287:3215-3222
15 Ding Chao, Fu Xianghua, He Zhenshan, et al. Cardioprotective effects of simvastatin on reversing electrical remodeling induced by myocardial ischemia-reperfusion in normcholesterolemic rabbits. Chinese Medical Journal. 2008;121:551-556
16 Schwartz GG, Olsson AG, Ezekowitz MD, Ganz P, Oliver MF, Waters D, Zeiher A, Chaitman BR, Leslie S, Stern T, Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study Investigators. Effects of storvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL Study, a randomized controlled trial. JAMA, 2001,285:1711-1718
17 Cannon CP, Braunwald E, McCabe CH, et al. Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 Investigators. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med, 2004;350:1495-1504
18 de Lemos JA, Blazing MA, Wiviott MB, et al. A to Z Investigators. Early intensive vs delayed conservative simvastatin strategy in patients with acute coronary syndrome. Phase Z of the A to Z trial. JAMA, 2004;292:1307-1316
19 Fu XH, Fan WZ, Gu XS, et al. Effect of intracoronary administration of anisodamine on slow reflow phenomenon following primary percutaneouscoronary intervention in patients with acute myocardial infarction. Chin Med J 2007; 120: 1226-1231.
20 Lee HC, An SG, Choi JH, et al. Effect of intra-coronary nicarandil administration prior to reperfusion in acute ST segment elevation myocardial infarction. Circ J. 2008;72:1425-1429.
21 Matsuo H, Watanabe S, Watanabe T, et al. Prevention of no-reflow/slow-flow phenomenon during rotational atherectomy--a prospective randomized study comparing intracoronary continuous infusion of verapamil and nicorandil. Am Heart J. 2007;154:994.e1-e6
22 Shinozaki N, Ichinose H, Yahikozawa K, et al. Selective intracoronary administration of nitroprusside before balloon dilatation prevents slow reflow during percutaneous coronary intervention in patients with acute myocardial infarction. Int Heart J. 2007;48:423-433
23 Haendeler J, Hoffmann J, Zeiher AM, et al. Antioxidant effects of statins via S-nitrosylation and activation of thioredoxin in endothelial cells: a novel vasculoprotective function of statins. Circulation. 2004;110:856-861
24 Liu PY, Liu YW, Lin LJ, et al. Evidence for Statin Pleiotropy in Humans. Differential Effects of Statins and Ezetimibe on Rho-Associated Coiled-Coil Containing Protein Kinase Activity, Endothelial Function, and Inflammation. Circulation. 2009;119(1):131-138
25 Sanguigni V, Pignatelli P, Lenti L, et al. Short-term treatment with atorvastatin reduces platelet CD40 ligand and thrombin generation in hypercholesterolemic patients. Circulation. 2005;111:412-419
26 Chello M, Goffredo C, Patti G, et al. Effects of atorvastatin on arterial endothelial function in coronary bypass surgery. Eur J Cariodothorac Surg. 2005; 28:805-810
27 Chyrchel M, Rakowski T, Rzeszutko L, et al. Effects of high-dose administered prior to coronary angioplasty on the incidence of cardiac events in patients with acute coronary syndrome. Kardiol Pol. 2006;64:1357-1362
28 Celik T, Iyisoy A, Yuksel UC, et al. The impact of admission C-reactive protein levels on the development of no-reflow phenomenon after primaryPCI in patients with acute myocardial infarction: The role of inflammation. Int J Cardiol. 2009;136(1):86-88
29 Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359:2195-207
30 Patti G, Chello M, Pasceri V, et al. Protection from procedural myocardial injury by atorvastatin is associated with lower levels of adhesion molecules after percutaneous coronary intervention: results from the ARMYDA-CAMs (Atorvastatin for Reduction of Myocardial Damage during Angioplasty-Cell Adhesion Molecules) substudy. J Am Coll Cardiol. 2006;48:1560-1566
31 Yang YJ, Qian HY, Huang J, et al. Atorvastatin treatment improves survival and effects of implanted mesenchymal stem cells in post-infarct swine hearts. Eur Heart J. 2008; 29:1578-1590
1 Vrints CJ. Pathophysiology of the no-reflow phenomenon. Acute Card Care. 2009;11(2):69-76
2 Ito H, Maruyama A, Iwakura K, et al. Clinical implications of the no reflow phenomenon: a predictor of complications and left ventricular remodeling in reperfused anterior wall myocardial infarction. Circulation, 1996, 93:223-228
3 Kloner RA, Ganote CE, Jennings RB. The“no reflow”phenomenon after temporary coronary occlusion in the dog. J Clin Invest, 1974, 54:1496-1508
4 Tesic MB, Stankovic G, Vukcevic V, Ostojic MCThe use of intracoronary sodium nitroprusside to treat no-reflow after primary percutaneous coronary intervention in acute myocardial infarction. Herz. 2010;35(2):114-118.
5 Iwasaki K, Samukawa M, Furukawa H et al. Comparison of the effects of nicorandil versus verapamil on the incidence of slow flow/no reflow during rotational atherectomy. Am J Cardiol. 2006;98(10):1354-1356
6 Zhao JL, Yang YJ, Cui CJ, et al. Different effects of adenosine and calcium channel blockade on myocardial no-reflow after acute myocardial infarction and reperfusion. Cardiovasc Drugs Ther. 2006;20(3):167-175
7 Hale SL, Kloner RA. Cardioprotection with adenosine-regulating agent, GP531: effects on no-reflow, infarct size, and blood flow following ischemia/ reperfusion in the rabbit. J Cardiovasc Pharmacol Ther. 2010;15(1):60-67
8 FU Xiang-hua, HAO Qing-qing, JIA Xin-wei et al. Effect of tirofiban plus clopidogrel and aspirin on urgent percutaneous coronary intervention via transradial approach in patients with acute myocardial infarction. Chinese Medical Journal.2008;121(6):522-527
9 Fischell TA. Pharmaceutical interventions for the management of no-reflow. J Invasive Cardiol. 2008;20(7):374-379
10 Maluenda G, Ben-Dor I, Delhaye C, et al. Clinical Experience with a Novel Intracoronary Perfusion Catheter to Treat No-Reflow Phenomenon in Acute Coronary Syndromes J Interv Cardiol. 2010 Mar 12. [Epub ahead of print]
11 Ndrepepa G, Tiroch K, Keta D, et al. Predictive factors and impact of noreflow after primary percutaneous coronary intervention in patients with acute myocardial infarction. Circ Cardiovasc Interv. 2010;3(1):27-33
12刑卉春,赵龙凤,王守义。山莨菪碱对大鼠急性肝损伤的保护作用及其机制.中国危重病急救医学,1998,10:658-660
13范卫泽,傅向华,姜云发等,冠脉内应用山莨菪碱对急性心肌梗塞患者经皮冠状动脉介入治疗中冠脉无复流、心功能和心室收缩同步性的影响。中华心血管病杂志,2007;35(10)908-913
14 Haendeler J, Hoffmann J, Zeiher AM, et al. Antioxidant effects of statins via S-nitrosylation and activation of thioredoxin in endothelial cells: a novel vasculoprotective function of statins. Circulation. 2004;110:856-861
15 Liu PY, Liu YW, Lin LJ, et al. Evidence for Statin Pleiotropy in Humans. Differential Effects of Statins and Ezetimibe on Rho-Associated Coiled-Coil Containing Protein Kinase Activity, Endothelial Function, and Inflammation. Circulation. 2008 (Epub ahead of print).
16 Sanguigni V, Pignatelli P, Lenti L, et al. Short-term treatment with atorvastatin reduces platelet CD40 ligand and thrombin generation in hypercholesterolemic patients. Circulation. 2005;111:412-419
17 Chello M, Goffredo C, Patti G, et al. Effects of atorvastatin on arterial endothelial function in coronary bypass surgery. Eur J Cariodothorac Surg. 2005; 28:805-810
18 Schwartz GG, Olsson AG, Ezikowitz MD, et al. Myocardial Ischemia Reduction with Aggressive Cholesterol-lowering (MIRACL) Study Investigators: Effects of atovastatin on early recurrent ischemic events in acute coronary syndrome: the MIRACL study. JAMA 2001;285:1711-1718
19 Pedersen TR, Faergeman O, Kastelein JJ, et al. Incremental Decrease in End Points Through Aggressive Lipid Lowering (IDEAL) Study Group. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. JAMA 2005; 294:2437-2445
20 Pasceri V, Patti G, Nusca A, Pristipino C, et al. Randomized trial of atorvastatin for reduction of myocardial damage during coronary intervention,Results from the ARMYDA (Atorvastatin for Reduction of Myocardial Damage during Angioplasty) study. Circulation 2004;110:674-678
21 Jia Xinwei,Fu Xianghua, Zhang Jing, et al. Intensive cholesterol lowering with statin improves the outcomes of percutaneous coronary intervention in patients with acute coronary syndrome Chinese Medical Journal, 2009;122(6):659-664
22 Patti G, Pasceri V, Colonna G, et al. Atorvastatin pretreatment improves outcomes in patients with acute coronary syndromes undergoing early percutaneous coronary intervention: results of the ARMYDA-ACS randomized trial J Am Coll Cardiol. 2007;49(12):1272-1278
23 Di Sciascio G, Patti G, Pasceri V, et al. Clopidogrel reloading in patients undergoing percutaneous coronary intervention on chronic clopidogrel therapy: results of the ARMYDA-4 RELOAD (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty) randomized trial. Eur Heart J. 2010 Apr 2. [Epub ahead of print]
24蔚永运,傅向华,刘君等,冠状动脉内注射山莨菪碱对急性心肌梗死介入治疗后缓再血流现象的作用,临床心血管病杂志,2006;22(1):21-24
25 Settergren M, B?hm F, Rydén L, et al. Cholesterol lowering is more important than pleiotropic effects of statins for endothelial function in patients with dysglycaemia and coronary artery disease. Eur Heart J. 2008 Jul;29(14):1753-60
26 Pasceri V, Cheng JS, Willerson JT, et al. Modulation of C reactive protein mediated monocyte chemoattractant protein 1 induction in human endothelial cells by anti atherosclerosis drugs. Circulation ,2001,103:2531-2534
27 Sanchez A, Mirabel JL, Barrenechea E, et al. Evaluation of an improved immunoturbidimetric assay for serum C reactive protein on a COBAS ITEGRA 400 Analyzer. Clin Lab,2002,48:313-317
28 Yamashiya H,Shimada K,Seki E, et al. Concentration of interleukins, interferon and C reactive protein in stable and unstable angina pectoris. Am J Cardiol 2003,91:133-136
29 Rosendo AB, Lima LO, Dal-Pizzol F, et al. Lipid and C-Reactive Protein Levels, Cardiovascular Disease Risk Factors and Simvastatin Treatment in Brazilian Individuals. Inflammation. 2010 Jan 19. [Epub ahead of print]
30 Poupko JM, Baskin SI, Moore E. The pharmacological properties of anisodamine J Appl Toxicol. 2007;27(2):116-121
31 Vrints CJ. Pathophysiology of the no-reflow phenomenon. Acute Card Care. 2009;11(2):69-76
32 Schmidt-Lucke C, Fichtlscherer S, R?ssig L, et al. Improvement of endothelial damage and regeneration indexes in patients with coronary artery disease after 4 weeks of statin therapy. Atherosclerosis. 2010 Feb 13. [Epub ahead of print]
1 Bartholomew BA, Harjai KJ, Dukkipati S, et al. Impact of nephropathy after percutaneous coronary intervention and a method for risk stratification. Am J Cardiol 2004;93:1515-1519
2 Sadeghi HM, Stone GW, Grines CL, et al. Impact of renal insufficiency in patients undergoing primary angioplasty for acute myocarial infarction. Circulation 2003;108:2769-2775
3 Marenzi G, Lauri G, Assanelli E, et al. Contrast-induced nephropathy in patients undergoing primary angioplasty for acute myocardial infarction. J Am Coll Cardiol 2004;44:1780-1785
4 Lindsay J, Canos DA, Apple S, et al. Causes of acute renal dysfunction after percutaneous coronary intervention and comparison of late mortality rates with postprocedure rise of creatine kinase-MB versus rise of serum creatinine. Am J Cardiol 2004;94:786-789
5 Dangas G, Iakovou I, Nikolsky E, et al. Contrast-induced nephropathy after percutaneous coronary intervenions in relation to chronic kidney disease and hemodynamic variables. Am J Cardiol 2005;95:13-19
6 Peter A, McCullough. Contrast-induced acute kidney injury.J Am Coll Cardiol 2008;51;1419-1428
7 Birck R, Krzossok S, Markowetz F, et al. Acctylcysteine for prevention of contrast nephropathy; meta-nanalysis. Lancet 2003;362:598-603
8 McCullough PA, Adam A, Becker CR, et al. Risk prediction of contrast-induced nephropathy. Am J Cardiol 2006;98:27k-36k
9 Mchran R, Aymong ED, Nikolsky E, et al. A simple risk score for prediction of contrast-induced nephropathy agter percutaneous coronary intervention: development and initial validation. J Am Coll Cardiol 2004;44:1393-1399
10 Mueller C, Buerkle G, Buettner HJ, et al. Prevention of contrast media-associated nephropathy: randomized comparison of 2 hydration regimens in 1620 patients undergoing coronary angioplasty. Arch Intern Med 2002;162:329-336
11 Marenzi G, Lauri G, Campodonico J, et al.Comparison of two hemofiltration protocols for prevention of cintrast-induced nephropathy in high risk patients. Am J Med 2006;119:155-162
12 Stacul F, Adam A, Becker CR, et al. Strategics to reduce the risk of contrast-induced nephropathy. Am J Cardiol 2006;98:59k-77k
13 Spargias K, Alcxopoulos E, Kyrzopoulos S, et al. Ascorbic acid prevents contrast-mediated nephropathy in patients with renal dysfunction undergoing coronary angiography or intervention. Circulation 2004;110:2837-2842
14 Marenzi G, Assanelli E, Marana I, et al. N-acctylcystiene and contrast-induced nephropathy in primary angioplasty. N Engl J Med 2006;354:2773-2782
15 Briguori C, Airoldi F, D’Andrea D, et al. Renal insufficiency folllowing contrast media administration trial (REMEDIAL): a randomized comparison of 3 preventive strategics. Circulation 2007;115:1211-1217
16 McCullough PA, Rocher LR. Statin therapy in renal disease: harmful or protective. Curr Atheroscler Rep 2007;9:18-24
17 Chcllo M, Barbato R, Patti G, et al. Prevention of postoperative acute renal failure by statin therapy in patients undergoing cardiac surgery. J Am Coll Cardiol 2008. In press
18 Khanal S, Attallah N, Smith DE, et al. Statin therapy reduces contrast-induced mephropathy: an analysis of contemporary percutaneous interventions. Am J Med 2005;18:843-849
19 Patti G, Nusca A, Chello M, et al. Usefulness of statin pretreatment to prevent contrast-induced nephropathy and to improve long-term outcomes in patients undergoing percutaneous coronary intervention. Am J Cardiol 2008;101:279-285
20 Athyros VG,Mikhailidis DP, Papageorgious AA, et al. The effect of statins versus untreated dyslipidaemia on renal function in patients with coronary heart disease. A subgroup analysis of the Greek atorvastatin and coronary heart disease evaluation (GREACE) study. J Clin Pathol,2004;57:728-734
21 Khanal S, Attallah N, Simth DE, et al, Statin therapy reduces contrast-inducednephropathy: An analysis of contemporary percutaneous interventions. The American Journal of Medicine,2005;118:843-849
22 Patti G, Nusca A, Chello M, et al. Usefulness of statin pretreatment to prevent contrast-induced nephropathy and to improve long-term outcome in patients undergoing percutaneous coronary intervention. Am J Cardiol, 2008; 101:279-285
23 Zhao JL, Yang YJ, Zhang YH, et al. Effect of statins on contrast-induced nephropathy in patients with acute myocardial infarction treated with primary angioplasty. International journal of cardiology,2008;126:435-436
24 Pedersen TR, Faergeman O, Kastelein JJ, et al. Incremental Decrease in End Points Through Aggressive Lipid Lowering (IDEAL) Study Group.High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. JAMA. 2005;16;294(19):2437-45
25 Murphy SA, Cannon CP, Wiviott SD, et al. Effect of intensive lipid-lowering therapy on mortality after acute coronary syndrome (a patient-level analysis of the Aggrastat to Zocor and Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 trials). Am J Cardiol. 2007 Oct 1;100(7):1047-51. Epub 2007 Jul 18
26 LaRosa JC, Grundy SM, Kastelein JJ, et al. Treating to New Targets (TNT) Steering Committee and Investigators. Safety and efficacy of Atorvastatin-induced very low-density lipoprotein cholesterol levels in Patients with coronary heart disease (a post hoc analysis of the treating to new targets [TNT] study). Am J Cardiol. 2007 Sep 1;100(5):747-52. Epub 2007 Jun 14
27 Grundy SM, Cleeman JI, Merz CNB, et al. Implications of recent clinical trials form the National Cholesterol Education Program adult treatment panel III guidelines. [J] Circulation, 2004, 110(2):227-239
28 Rihal CS, Textor SC, Grill DE, et al. Incidence and prognostic importance of acute renal failure after percutaneous coronary intervention. Circulation 2002; 105:2259-64
29 Lindsay J, Apple S, Pinnow EE, et al. Percutaneous coronary intervention-associated nephropathy foreshadows inncreased risk of late adverse events in patients with normal baseline serum creatinine. Catheter Cardiovasc Ieterv 2003; 59:338-43
30 Cannon CP, Braunwald E, McCabe CH, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndrome. N Engl J Med 2004;350:1495-1504
31 Schwartz GG, Olsson AG, Ezikowitz MD, et al. The Myocardial Ischemia Reduction with Aggressive Cholesterol-lowering (MIRACL) Study Investigators: Effects of atovastatin on early recurrent ischemic events in acute coronary syndrome: the MIRACL study. JAMA 2001;285:1711-1718
32 Pedersen TR, Faergeman O, Kastelein JJ, et al. Incremental Decrease in End Points Through Aggressive Lipid Lowering (IDEAL) Study Group. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. JAMA 2005; 294:2437-2445
33 Patti G, Chello M, Pasceri V, et al. Protection from procedural myocardial injury by atorvastatin is associated with lower levels of adhesion molecules after percutaneous coronary intervention: results from the ARMYDA-CAMs(Atorvastatin for Reduction of Myocardial Dmamge during Angioplasty-Cell Adhesion Molecules) substudy. J Am Coll Cardiol. 2006;48(8):1560-1566
34 Patti G, Pasceri V, Colonna G, et al. Atorvastatin pretreatment improves outcomes in patients with acute coronary syndromes undergoing early percutaneous coronary intervention: results of the ARMYDA-ACS randomized trial. J Am Coll Cardiol 2007;49(12):1272-1278
35 Tumlin J, Stacul F, Adam A, et al. on behalf of the CIN Consensus Working Panel. Pathophysiology of contrast-induced nephropathy. Am J Cardiol 2006;98(suppl):14k-20k
36 Chello M, Goffredo C, Patti G, et al. Effects of atorvastatin on arterial endothelial function in coronary bypass surgery. Eur J Caridothorac Surg 2005; 28:805-810
1 McCullough PA, Soman SS. Contrast-induced nephropathy[J]. Crit Care Clin, 2005,21(2):261-280
2 Chew DP, Astley C, Molloy D, et al. Morbidity, mortality and ecconomic burden of renal impairment in cardiac intensive care[J]. Intern Med J, 2006,36(3):185-192
3 Bagshaw SM, Mortis G, Doig CJ, et al. One-year mortality in critically ill patients by severity of kidney dysfunction: a population-based assessment [J]. Am J Kidney Dis, 2006,48(3):402-409
4 Nash K, Hafeez A, Hou S. Hospital-acquired renal insufficiency[J]. Am J Kidney Dis, 2002,39(5):930-936
5 Joyce M, Kelly C, Winter D, et al. Pravastatin, a 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor, attenuates renal injury in an experimental model of ischemia-reperfusion. Journal of surgical research. 2001; 101(1):79-84
6 McCullough PA, Adam A, Becker CR, et al. Risk prediction of contrast-induced nephropathy[J]. Am J Cardiol, 2006,98(6A):27k-36k.
7 Mchran R, Aymong ED, Nikolsky E, et al. A simple risk score for prediction of contrast-induced nephropathy after percutaneous coronary intervention: development and initial validation. J Am Coll Cardiol, 2004, 44(7):1393-1399
8 Bonventre J. Mechanism of ischemic acute renal failure. Kidney Int.1993;43:1160
9 Nouwen EJ, Verstrepen WA, Buyssen N, et al. Hyperplasia, hypertrophy, and phenotypic alterations in the distal nephron after acute proximal tubular injury in the rat. Lab Invest.1994;79:479
10 Racusen L, Firush B, Li YL, et al. Dissociation of tubular cell detachment and tubular cell death in clinical and experimental“acute tubular necrosis”. Lab Invest. 1987;56:273
11 Granata A, Andrulli S, Bigi MQ, et al. Predictive role of duplex Doppler ultrasonography in the diagnosis of acute renal obstruction in patients with unilateral renal colic Clin Nephrol. 2009 Jun;71(6):680-6
12 Jimenez C, Lopez MO, Gonzalez E, et al. Ultrasonography in kidney transplantation: values and new developments. Transplant Rev (Orlando). 2009 Oct;23(4):209-13. Epub 2009 Aug 4
13 Garcia-Covarrubias L, Martinez A, Morales-Buenrostro LE, et al. Parameters of Doppler ultrasound at five days posttransplantation as predictors of histology and renal function at one year. Transplant Proc. 2010 Jan-Feb; 42(1):262-5
14 Shimizu Y, Itoh T, Hougaku H, et al. Clinical usefulness of duplex ultrasonography for the assessment of renal arteriosclerosis in essential hypertensive patitents. Hypertens Res.2001,24(1):13-17
15 Pontremoli R, Viazzi F, Martinoli C, et al. Increased renal resistive index in patients with essential hypertension: a marker of target organ damages. Nephrol Dial Transplant.2003,14:360-365
16 Peterseen LJ, Petersen JR, Talleruphus U, et al. The pulsatility index and resistive index in renal arteries associations with long-term progression in chronic renal failure. Nephrol Dial Transplant, 2005;12:1376-1380
17 Cronin RE. Contrast-induced nephropathy: pathogenesis and prevention. Pediatr Nephrol. 2010 Feb;25(2):191-204
1 McCullough PA, Soman SS. Contrast-induced nephropathy[J]. Crit Care Clin, 2005,21(2):261-280
2 Nash K, Hafeez A, Hou S. Hospital-acquired renal insufficiency[J]. Am J Kidney Dis, 2002,39(5):930-936
3 Chew DP, Astley C, Molloy D, et al. Morbidity, mortality and ecconomic burden of renal impairment in cardiac intensive care[J]. Intern Med J, 2006,36(3):185-192
4 Bagshaw SM, Mortis G, Doig CJ, et al. One-year mortality in critically ill patients by severity of kidney dysfunction: a population-based assessment [J]. Am J Kidney Dis, 2006,48(3):402-409
5 Sarafidis PA,Statin Pleiotropy Against Renal Injury J Cardiometab Syndr. 2009;4: E4–E9
6 Zhou MS, Jaimes EA, Raij L. Atorvastatin prevents end-organ injury in salt-sensitive hypertension: role of eNOS and oxidant stress. Hypertension. 2004;44:186–190
7 Athyros VG, Mikhailidis DP, Papageorgious AA, et al. The effect of statins versus untreated dyslipidaemia on renal function in patients with coronary heart disease. A subgroup analysis of the Greek atorvastatin and coronary heart disease evaluation (GREACE) study. J Clin Pathol,2004;57:728-734
8 Khanal S, Attallah N, Simth DE, et al, Statin therapy reduces contrast-induced nephropathy: An analysis of contemporary percutaneous interventions. The American Journal of Medicine,2005;118:843-849
9 Patti G, Nusca A, Chello M, et al. Usefulness of statin pretreatment to prevent contrast-induced nephropathy and to improve long-term outcome in patients undergoing percutaneous coronary intervention. Am J Cardiol, 2008; 101:279-285
10 Zhao JL, Yang YJ, Zhang YH, et al. Effect of statins on contrast-induced nephropathy in patients with acute myocardial infarction treated with primary angioplasty. International journal of cardiology,2008;126:435-436
11 Shepherd J, Kastelein P, Bittner V, et al. Intensive lipid lowering with atorvastatin in patients with coronary heart disease and chronic kidney disease. The TNT (Treating to New Targets) Study. J Am Coll Cardiol, 2008; 51:1448-1454
12 Jia Xinwei, Fu Xianghua, Zhang Jing, et al. Comparison of usefulness of simvastatin 20 mg versus 80 mg in preventing contrast-induced nephropathy in patiants with acute coronary syndrome undergoing percutaneous coronary intervention. American journal of cardiology,2009;104(4): 519-524
13范卫泽,傅向华,姜云发等,冠脉内应用山莨菪碱对急性心肌梗塞患者经皮冠状动脉介入治疗中冠脉无复流、心功能和心室收缩同步性的影响。中华心血管病杂志,2007;35(10)908-913
14蔚永运,傅向华,刘君,急性心急梗死经皮冠脉介入治疗后无复流现象及654-2的干预,中国急救医学,2006;26(2):95-97
15蔚永运,傅向华,刘君等,冠状动脉内注射山莨菪碱对急性心急梗死介入治疗后缓再血流现象的作用,临床心血管病杂志,2006;22(1):21-24
16蔚永运,傅向华,刘君等,冠脉内注射山莨菪碱对急性心急梗死经皮介入介入术后缓再血流现象的影响,中国中西医结合杂志,2008;28(4):295-299
17刘晓城,唐望先。山莨菪碱治疗兔缺血性急性肾功能衰竭的实验研究,中国急救医学,1999;19(5):259-261
18吴广礼,温进坤,韩梅等,山莨菪碱、旋覆花素、苦碟子对过度训练大鼠肾细胞凋亡的影响,中华麻醉学杂志,2007;27(5):463-466
19潘光辉,白寒,陈彤等,山莨菪碱防治甘油所致急性肾功能衰竭的实验研究,中国病理生理杂志,1997;13(6):615-618
20唐望先,刘晓城,邵菊芳等,山莨菪碱对急性肾缺血再灌注损伤的保护机制,中华实验外科杂志,1997;14(5):304-305
21陈志勇,廖立生,张风等,山莨菪碱对毒蕈所致大鼠急性肾损伤的保护作用,肾脏病与透析肾移植杂志,1995;4(3):240-241
22刘晓城,唐望先,吕永曼等,山莨菪碱对兔急性肾缺血及再灌注损伤时肾小管超微病理变化的影响,同济医科大学学报,1998;27(5):380-382
23吴广礼,温进坤,韩梅等,山莨菪碱对过度训练大鼠急性肾损伤的保护作用,中国微循环,2006;10(4)241-244
24吴广礼,郑秋月,田牛等,樟柳碱、东莨菪碱、山莨菪碱对急性肾衰大鼠肾微血管损伤的保护作用,微循环杂志,2002;12(1):6-8
25周智广,廖二元,伍汉文等,糖尿病患者肾血浆流量的变化及山莨菪碱治疗的影响,湖南医科大学学报,1994;19(2):122-124
26吴广礼,张丽霞,张文玉等,内皮素在过度训练致大鼠急性肾损伤中的作用及山莨菪碱的干预效应,中国中西医结合杂志,2009;10(2):120-123
27吴广礼,黄旭。过度训练大鼠肾组织细胞凋亡的基因调控机制及山莨菪碱干预的影响,解放军医学杂志,2008;33(10):1209-1211
28 McCullough PA, Adam A, Becker CR, et al. Risk prediction of contrast-induced nephropathy[J]. Am J Cardiol, 2006,98(6A):27k-36k
29 Mchran R, Aymong ED, Nikolsky E, et al. A simple risk score for prediction of contrast-induced nephropathy after percutaneous coronary intervention:development and initial validation[J]. J Am Coll Cardiol, 2004, 44(7):1393-1399
30 Stacul F, Adam A, Becker CR, et al. Strategies to reduce the risk of contrast-induced nephropathy[J]. Am J Cardiol, 2006,98(6A):59k-77k
31 Joyce M, Kelly C, Winter D, et al. Pravastatin, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, attenuates renal injury in an experimental model of ischemia-reperfusion. J Surg Res. 2001;101:79–84
32 Pisani A, Uccello F, Cesaro A, et al. Effects of atorvastatin on ischemic acute renal failure in aging rats. G Ital Nefrol. 2002; 19:534–539
33 Schwartz IF, Ayalon R, Chernichovski T, et al. Arginine uptake is attenuated through modulation of cationic amino-acid transporter-1, in uremic rats. Kidney Int. 2006;69:298–303
34 Granata A, Andrulli S, Bigi MQ, et al. Predictive role of duplex Doppler ultrasonography in the diagnosis of acute renal obstruction in patients with unilateral renal colic Clin Nephrol. 2009 Jun;71(6):680-686
35 Jimenez C, Lopez MO, Gonzalez E, et al. Ultrasonography in kidney transplantation: values and new developments. Transplant Rev (Orlando).2009 Oct;23(4):209-213
36 Garcia-Covarrubias L, Martinez A, Morales-Buenrostro LE, et al. Parameters of Doppler ultrasound at five days posttransplantation as predictors of histology and renal function at one year. Transplant Proc. 2010 Jan-Feb;42(1):262-265
37 Bommart S, Cliche A, Therasse E, et al. Renal artery revascularization: predictive value of kidney length and volume weighted by resistive index. AJR Am J Roentgenol. 2010 May;194(5):1365-1372
38 Santos SN, Leite LR, Tse TS, et al. Renal resistance index predicting outcome of renal revascularization for renovascular hypertension Arq Bras Cardiol. 2010 Mar 26. pii: S0066-782X2010005000018. [Epub ahead of print]
39 Li JC, Jiang YX, Zhang SY, et al. Evaluation of renal artery stenosis with hemodynamic parameters of Doppler sonography J Vasc Surg. 2008 Aug;48(2):323-328
40 Wan L, Yang N, Hiew CY, et al. An assessment of the accuracy of renal blood flow estimation by Doppler ultrasound. Intensive Care Med. 2008 Aug;34(8):1503-10. Epub 2008 Apr 12
41 Verma A, Ranganna KM, Reddy RS, et al. Effect of rosuvastatin on C-reactive protein and renal function in patients with chronic kidney disease. Am J Cardiol. 2005;96:1290-1292
42 Ota T, Takamura T, Ando H, et al. Preventive effect of cerivastatin on diabetic nephropathy through suppression of glomerular macrophage recruitment in a rat model. Diabetologia. 2003;46:843-851
43 Usui H, Shikata K, Matsuda M, et al. HMG-CoA reductase inhibitor ameliorates diabetic nephropathy by its pleiotropic effects in rats. Nephrol Dial Transplant. 2003; 18:265-272
44 Park JK, Muller DN, Mervaala EM, et al. Cerivastatin prevents angiotensin II-induced renal injury independent of blood pressure- and cholesterol- lowering effects. Kidney Int. 2000;58:1420-430
45 Li H, Li X, Lin D, et al. Inhibition of lovastatin on proliferation and expression of proinflammatory cytokines in cultured human glomerularmesangial cells. Chin Med J. 2003;116:1366-1369
46 Massy ZA, Kim Y, Guijarro C, et al. Low-density lipoprotein-induced expression of interleukin-6, a marker of human mesangial cell inflammation: effects of oxidation and modulation by lovastatin. Biochem Biophys Res Commun. 2000;267:536-540
47 Sonmez A, Yilmaz MI, Korkmaz A, et al. Hyperbaric oxygen treatment augments the efficacy of cilazapril and simvastatin regimens in an experimental nephrotic syndrome model. Clin Exp Nephrol. 2008;12:110-118
48 Yagi S, Aihara K, Ikeda Y, et al. Pitavastatin, an HMG-CoA reductase inhibitor, exerts eNOS-independent protective actions against angiotensin II induced cardiovascular remodeling and renal insufficiency. Circ Res. 2008;102:68-76
49 Liang XM, Otani H, Zhou Q, et al. Renal protective effects of pitavastatin on spontaneously hypercholesterolaemic Imai Rats. Nephrol Dial Transplant. 2007;22:2156-2164
50 Gueler F, Rong S, Park JK, et al. Postischemic acute renal failure is reduced by short-term statin treatment in a rat model. J Am Soc Nephrol. 2002;13: 2288-2298
51 Whaley-Connell A, Habibi J, Nistala R, et al. Attenuation of NADPH oxidase activation and glomerular filtration barrier remodeling with statin treatment. Hypertension. 2008;51:474-480
52 Ott C, Schlaich MP, Schmidt BM, et al. Rosuvastatin improves basal nitric oxide activity of the renal vasculature in patients with hypercholesterolemia. Atherosclerosis. 2008;196:704-711
53 Moriyama T, Kawada N, Nagatoya K, et al. Fluvastatin suppresses oxidative stress and fbrosis in the interstitium of mouse kidneys with unilateral ureteral obstruction. Kidney Int. 2001;59:2095-2103
1 LaRosa JC, Hunninghake D, Bush D, et al. The cholesterol facts. A summary of the evidence relating dietary fats, serum cholesterol, and coronary heart disease. A joint statement by the American Heart Association and the National Heart, Lung, and Blood Institute. The Task Force on Cholesterol Issues, American Heart Association. Circulation. 1990;81(5):1721-1733
2 Castelli WP. Epidemiology of coronary heart disease: the Framingham study. Am J Med. 1984;27;76(2A):4-12
3 Endo A, Kuroda M, Tanzawa K. Competitive inhibition of3- hydroxy-
3-methylglutaryl coenzyme A reductase by ML-236A and ML-236B fungal metabolites, having hypocholesterolemic activity FEBS Lett. 1976;72(2):323-326
4 Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA. 1998;279(20):1615-1622
5 Barringer TA 3rd. WOSCOPS. West of Scotland Coronary Prevention Group. Lancet. 1997 Feb 8;349(9049):432-433
6 Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S) Lancet. 1994;19;344(8934):1383-1389
7 Flaker GC, Warnica JW, Sacks FM, et al. Pravastatin prevents clinical events in revascularized patients with average cholesterol concentrations. Cholesterol and Recurrent Events CARE Investigators. J Am Coll Cardiol. 1999;34(1):106-112
8 LaRosa JC, Grundy SM, Kastelein JJ, et al. Safety and efficacy of Atorvastatin-induced very low-density lipoprotein cholesterol levels in Patients with coronary heart disease (a post hoc analysis of the treating to new targets [TNT] study). Am J Cardiol. 2007;100(5):747-52
9 Cannon CP, Braunwald E, McCabe CH, et al. Comparison of intensive and moderate lipid lowering with statins after acute coronary syndroms. N Engl JMed, 2004, 350(15):1495-1504
10 LaRosa JC, Grundy SM, Water DD, et al. Intensive lipid lowering with atovastatin in patients with stable coronary disease. N Engl J Med, 2005, 352
11 Pedersen TR. Incremental Decrease in End Points Through Aggressive Lipid Lowering study.JAMA,2005;294:2437-2444
12 Pedersen TR, Faergeman O, Kastelein JJ, et al. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. JAMA. 2005;16; 294(19): 2437-2445
13 Shepherd J, Blauw GJ, Murphy MB,et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet. 2002 Nov 23;360(9346):1623-1630
14 Sever PS, Poulter NR, Dahl?f B,et al. Different time course for prevention of coronary and stroke events by atorvastatin in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid-Lowering Arm (ASCOT-LLA). Am J Cardiol. 2005;96(5A):39F-44F
15 Farmer JA, Gotto AM Jr, et al. The Heart Protection Study: expanding the boundaries for high-risk coronary disease prevention. Am J Cardiol. 2003 ;92(1A):3i-9i
16 Murphy SA, Cannon CP, Wiviott SD, et al. Effect of intensive lipid-lowering therapy on mortality after acute coronary syndrome (a patient-level analysis of the Aggrastat to Zocor and Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 trials). Am J Cardiol. 2007;100(7):1047-1051.
17 LaRosa JC, Grundy SM, Kastelein JJ, et al. Safety and efficacy of Atorvastatin-induced very low-density lipoprotein cholesterol levels in Patients with coronary heart disease (a post hoc analysis of the treating to new targets [TNT] study). Am J Cardiol. 2007;100(5):747-52
18 Grundy SM, Cleeman JI, Merz CNB, et al. Implications of recent clinical trials form the National Cholesterol Education Program adult treatment panel III guidelines. Circulation, 2004, 110(2):227-239
19 Haendeler J, Hoffmann J, Zeiher AM, et al. Antioxidant effects of statins via S-nitrosylation and activation of thioredoxin in endothelial cells: a novel vasculoprotective function of statins. Circulation. 2004;110:856-861
20 Liu PY, Liu YW, Lin LJ, et al. Evidence for Statin Pleiotropy in Humans. Differential Effects of Statins and Ezetimibe on Rho-Associated Coiled-Coil Containing Protein Kinase Activity, Endothelial Function, and Inflammation. Circulation. 2009;119(1):131-138
21 Sanguigni V, Pignatelli P, Lenti L, et al. Short-term treatment with atorvastatin reduces platelet CD40 ligand and thrombin generation in hypercholesterolemic patients. Circulation. 2005;111:412-419
22 19 Chello M, Goffredo C, Patti G, et al. Effects of atorvastatin on arterial endothelial function in coronary bypass surgery. Eur J Cariodothorac Surg. 2005; 28:805-810.
23 Shinohara K, Shoji T, Kimoto E, et al. Effect of atorvastatin on regional arterial stiffness in patients with type 2 diabetes mellitus. J Atheroscler Thromb. 2005,12(4):205-210
24 Raison J, Rudnichi A, Safar ME. Effects of atorvastatin on aortic pulse wave velocity in patients with hypertension and hypercholesterolaemia: a preliminary study. J Hum Hypertens. 2002,16(10):705-710
25 Rubba P. Effects of atorvastatin on the different phases of atherogenesis Drugs. 2007;67 Suppl 1:17-27
26 Choi SH, Chae A, Miller E, et al. Relationship between biomarkers of oxidized low-density lipoprotein, statin therapy, quantitative coronary angiography, and atheroma: volume observations from the REVERSAL (Reversal of Atherosclerosis with Aggressive Lipid Lowering) studyJ Am Coll Cardiol. 2008;1;52(1):24-32
27 Jensen LO, Thayssen P, Pedersen KE, et al. Regression of coronary atherosclerosis by simvastatin: a serial intravascular ultrasound study. Circulation, 2004,110(3):265-270
28 Lima JA,Desai MY, Steen H,et al. Statin-induced cholesterol lowering and plaque regression after 6 months of magnetic resonance imaging-monitoredtherapy. Circulation. 2004;110(16):2336-2341
29 Ding C, Fu XH, He ZS, et al. Cardioprotective effects of simvastatin on reversing electrical remodeling induced by myocardial ischemia-reperfusion in normocholesterolemic rabbits.Chin Med J (Engl). 2008;20;121(6):551-556
30 McCullough PA, Rocher LR. Statin therapy in renal disease: harmful or protective. Curr Atheroscler Rep 2007;9:18-24
31 Chyrchel M, Rakowski T, Rzeszutko L, et al. Effects of high-dose administered prior to coronary angioplasty on the incidence of cardiac events in patients with acute coronary syndrome. Kardiol Pol. 2006;64:1357-1362
32 Celik T, Iyisoy A, Yuksel UC, et al. The impact of admission C-reactive protein levels on the development of no-reflow phenomenon after primary PCI in patients with acute myocardial infarction: The role of inflammation. Int J Cardiol. 2009;136(1):86-88
33 Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359:2195-2207
34 Patti G, Chello M, Pasceri V, et al. Protection from procedural myocardial injury by atorvastatin is associated with lower levels of adhesion molecules after percutaneous coronary intervention: results from the ARMYDA-CAMs (Atorvastatin for Reduction of Myocardial Damage during Angioplasty-Cell Adhesion Molecules) substudy. J Am Coll Cardiol. 2006;48:1560-1566
35 Yang YJ, Qian HY, Huang J, et al. Atorvastatin treatment improves survival and effects of implanted mesenchymal stem cells in post-infarct swine hearts. Eur Heart J. 2008; 29:1578-1590
36 Atorvastatin pretreatment improves outcomes in patients with acute coronary syndromes undergoing early percutaneous coronary intervention: results of the ARMYDA-ACS randomized trial. J Am Coll Cardiol 2007; 49:1272-1278
37 Randomized trial of atorvastatin for reduction of myocardial damage during coronary intervention, Results from the ARMYDA (Atorvastatin for2004; 110: 674-678 Reduction of Myocardial Damage during Angioplasty) study. Circulation
1 Irani K. Oxidant signaling in vascular cell growth, death, and survival: a review of the roles of reactive oxygen species in smooth muscle and endothelial cell mitogenic and apoptotic signaling. Circ Res 2000;87:179-183
2 Fenster BE, Tsao S, Rockson SG et al, Endothelial dysfunction: Clinical strategies for treating oxidant stress. Am Heart J,2003;146:216-226
3 WAng HD, Xu S, Johns DG, et al. Role of NADPH oxidase in the vascular hypertrophic and oxidative stress response to Angiotensin II in mice. Circ Res, 2001;88:947-953
4 Azumi H, Inoue N, Takeshita S, et al. Expression of NADH/NADPH oxidase p22phox in human coronary arteries. Circulation, 1999;100:1494-1498
5 Cahilly C, Ballantyne CM, Lim DS et al. A variant of p22(phox) involved in generation of reactive oxygen species in the vessel wall, is associated with progression of coronary atheroscelerosis. Circ Res, 2000;86:391-385
6 Heitzer T, Brockhoff C, Mayer B,et al. Tetrahydrobiopterin improves endothelium-dependent vasodilation in chronic smokers: evidence for a dysfunctional nitric oxide synthase. Curc Res. 2000;86:E36-41
7 Mervaala EM, Cheng ZJ, Tikkanen I, et al. Endothelial dysfunction and xanthine oxidoreductase activity in rats with human renin and Angiotensinogen genes. Hypertension, 2001;37:414-418
8 Brtler R, Morris AD, Belch JJ, et al. Allopurinol mormalizes endothelial dysfunction in type 2 diabetics with mild hypertension. Hypertension, 000;35:746-751
9 Ting HH, Timimi FK, Boles KS, et al. Vitamin C improves endothelium- dependent vasodialtion in patients with non-insulin-dependent diabetes mellitus. J Clin Invest. 1996;97:22-28
10 Motoyama T, Kawano H, Kugiyama K, et al. Vitamin E administration improves impairment of endothelium-dependent vasodilation in patients with coronary spastic Angina. J Am Cardiol,1998;32:1672-1679
11 Elliott TG, Barth JD, Mancini GB. Effect of vitamin E on endothelial function in men after myocardial infarction. Am J Cardiol,1995;76:1188-1190
12 Mancini GB, Henry GC, Macaya C, et al. Angiotensin-converting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction in patients with coronary artery disease: the TREND (Trial on Reversing ENdothelial Dysfunction) Study. Circulation, 1996;94:258-265
13 Anderson TJ, Elstein E, Haber H, et al. Comparative study of ACE-inhibition, Angiotensin II antagonism, and calcium channel blockade on flow-mediated vasodilation in patients with coronary disease (BANFF study). J Am Coll Cardiol.2000;35:60-66
14 Yusuf S, Sleight P, Pogue J, et al. Effects of an Angiotensin- converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients: the Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med, 2000;342:145-153
15 Wilson SH, Simari RD, Best PJ, et al. Simvastatin preserves coronary endothelial function in hypercholesterolemia in the absence of lipid lowering, Arterioscler Thromb Vasc Biol, 2001;21:122-128
16 Wassmann S, Laufs U, Baumer AT, et al. HMG-COA reductase inhibitors improve endothelial dysfunction in normocholesterolemic hypertension viareduced production of reactive oxygen species. Hypertension, 2001;37: 1450-1457
17 Garg R, Kumbkarni Y, Aljado A, et al. Troglitazone reduces reactive oxygen apecise generation by leukocytes and lipid peroxidation and improves folw-mediated vasodilatation in obese subjects. Hypertension, 2000; 36: 430-435
18 Aljada A, Garg R, Ghanim H, et al. Nuclear factor-kappaB suppressive and inhibitor-kappaB stimulatory effects of troglitazone in obese patients with type 2 diabetes: evidence of an anti-inflammatory action? J Clin Endocrinol Metab. 2001;86:3250-3256
19 Mather KJ, Verma S, Anderson TJ, et al. Improved endothelial function with metformin in type 2 diabetes mellitus. J Am Coll Cardiol. 2001;37:1344-50.
20 Kanani PM, Sinkey CA, Browning RL, et al. Role of oxidant stress in endothelial dysfunction produced by experimental hyperhomocyst(e)inemia in humans. Circulation. 1999; 100:1161-1168
21 Raghuveer G, Sinkey CA, Clenard C, et al. Effect of vitamin E on resistance vessel endothelial dysfunction induced by methionine. Am J Cardiol. 2001; 88:285-290
22 Thambyrajah J, Landray MJ, Jones HJ, et al. A randomized double-blind placebo-controlled trial of the effect of homocysteine-lowering therapy with folic acid on endothelial function in patients with coronary artery disease. J Am Coll Cardiol. 2001;37:1858-1863
23 Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA, 1998;280:605-613
24 Brown BG, Zhao XQ, Chait A, et al. Simvastatin and niacin, antioxidant vitamins, for the prevention of coronary disease. N Engl J Med, 2001; 345:1583-1592
1 Niccoli G, Burzotta F, Galiuto L, et al. Myocardial no-reflow in humans. J Am Coll Cardiol,2009,54:281-292
2 Anderson JL, Karagounis LA, Califf RM.Metaanalysis of five reported studies on the relation of early coronary patency grades with mortality and outcomes after acute myocardial infarction. Am J Cardiol. 1996; 78(1):1-8
3 Cura FA, L'Allier PL, Kapadia SR, et al. Predictors and prognosis of suboptimal coronary blood flow after primary coronary angioplasty in patients with acute myocardial infarction. Am J Cardiol. 2001;88(2):124-128
4 Shah A, Wagner GS, Granger CB, et al. Prognostic implications of TIMI flow grade in the infarct related artery compared with continuous 12-lead ST-segment resolution analysis. Reexamining the "gold standard" for myocardial reperfusion assessment. J Am Coll Cardiol. 2000;35(3):666-672
5 Johnson TL, Topol EJ.Early, et al. Complete Infarct Vessel Patency: Arriving at a Gold Standard for Future Clinical Investigation in Myocardial Reperfusion. J Thromb Thrombolysis. 1997;4(2):259-266
6 Ito H, Okamura A, Iwakura K, Masuyama T, et al. Myocardial perfusion patterns related to thrombolysis in myocardial infarction perfusion grades after coronary angioplasty in patients with acute anterior wall myocardial infarction. Circulation. 1996;93(11):1993-1999
7 Ito H, Iwakura K, Oh H, Masuyama T, et al. Temporal changes in myocardial perfusion patterns in patients with reperfused anterior wall myocardial infarction. Their relation to myocardial viability. Circulation. 1995;91(3):656-662
8 Halkin A, Aymong E, Cox DA, et al. Relation between late patency of the infarct-related artery, left ventricular function, and clinical outcomes after primary percutaneous intervention for acute myocardial infarction (CADILLAC trial). Am J Cardiol. 2004;93(3):349-353
9 Ames A 3rd, Wright RL, Kowada M, et al. Cerebral ischemia. II. The no-reflow phenomenon. Am J Pathol. 1968;52(2):437-453
10 Krug A. Alterations in myocardial hydrogen ion concentration after temporary coronary occlusion: a sign of irreversible cell damage. Am J Cardiol. 1975;36(2):214-217
11 Kloner RA, Ganote CE, Jennings RB, et al. The "no-reflow" phenomenon after temporary coronary occlusion in the dog. J Clin Invest. 1974;54(6):1496-1508
12 DeGeare VS, Stone GW, Grines L, et al. Angiographic and clinical characteristics associated with increased in-hospital mortality in elderly patients with acute myocardial infarction undergoing percutaneous intervention (a pooled analysis of the primary angioplasty in myocardial infarction trials). Am J Cardiol. 2000;86(1):30-34
13 Resnic FS, Wainstein M, Lee MK, et al. No-reflow is an independent predictor of death and myocardial infarction after percutaneous coronary intervention. Am Heart J. 2003;145(1):42-46
14 Piana RN, Paik GY, Moscucci M, et al. Incidence and treatment of 'no-reflow' after percutaneous coronary intervention. Circulation. 1994;89(6):2514-2518
15 Abbo KM, Dooris M, Glazier S, et al. Features and outcome of no-reflow after percutaneous coronary intervention. Am J Cardiol. 1995;75(12):778-782
16 Ito H. No-reflow phenomenon in patients with acute myocardial infarction: its pathophysiology and clinical implications. Acta Med Okayama. 2009;63(4):161-168
17 Kloner RA, Ganote CE, Whalen DA Jr, et al. Effect of a transient period of ischemia on myocardial cells. II. Fine structure during the first few minutes of reflow. Am J Pathol. 1974;74(3):399-422
18 Ambrosio G, Tritto I. Reperfusion injury: experimental evidence and clinical implications. Am Heart J. 1999;138(2 Pt 2):S69-S75
19 Byrne JG, Smith WJ, Murphy MP, et al. Complete prevention of myocardial stunning, contracture, low-reflow, and edema after heart transplantation by blocking neutrophil adhesion molecules during reperfusion. J Thorac Cardiovasc Surg. 1992;104(6):1589-1596
20 Willerson JT, Scales F, Mukherjee A, et al. Abnormal myocardial fluid retention as an early manifestation of ischemic injury. Am J Pathol. 1977;87(1):159-188
21 Kunichika H, Ben-Yehuda O, Lafitte S, et al. Effects of glycoprotein IIb/IIIa inhibition on microvascular flow after coronary reperfusion. A quantitative myocardial contrast echocardiography study. J Am Coll Cardiol. 2004;43(2):276-283
22 Punch J, Rees R, Cashmer B, et al. Acute lung injury following reperfusion after ischemia in the hind limbs of rats. J Trauma. 1991;31(6):760-5; discussion 765-767
23 Grech ED, Dodd NJ, Jackson MJ, et al. Evidence for free radical generation after primary percutaneous transluminal coronary angioplasty recanalization in acute myocardial infarction. Am J Cardiol. 1996;77(2):122-127
24 Engler RL. Free radical and granulocyte-mediated injury during myocardial ischemia and reperfusion. Am J Cardiol. 1989;63(10):19E-23E
25 Baran KW, Nguyen M, McKendall GR, et al. Double-blind, randomized trial of an anti-CD18 antibody in conjunction with recombinant tissue plasminogen activator for acute myocardial infarction: limitation of myocardial infarction following thrombolysis in acute myocardial infarction (LIMIT AMI) study. Circulation. 2001;104(23):2778-2783
26 Sdringola S, Assali AR, Ghani M, et al. Risk assessment of slow or no-reflow phenomenon in aortocoronary vein graft percutaneous intervention. Catheter Cardiovasc Interv. 2001;54(3):318-324
27 Kotani J, Nanto S, Mintz GS, et al. Plaque gruel of atheromatous coronary lesion may contribute to the no-reflow phenomenon in patients with acute coronary syndrome. Circulation. 2002;106(13):1672-1677
28 Hamada S, Nishiue T, Nakamura S, et al. TIMI frame count immediately after primary coronary angioplasty as a predictor of functional recovery in patients with TIMI 3 reperfused acute myocardial infarction. J Am Coll Cardiol. 2001;38(3):666-671
29 De Luca G, Ucci G, Cassetti E, et al. Benefits from small molecule administration as compared with abciximab among patients with ST-segment elevation myocardial infarction treated with primary angioplasty: a meta-analysis. J Am Coll Cardiol, 2009,53:1668-1673
30 Van'T H A, Ten B J, Heestermans T, et al. Prehospital initiation of tirofiban in patients with ST-elevation myocardial infarction undergoing primary angioplasty (On-TIME 2): a multicentre, double-blind, randomised controlled trial. Lancet,2008,372(9638):537-546
31 Fu XH, Hao QQ, Jia XW, et al. Effect of tirofiban plus clopidogrel and aspirin on primary percutaneous coronary intervention via transradial approach in patients with acute myocardial infarction. Chin Med J (Engl). 2008;121(6):522-527
32 Sakuma T, Motoda C, Tokuyama T, et al. Exogenous adenosine triphosphate disodium administration during primary percutaneous coronary intervention reduces no-reflow and preserves left ventricular function in patients withacute anterior myocardial infarction: a study using myocardial contrast echocardiography. Int J Cardiol. 2010;140(2):200-209
33 Kopecky SL, Aviles RJ, Bell MR, et al. A randomized, double-blinded, placebo-controlled, dose-ranging study measuring the effect of an adenosine agonist on infarct size reduction in patients undergoing primary percutaneous transluminal coronary angioplasty: the ADMIRE (AmP579 Delivery for Myocardial Infarction REduction) study. Am Heart J. 2003;146(1):146-152
34 Ikeda N, Yasu T, Kubo N, et al. Nicorandil versus isosorbide dinitrate as adjunctive treatment to direct balloon angioplasty in acute myocardial infarction. Heart. 2004;90(2):181-185
35 Minamino T, Jiyoong K, Asakura, et al. Rationale and design of a large-scale trial using nicorandil as an adjunct to percutaneous coronary intervention for ST-segment elevation acute myocardial infarction: Japan-Working groups of acute myocardial infarction for the reduction of Necrotic Damage by a K-ATP channel opener (J-WIND-KATP). Circ J. 2004;68(2):101-106
36 Rupprecht HJ, vom Dahl J, Terres W, et al. Cardioprotective effects of the Na(+)/H(+) exchange inhibitor cariporide in patients with acute anterior myocardial infarction undergoing direct PTCA. Circulation. 2000;101(25):2902-2908
37 Moens AL, Claeys MJ, Timmermans JP, et al. Myocardial ischemia/reperfusion-injury, a clinical view on a complex pathophysiological process. Int J Cardiol. 2005;100(2):179-190
38 Mahaffey KW, Granger CB, Nicolau JC,et al. Effect of pexelizumab, an anti-C5 complement antibody, as adjunctive therapy to fibrinolysis in acute myocardial infarction: the COMPlement inhibition in myocardial infarction treated with thromboLYtics (COMPLY) trial. Circulation. 2003;108(10):1176-1183
39 Granger CB, Mahaffey KW, Weaver WD, et al. Pexelizumab, an anti-C5 complement antibody, as adjunctive therapy to primary percutaneous coronary intervention in acute myocardial infarction: the COMplementinhibition in Myocardial infarction treated with Angioplasty (COMMA) trial. Circulation. 2003;108(10):1184-1190
40 Dangas G, Stone GW, Weinberg MD, et al. Contemporary outcomes of rescue percutaneous coronary intervention for acute myocardial infarction: comparison with primary angioplasty and the role of distal protection devices (EMERALD trial). Am Heart J. 2008;155(6):1090-1096
41 Yip HK, Wu CJ, Chang HW, et al. Effect of the PercuSurge GuardWire device on the integrity of microvasculature and clinical outcomes during primary transradial coronary intervention in acute myocardial infarction. Am J Cardiol. 2003;92(11):1331-1335
1 McCullough PA, Soman SS. Contrast-induced nepropathy. Crit Care Clin, 2005,21(2):261-280
2 Chew DP, Astley C, Molloy D, et al. Morbidity, mortality and ecconomic burden of renal impairment in cardiac intensive care. Intern Med J, 2006,36(3):185-192
3 Bagshaw SM, Mortis G, Doig CJ, et al. One-year mortality in critically ill patients by severity of kidney dysfunction: a population-based assessment. Am J Kidney Dis, 2006,48(3):402- 409
4 Thomsen HS. Guidelines for cintrast media from the European Society of Urogenital Radiology. Am J Roentgenol, 2003,181(6):1463-1471
5 Bartholomew BA, Harjai KJ, Dukkipati S, et al. Impact of nephropathy after percutaneous coronary intervention and a method for risk stratification. Am J Cardiol ,2004,93(12):1515-1519
6 Nash K, Hafeez A, Hou S. Hospital-acquired renal insufficiency. Am J Kidney Dis, 2002,39(5):930-936
7 Rihal CS, Textor SC, Grill DE, et al. Incidence and prognostic importance ofacute renal failure after percutaneous coronary intervention. Circulation, 2002,105(19):2259-2264
8 Nikolsky E, Mchran R, Turcot DB, et al. Impact of chronic kidney disease on prognosis of patients with diadetes mellitus treated with percutaneous coroanry intervention. Am J Cardiol, 2004,94(3):300-305
9 McCullough PA, Adam A, Becker CR, et al. Risk prediction of contrast-induced nephropathy. Am J Cardiol, 2006,98(6A):27k-36k
10 Mchran R, Aymong ED, Nikolsky E, et al. A simple risk score for prediction of contrast-induced nephropathy after percutaneous coronary intervention:development and initial validation. J Am Coll Cardiol, 2004, 44(7):1393-1399
11 Nikolsky E, Mehran R, Lasic Z, et al. Low hematocrit predicts contrast-induced nephropathy after percutaneous coronary interventions. Kidney Int, 2005,67(2):706-713
12 Becker CR, Davidson C, Lameire N, et al. High-risk situations and procedures. Am J Cardiol, 2006,98(6A):37k-41k
13 Bachorzcwska-gajcwska H, Malyszko J, Sitnicwska E, et al. Neutrophil-gelatinase-associated lipocalin and renal function after percutaneous coronary interventions. Am J Nephrol, 2006,26(3):287-292
14 Mishra J, Dent C, Tarabishi R, et al. Neutrophil gelatinase-associated lipocalin(NGAL) as a biomarker for acute renal injury after cardiac surgery. Lancet, 2005,365(9466):1231-1238
15 McCullough. Contrast-induced acute kidney injury. J Am Coll Cardiol, 2008,51(22);1419-1428
16 Nikolsky E, Mchran R, Turcot DB, et al. Impact of chronic kidney disease on prognosis of patients with diabetes mellitus treated with perutaneous coronary intervention. Am J Cardiol, 2004,94(3):300-305
17 Martin JH, Fay MF, Ungerer JP. eGFR-use beyond the evidence. Med J Aust, 2009,190(4):197-199
18 Tippins RB, Torres WE, Baumgartner BR, et al. Are screening serum creatinine levels necessary prior to outpatient CT examination? Radiology,2000,216(2):481-484
19 Lameire N, Adam A, Becker CR, et al. Baseline renal function screening. Am J Cardiol, 2006,98(6A):21k-26k
20 Davidson C, Stacul F, McCullough PA, et al. Contrast medium use. Am J Cardiol, 2006,98(6A):42k-58k
21 McCullough PA, Bertrand ME, Brinker JA, et al. A meta-analysis of the renal safety of isosmolar iodixanol compared with low-osmolar cintrast media. J Am Coll Cardiol, 2006,48(4):692-699
22 Solomon R. The role of osmolality in the incidence of contrast-induced nephropathy: a systematic review of angiographic contrast media in high risk patients. Kidney Int, 2005,68(5):2256-2263
23 Jo SH, Youn TJ, Koo BK, et al. Renal toxicity evaluation and comparison between visipaque(iodixanol) and hexabrix(ioxaglate) in patients with reanl insufficiency undergoing coronary angiopraphy: the RECOVER study: a randomized controlled trial. J Am Coll Cardiol, 2006,48(5):924-930
24 Anderson JL, Adams CD, Antman EM, et al. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-elevation muocardial infarction-exceutive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guideline for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction). J Am Coll Cardiol, 2007;50:652-726
25 Solomn RJ, Natarajan MK, Doucct S, et al. Cardiac Angiography in Renally Impaired Patients(CARE) study: a randomized double-blind trial of contrast-induced nephropathy in patients with chronic kidney disease. Circulation,2007,115(25):3189-3196
26 Laskey WK, Jenkins C, Sclzer F, et al. NHLBI Dynamic Registry Investigators. Volume-to-creatinine clearence ratio: a pharmacokinetically based risk factor for prediction of early creatinine increase after percutaneous coronary intervention. J Am Cardiol, 2007,50(7):584-590
27 Mueller C, Buerkle G, Buettner HJ, et al. Prevention of contrastmedia-associated nephropathy: randomized comparison of 2 hydration regimens in 1620 patients undergoing coronary angioplasty. Arch Intern Med, 2002,162(3):329-336
28 Marenzi G, Lauri G, Campodonico J, et al. Comparison of two hemofiltration protocols for prevention of contrast-induced nephropathy in high risk patients. Am J Med, 2006,119(2):155-162
29 Stacul F, Adam A, Becker CR, et al. Strategies to reduce the risk of contrast-induced nephropathy. Am J Cardiol, 2006,98(6A):59k-77k
30 Spargias K, Alcxopoulos E, Kyrzopoulos S, et al. Ascorbic acid prevents contrast-mediated nephropathy in patients with renal dysfunction undergoing coronary angiography or intervention. Circulation, 2004,110(18):2837-2842
31 Marenzi G, Assanelli E, Marana I, et al. N-acetylcystiene and contrast-induced nephropathy in primary angioplasty. N Engl J Med, 2006,354(26):2773-2782
32 Briguori C, Airoldi F, D’Andrea D, et al. Renal insufficiency folllowing contrast media administration trial (REMEDIAL): a randomized comparison of 3 preventive strategics. Circulation, 2007,115(10):1211-1217
33 Khanal S, Attallah N, Smith DE, et al. Statin therapy reduces contrast-induced mephropathy: an analysis of contemporary percutaneous interventions. Am J Med, 2005,118(8):843-849
34 McCullough PA, Rocher LR. Statin therapy in renal disease: harmful or protective. Curr Atheroscler Rep, 2007,9(1):18-24
1 Agarwal R. Effects of statins on renal function. Am J Cardiol. 2006;97(5):748-755
2 Sandhu S, Wiebe N, Fried LF, et al. Statins for improving renal outcomes: a meta-analysis. J Am Soc Nephrol. 2006;17(7):2006-2016
3 Kshirsagar AV, Shoham DA, Bang H, et al. The effect of cholesterol reduction with cholestyramine on renal function. Am J Kidney Dis. 2005;46(5):812-819
4 Kostapanos MS, Milionis HJ, Elisaf MS. An overview oth the extra-lipid effects of rosuvastatin. J Cardiovasc Pharmacol Ther. 2008;13(3):157-174
5 Usui H, Shikata K, Matsuda M, et al. HMG-CoA reductase inhibitor ameliorates diabetic nephropathy by its pleiotropic effects in rats. Nephrol Dial Transplant. 2003; 18(2):265-272
6 Sharyo S, Yokota-Ikeda N, Mori M, et al. Pravastatin improves renal ischemia-reperfusion injury by inhibiting the mevalonate pathway. Kidney Int. 2008;74(5): 577-584
7 Li H, Li X, Lin D, et al. Inhibition of lovastatin on proliferation and expression of proinflammatory cytokines in cultured human glomerular mesangial cells. Chin Med J. 2003;116(9):1366-1369
8 Matsumoto M, Tanimoto M, Gohda T, et al. Effect of pitavastatin on type 2 diabetes mellitus nephropathy in KK-Ay/Ta mice. Metabolism. 2008;57(5):691-697
9 Fujii M, Inoguchi T, Maeda Y, et al. Pitavastatin ameliorates albuminuria and renal mesangial expansion by downregulating NOX4 in db/db mice. KidneyInt. 2007;72(4):473-480
10 Yagi S, Aihara K, Ikeda Y, et al. Pitavastatin, an HMG-CoA reductase inhibitor, exerts eNOS-independent protective actions against angiotensin II induced cardiovascular remodeling and renal insufficiency. Circ Res. 2008;102(1):68-76
11 Sonmez A, Yilmaz MI, Korkmaz A, et al. Hyperbaric oxygen treatment augments the efficacy of cilazapril and simvastatin regimens in an experimental nephrotic syndrome model. Clin Exp Nephrol. 2008; 12(2):110-118
12 Liang XM, Otani H, Zhou Q, et al. Renal protective effects of pitavastatin on spontaneously hypercholesterolaemic Imai Rats. Nephrol Dial Transplant. 2007;22(8):2156-2164
13 Whaley-Connell AT, Morris EM, Rehmer N, et al. Albumin activation of NAD(P)H oxidase activity is mediated via Rac1 in proximal tubule cells. Am J Nephrol. 2007;27(1):15-23
14 Whaley-Connell A, Habibi J, Nistala R, et al. Attenuation of NADPH oxidase activation and glomerular filtration barrier remodeling with statin treatment. Hypertension. 2008;51(2):474-480
15 Yu HY, Inoguchi T, Nakayama M, et al. Statin attenuates high glucose-induced and angiotensin II-induced MAP kinase activity through inhibition of NAD(P)H oxidase activity in cultured mesangial cells. Med Chem. 2005;1(5):461-466
16 Ott C, Schlaich MP, Schmidt BM, et al. Rosuvastatin improves basal nitric oxide activity of the renal vasculature in patients with hypercholesterolemia. Atherosclerosis. 2008;196(2):704-711
17 Yu YH, Wang Y, Dong B, et al. Fluvastatin prevents renal injury and expression of lactin-like oxidized low-density lipoprotein receptor-1 in rabbits with hypercholesterolemia. Chin Med J. 2005;118(8):621-626
18 Zhou MS, Schuman IH, Jaimes EA, et al. Renoprotection by statins is linked to a decrease in renal oxidative stress, TGF-beta, and fibronectin with concomitant increase in nitric oxide bioavailability. Am J Physiol RenalPhysiol. 2008;295(1):F53-F59
19 Kuwahara N, Sasaki S, Kobara M, et al. HMG-CoA reductase inhibition improves anti-aging klotho protein expression and arteriosclerosis in rats with chronic inhibition of nitric oxide synthesis. Int J Cardiol. 2008;123(2):84-90
20 Joyce M, Kelly C, Winter D, et al. Pravastatin, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, attenuates renal injury in an experimental model of ischemia-reperfusion. J Surg Res. 2001;101(1):79-84
21 Pisani A, Uccello F, Cesaro A, et al. Effects of atorvastatin on ischemic acute renal failure in aging rats. G Ital Nefrol. 2002; 19(5):534-539
22 Schwartz IF, Ayalon R, Chernichovski T, et al. Arginine uptake is attenuated through modulation of cationic amino-acid transporter-1, in uremic rats. Kidney Int. 2006;69(2):298-303
23 Chade AR, Zhu XY, Grande JP, et al. Simvastatin abates development of renal fibrosis in experimental renovascular disease. J Hypertens. 2008; 26(8):1651-1660
24 Vieira JM Jr, Rodrigues LT, Mantovani E, et al. Statin monotherapy attenuates renal injury in a salt-sensitive hypertension model of renal disease. Nephron Physiol. 2005;101(4):82-91
25 Yamashita T, Kawashima S, Miwa Y, et al. A 3-hydroxy-3-methylglutaryl co-enzyme A reductase inhibitor reduces hypertensive nephrosclerosis in stroke-prone spontaneously hypertensive rats. J Hypertens. 2002; 20 (12):2465-2473
26 Gianella A, Nobili E, Abbate M, et al. Rosuvastatin treatment prevents progressive kidney inflammation and fibrosis in stroke-prone rats. Am J Pathol. 2007;170(4):1165-1177
27 Kramer S, Kron S, Wang-Rosenke Y, et al. Rosuvastatin is additive to high-dose candesartan in slowing progression of experimental mesangioproliferative glomerulosclerosis. Am J Physiol Renal Physiol. 2008;294(4):F801-F811
28 Ikeuchi H, Kuroiwa T, Yamashita S, et al. Fluvastatin reduces renal fibroblast proliferation and production of type III collagen: therapeutic implications fortubulointerstitial fibrosis. Nephron Exp Nephrol. 2004;97(4):e115-122
29 Heusinger-Ribeiro J, Fischer B, Goppelt-Struebe M. Differential effects of simvastatin on mesangial cells. Kidney Int. 2004;66(1):187-195
30 Xu H, Zeng L, Peng H, et al. HMG-CoA reductase inhibitor simvastatin mitigates VEGF-induced‘‘inside-out’’signaling to extracellular matrix by preventing RhoA activation. Am J Physiol Renal Physiol. 2006; 291 (5):F995-1004
31 Danesh FR, Sadeghi MM, Amro N, et al. 3-Hydroxy-3-methylglutaryl CoA reductase inhibitors prevent high glucose-induced proliferation of mesangial cells via modulation of Rho GTissue plasminogen activator se/ p21 signaling pathway: implications for diabetic nephropathy. Proc Natl Acad Sci USA. 2002;99(12):8301-8305
32 Athyros VG, Mikholidis DP, Papageorgiou A, et al. The effect of statins versus untreated dyslipidemia on renal function in patients with coronary heart disease. A subgroup analysis of the Greek atorvastatin and coronary heart disease evaluation (GRACE) study. J Clin Pathol, 2004;57(7):728-734
33 Patti G, Nusea A, Chello M, et al. Usefulness of statin pretreatment to prevent contrast-induced mephropathy and to improve long-term outcome in patients undergoing percutaneous coronary intervention. Am J Cardiol, 2008; 101(3):279-285
34 Shepherd J, Kastelein JJP, Bitmer V, et al. Intensive lipid lowering with atorvastatin in patients with coronary heart disease and chronic kidney disease, the TNT (Treating to New Target) study. J Am Coll Cardiol. 2008; 51(15):1448-1454
35 Xinwei J, Xianghua F, Jing Z, et al. Comparison of usefulness of simvastatin
20 mg versus 80 mg in preventing contrast-induced nephropathy in patients with acute coronary coronary syndrome undergoing percutaneous coronary intervention. Am J Cardiol.2009;104(4):519-524
2 Flaker GC, Warnica JW, Sacks FM, et al. Pravastatin prevents clinical events in revascularized patients with average cholesterol concentrations. Cholesterol and Recurrent Events CARE Investigators. J Am Coll Cardiol. 1999 Jul;34(1):106-12
3 Schwartz GG, Olsson AG, Ezikowitz MD, et al. Myocardial Ischemia Reduction with Aggressive Cholesterol-lowering (MIRACL) StudyInvestigators: Effects of atovastatin on early recurrent ischemic events in acute coronary syndrome: the MIRACL study. JAMA 2001;285:1711-1718
4 Pedersen TR, Faergeman O, Kastelein JJ, et al. Incremental Decrease in End Points Through Aggressive Lipid Lowering (IDEAL) Study Group. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. JAMA 2005; 294:2437-2445
5 Patti G, Pasceri A, Colonna G, et al. Atorvastatin pretreatment improves outcomes in patients with acute coronary syndromes undergoing early percutaneous coronary intervention: results of the ARMYDA-ACS randomized trial. J Am Coll Cardiol.2007;49:1272-1278
6 Pasceri V, Patti G, Nusca A, et al. Randomized trial of atorvastatin for reduction of myocardial damage during coronary intervention, Results from the ARMYDA (Atorvastatin for Reduction of Myocardial Damage during Angioplasty) study. Circulation 2004;110:674-678
7 National Cholesterol Education Program (ECEP) Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adults Treatment Panel III). Third Report of the National Cholesterol Education Program (NECP) Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation, 2002;106:3143-3421
8 Melberg T, Burman R, Dickstein K, et al. The impact of the 2007 ESC-ACC-AHA-WHF Universal definition on the incidence and classification of acute myocardial infarction: A retrospective cohort study. Int J Cardiol. 2008 Nov 21
9 Brener SJ, Ellis SG, Schneider J, et al. Frequency and long-term impact of myonecrosis after coronary stenting. Eur Heart J, 2002;23:869-876
10 Nallamothu BK, Bates ER. Periprocedural myocardial infarction and mortality: causality versus association. J Am Coll Cardiol. 2003;42:1412-1414
11 Ioannidis JPA, Karvouni E, Katritis DG. Mortality risk conferred by smallelevations of creatine kinase-MB isoenzyme after percutaneous intervenion. J Am Coll Cardiol. 2003;42:1406-1411
12 Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet, 1994;344:1383-1389
13 Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia: West of Scotland Coronary Prevention Study Group. N Engl J Med. 1995;333:1301-1307
14 Serruys PW, De Feyter P, Macaya C, et al. Lescol Intervention Prevention Study (LIPS) Investigators. Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention: a randomized controlled trial. JAMA, 2002;287:3215-3222
15 Ding Chao, Fu Xianghua, He Zhenshan, et al. Cardioprotective effects of simvastatin on reversing electrical remodeling induced by myocardial ischemia-reperfusion in normcholesterolemic rabbits. Chinese Medical Journal. 2008;121:551-556
16 Schwartz GG, Olsson AG, Ezekowitz MD, Ganz P, Oliver MF, Waters D, Zeiher A, Chaitman BR, Leslie S, Stern T, Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study Investigators. Effects of storvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL Study, a randomized controlled trial. JAMA, 2001,285:1711-1718
17 Cannon CP, Braunwald E, McCabe CH, et al. Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 Investigators. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med, 2004;350:1495-1504
18 de Lemos JA, Blazing MA, Wiviott MB, et al. A to Z Investigators. Early intensive vs delayed conservative simvastatin strategy in patients with acute coronary syndrome. Phase Z of the A to Z trial. JAMA, 2004;292:1307-1316
19 Fu XH, Fan WZ, Gu XS, et al. Effect of intracoronary administration of anisodamine on slow reflow phenomenon following primary percutaneouscoronary intervention in patients with acute myocardial infarction. Chin Med J 2007; 120: 1226-1231.
20 Lee HC, An SG, Choi JH, et al. Effect of intra-coronary nicarandil administration prior to reperfusion in acute ST segment elevation myocardial infarction. Circ J. 2008;72:1425-1429.
21 Matsuo H, Watanabe S, Watanabe T, et al. Prevention of no-reflow/slow-flow phenomenon during rotational atherectomy--a prospective randomized study comparing intracoronary continuous infusion of verapamil and nicorandil. Am Heart J. 2007;154:994.e1-e6
22 Shinozaki N, Ichinose H, Yahikozawa K, et al. Selective intracoronary administration of nitroprusside before balloon dilatation prevents slow reflow during percutaneous coronary intervention in patients with acute myocardial infarction. Int Heart J. 2007;48:423-433
23 Haendeler J, Hoffmann J, Zeiher AM, et al. Antioxidant effects of statins via S-nitrosylation and activation of thioredoxin in endothelial cells: a novel vasculoprotective function of statins. Circulation. 2004;110:856-861
24 Liu PY, Liu YW, Lin LJ, et al. Evidence for Statin Pleiotropy in Humans. Differential Effects of Statins and Ezetimibe on Rho-Associated Coiled-Coil Containing Protein Kinase Activity, Endothelial Function, and Inflammation. Circulation. 2009;119(1):131-138
25 Sanguigni V, Pignatelli P, Lenti L, et al. Short-term treatment with atorvastatin reduces platelet CD40 ligand and thrombin generation in hypercholesterolemic patients. Circulation. 2005;111:412-419
26 Chello M, Goffredo C, Patti G, et al. Effects of atorvastatin on arterial endothelial function in coronary bypass surgery. Eur J Cariodothorac Surg. 2005; 28:805-810
27 Chyrchel M, Rakowski T, Rzeszutko L, et al. Effects of high-dose administered prior to coronary angioplasty on the incidence of cardiac events in patients with acute coronary syndrome. Kardiol Pol. 2006;64:1357-1362
28 Celik T, Iyisoy A, Yuksel UC, et al. The impact of admission C-reactive protein levels on the development of no-reflow phenomenon after primaryPCI in patients with acute myocardial infarction: The role of inflammation. Int J Cardiol. 2009;136(1):86-88
29 Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359:2195-207
30 Patti G, Chello M, Pasceri V, et al. Protection from procedural myocardial injury by atorvastatin is associated with lower levels of adhesion molecules after percutaneous coronary intervention: results from the ARMYDA-CAMs (Atorvastatin for Reduction of Myocardial Damage during Angioplasty-Cell Adhesion Molecules) substudy. J Am Coll Cardiol. 2006;48:1560-1566
31 Yang YJ, Qian HY, Huang J, et al. Atorvastatin treatment improves survival and effects of implanted mesenchymal stem cells in post-infarct swine hearts. Eur Heart J. 2008; 29:1578-1590
1 Vrints CJ. Pathophysiology of the no-reflow phenomenon. Acute Card Care. 2009;11(2):69-76
2 Ito H, Maruyama A, Iwakura K, et al. Clinical implications of the no reflow phenomenon: a predictor of complications and left ventricular remodeling in reperfused anterior wall myocardial infarction. Circulation, 1996, 93:223-228
3 Kloner RA, Ganote CE, Jennings RB. The“no reflow”phenomenon after temporary coronary occlusion in the dog. J Clin Invest, 1974, 54:1496-1508
4 Tesic MB, Stankovic G, Vukcevic V, Ostojic MCThe use of intracoronary sodium nitroprusside to treat no-reflow after primary percutaneous coronary intervention in acute myocardial infarction. Herz. 2010;35(2):114-118.
5 Iwasaki K, Samukawa M, Furukawa H et al. Comparison of the effects of nicorandil versus verapamil on the incidence of slow flow/no reflow during rotational atherectomy. Am J Cardiol. 2006;98(10):1354-1356
6 Zhao JL, Yang YJ, Cui CJ, et al. Different effects of adenosine and calcium channel blockade on myocardial no-reflow after acute myocardial infarction and reperfusion. Cardiovasc Drugs Ther. 2006;20(3):167-175
7 Hale SL, Kloner RA. Cardioprotection with adenosine-regulating agent, GP531: effects on no-reflow, infarct size, and blood flow following ischemia/ reperfusion in the rabbit. J Cardiovasc Pharmacol Ther. 2010;15(1):60-67
8 FU Xiang-hua, HAO Qing-qing, JIA Xin-wei et al. Effect of tirofiban plus clopidogrel and aspirin on urgent percutaneous coronary intervention via transradial approach in patients with acute myocardial infarction. Chinese Medical Journal.2008;121(6):522-527
9 Fischell TA. Pharmaceutical interventions for the management of no-reflow. J Invasive Cardiol. 2008;20(7):374-379
10 Maluenda G, Ben-Dor I, Delhaye C, et al. Clinical Experience with a Novel Intracoronary Perfusion Catheter to Treat No-Reflow Phenomenon in Acute Coronary Syndromes J Interv Cardiol. 2010 Mar 12. [Epub ahead of print]
11 Ndrepepa G, Tiroch K, Keta D, et al. Predictive factors and impact of noreflow after primary percutaneous coronary intervention in patients with acute myocardial infarction. Circ Cardiovasc Interv. 2010;3(1):27-33
12刑卉春,赵龙凤,王守义。山莨菪碱对大鼠急性肝损伤的保护作用及其机制.中国危重病急救医学,1998,10:658-660
13范卫泽,傅向华,姜云发等,冠脉内应用山莨菪碱对急性心肌梗塞患者经皮冠状动脉介入治疗中冠脉无复流、心功能和心室收缩同步性的影响。中华心血管病杂志,2007;35(10)908-913
14 Haendeler J, Hoffmann J, Zeiher AM, et al. Antioxidant effects of statins via S-nitrosylation and activation of thioredoxin in endothelial cells: a novel vasculoprotective function of statins. Circulation. 2004;110:856-861
15 Liu PY, Liu YW, Lin LJ, et al. Evidence for Statin Pleiotropy in Humans. Differential Effects of Statins and Ezetimibe on Rho-Associated Coiled-Coil Containing Protein Kinase Activity, Endothelial Function, and Inflammation. Circulation. 2008 (Epub ahead of print).
16 Sanguigni V, Pignatelli P, Lenti L, et al. Short-term treatment with atorvastatin reduces platelet CD40 ligand and thrombin generation in hypercholesterolemic patients. Circulation. 2005;111:412-419
17 Chello M, Goffredo C, Patti G, et al. Effects of atorvastatin on arterial endothelial function in coronary bypass surgery. Eur J Cariodothorac Surg. 2005; 28:805-810
18 Schwartz GG, Olsson AG, Ezikowitz MD, et al. Myocardial Ischemia Reduction with Aggressive Cholesterol-lowering (MIRACL) Study Investigators: Effects of atovastatin on early recurrent ischemic events in acute coronary syndrome: the MIRACL study. JAMA 2001;285:1711-1718
19 Pedersen TR, Faergeman O, Kastelein JJ, et al. Incremental Decrease in End Points Through Aggressive Lipid Lowering (IDEAL) Study Group. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. JAMA 2005; 294:2437-2445
20 Pasceri V, Patti G, Nusca A, Pristipino C, et al. Randomized trial of atorvastatin for reduction of myocardial damage during coronary intervention,Results from the ARMYDA (Atorvastatin for Reduction of Myocardial Damage during Angioplasty) study. Circulation 2004;110:674-678
21 Jia Xinwei,Fu Xianghua, Zhang Jing, et al. Intensive cholesterol lowering with statin improves the outcomes of percutaneous coronary intervention in patients with acute coronary syndrome Chinese Medical Journal, 2009;122(6):659-664
22 Patti G, Pasceri V, Colonna G, et al. Atorvastatin pretreatment improves outcomes in patients with acute coronary syndromes undergoing early percutaneous coronary intervention: results of the ARMYDA-ACS randomized trial J Am Coll Cardiol. 2007;49(12):1272-1278
23 Di Sciascio G, Patti G, Pasceri V, et al. Clopidogrel reloading in patients undergoing percutaneous coronary intervention on chronic clopidogrel therapy: results of the ARMYDA-4 RELOAD (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty) randomized trial. Eur Heart J. 2010 Apr 2. [Epub ahead of print]
24蔚永运,傅向华,刘君等,冠状动脉内注射山莨菪碱对急性心肌梗死介入治疗后缓再血流现象的作用,临床心血管病杂志,2006;22(1):21-24
25 Settergren M, B?hm F, Rydén L, et al. Cholesterol lowering is more important than pleiotropic effects of statins for endothelial function in patients with dysglycaemia and coronary artery disease. Eur Heart J. 2008 Jul;29(14):1753-60
26 Pasceri V, Cheng JS, Willerson JT, et al. Modulation of C reactive protein mediated monocyte chemoattractant protein 1 induction in human endothelial cells by anti atherosclerosis drugs. Circulation ,2001,103:2531-2534
27 Sanchez A, Mirabel JL, Barrenechea E, et al. Evaluation of an improved immunoturbidimetric assay for serum C reactive protein on a COBAS ITEGRA 400 Analyzer. Clin Lab,2002,48:313-317
28 Yamashiya H,Shimada K,Seki E, et al. Concentration of interleukins, interferon and C reactive protein in stable and unstable angina pectoris. Am J Cardiol 2003,91:133-136
29 Rosendo AB, Lima LO, Dal-Pizzol F, et al. Lipid and C-Reactive Protein Levels, Cardiovascular Disease Risk Factors and Simvastatin Treatment in Brazilian Individuals. Inflammation. 2010 Jan 19. [Epub ahead of print]
30 Poupko JM, Baskin SI, Moore E. The pharmacological properties of anisodamine J Appl Toxicol. 2007;27(2):116-121
31 Vrints CJ. Pathophysiology of the no-reflow phenomenon. Acute Card Care. 2009;11(2):69-76
32 Schmidt-Lucke C, Fichtlscherer S, R?ssig L, et al. Improvement of endothelial damage and regeneration indexes in patients with coronary artery disease after 4 weeks of statin therapy. Atherosclerosis. 2010 Feb 13. [Epub ahead of print]
1 Bartholomew BA, Harjai KJ, Dukkipati S, et al. Impact of nephropathy after percutaneous coronary intervention and a method for risk stratification. Am J Cardiol 2004;93:1515-1519
2 Sadeghi HM, Stone GW, Grines CL, et al. Impact of renal insufficiency in patients undergoing primary angioplasty for acute myocarial infarction. Circulation 2003;108:2769-2775
3 Marenzi G, Lauri G, Assanelli E, et al. Contrast-induced nephropathy in patients undergoing primary angioplasty for acute myocardial infarction. J Am Coll Cardiol 2004;44:1780-1785
4 Lindsay J, Canos DA, Apple S, et al. Causes of acute renal dysfunction after percutaneous coronary intervention and comparison of late mortality rates with postprocedure rise of creatine kinase-MB versus rise of serum creatinine. Am J Cardiol 2004;94:786-789
5 Dangas G, Iakovou I, Nikolsky E, et al. Contrast-induced nephropathy after percutaneous coronary intervenions in relation to chronic kidney disease and hemodynamic variables. Am J Cardiol 2005;95:13-19
6 Peter A, McCullough. Contrast-induced acute kidney injury.J Am Coll Cardiol 2008;51;1419-1428
7 Birck R, Krzossok S, Markowetz F, et al. Acctylcysteine for prevention of contrast nephropathy; meta-nanalysis. Lancet 2003;362:598-603
8 McCullough PA, Adam A, Becker CR, et al. Risk prediction of contrast-induced nephropathy. Am J Cardiol 2006;98:27k-36k
9 Mchran R, Aymong ED, Nikolsky E, et al. A simple risk score for prediction of contrast-induced nephropathy agter percutaneous coronary intervention: development and initial validation. J Am Coll Cardiol 2004;44:1393-1399
10 Mueller C, Buerkle G, Buettner HJ, et al. Prevention of contrast media-associated nephropathy: randomized comparison of 2 hydration regimens in 1620 patients undergoing coronary angioplasty. Arch Intern Med 2002;162:329-336
11 Marenzi G, Lauri G, Campodonico J, et al.Comparison of two hemofiltration protocols for prevention of cintrast-induced nephropathy in high risk patients. Am J Med 2006;119:155-162
12 Stacul F, Adam A, Becker CR, et al. Strategics to reduce the risk of contrast-induced nephropathy. Am J Cardiol 2006;98:59k-77k
13 Spargias K, Alcxopoulos E, Kyrzopoulos S, et al. Ascorbic acid prevents contrast-mediated nephropathy in patients with renal dysfunction undergoing coronary angiography or intervention. Circulation 2004;110:2837-2842
14 Marenzi G, Assanelli E, Marana I, et al. N-acctylcystiene and contrast-induced nephropathy in primary angioplasty. N Engl J Med 2006;354:2773-2782
15 Briguori C, Airoldi F, D’Andrea D, et al. Renal insufficiency folllowing contrast media administration trial (REMEDIAL): a randomized comparison of 3 preventive strategics. Circulation 2007;115:1211-1217
16 McCullough PA, Rocher LR. Statin therapy in renal disease: harmful or protective. Curr Atheroscler Rep 2007;9:18-24
17 Chcllo M, Barbato R, Patti G, et al. Prevention of postoperative acute renal failure by statin therapy in patients undergoing cardiac surgery. J Am Coll Cardiol 2008. In press
18 Khanal S, Attallah N, Smith DE, et al. Statin therapy reduces contrast-induced mephropathy: an analysis of contemporary percutaneous interventions. Am J Med 2005;18:843-849
19 Patti G, Nusca A, Chello M, et al. Usefulness of statin pretreatment to prevent contrast-induced nephropathy and to improve long-term outcomes in patients undergoing percutaneous coronary intervention. Am J Cardiol 2008;101:279-285
20 Athyros VG,Mikhailidis DP, Papageorgious AA, et al. The effect of statins versus untreated dyslipidaemia on renal function in patients with coronary heart disease. A subgroup analysis of the Greek atorvastatin and coronary heart disease evaluation (GREACE) study. J Clin Pathol,2004;57:728-734
21 Khanal S, Attallah N, Simth DE, et al, Statin therapy reduces contrast-inducednephropathy: An analysis of contemporary percutaneous interventions. The American Journal of Medicine,2005;118:843-849
22 Patti G, Nusca A, Chello M, et al. Usefulness of statin pretreatment to prevent contrast-induced nephropathy and to improve long-term outcome in patients undergoing percutaneous coronary intervention. Am J Cardiol, 2008; 101:279-285
23 Zhao JL, Yang YJ, Zhang YH, et al. Effect of statins on contrast-induced nephropathy in patients with acute myocardial infarction treated with primary angioplasty. International journal of cardiology,2008;126:435-436
24 Pedersen TR, Faergeman O, Kastelein JJ, et al. Incremental Decrease in End Points Through Aggressive Lipid Lowering (IDEAL) Study Group.High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. JAMA. 2005;16;294(19):2437-45
25 Murphy SA, Cannon CP, Wiviott SD, et al. Effect of intensive lipid-lowering therapy on mortality after acute coronary syndrome (a patient-level analysis of the Aggrastat to Zocor and Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 trials). Am J Cardiol. 2007 Oct 1;100(7):1047-51. Epub 2007 Jul 18
26 LaRosa JC, Grundy SM, Kastelein JJ, et al. Treating to New Targets (TNT) Steering Committee and Investigators. Safety and efficacy of Atorvastatin-induced very low-density lipoprotein cholesterol levels in Patients with coronary heart disease (a post hoc analysis of the treating to new targets [TNT] study). Am J Cardiol. 2007 Sep 1;100(5):747-52. Epub 2007 Jun 14
27 Grundy SM, Cleeman JI, Merz CNB, et al. Implications of recent clinical trials form the National Cholesterol Education Program adult treatment panel III guidelines. [J] Circulation, 2004, 110(2):227-239
28 Rihal CS, Textor SC, Grill DE, et al. Incidence and prognostic importance of acute renal failure after percutaneous coronary intervention. Circulation 2002; 105:2259-64
29 Lindsay J, Apple S, Pinnow EE, et al. Percutaneous coronary intervention-associated nephropathy foreshadows inncreased risk of late adverse events in patients with normal baseline serum creatinine. Catheter Cardiovasc Ieterv 2003; 59:338-43
30 Cannon CP, Braunwald E, McCabe CH, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndrome. N Engl J Med 2004;350:1495-1504
31 Schwartz GG, Olsson AG, Ezikowitz MD, et al. The Myocardial Ischemia Reduction with Aggressive Cholesterol-lowering (MIRACL) Study Investigators: Effects of atovastatin on early recurrent ischemic events in acute coronary syndrome: the MIRACL study. JAMA 2001;285:1711-1718
32 Pedersen TR, Faergeman O, Kastelein JJ, et al. Incremental Decrease in End Points Through Aggressive Lipid Lowering (IDEAL) Study Group. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. JAMA 2005; 294:2437-2445
33 Patti G, Chello M, Pasceri V, et al. Protection from procedural myocardial injury by atorvastatin is associated with lower levels of adhesion molecules after percutaneous coronary intervention: results from the ARMYDA-CAMs(Atorvastatin for Reduction of Myocardial Dmamge during Angioplasty-Cell Adhesion Molecules) substudy. J Am Coll Cardiol. 2006;48(8):1560-1566
34 Patti G, Pasceri V, Colonna G, et al. Atorvastatin pretreatment improves outcomes in patients with acute coronary syndromes undergoing early percutaneous coronary intervention: results of the ARMYDA-ACS randomized trial. J Am Coll Cardiol 2007;49(12):1272-1278
35 Tumlin J, Stacul F, Adam A, et al. on behalf of the CIN Consensus Working Panel. Pathophysiology of contrast-induced nephropathy. Am J Cardiol 2006;98(suppl):14k-20k
36 Chello M, Goffredo C, Patti G, et al. Effects of atorvastatin on arterial endothelial function in coronary bypass surgery. Eur J Caridothorac Surg 2005; 28:805-810
1 McCullough PA, Soman SS. Contrast-induced nephropathy[J]. Crit Care Clin, 2005,21(2):261-280
2 Chew DP, Astley C, Molloy D, et al. Morbidity, mortality and ecconomic burden of renal impairment in cardiac intensive care[J]. Intern Med J, 2006,36(3):185-192
3 Bagshaw SM, Mortis G, Doig CJ, et al. One-year mortality in critically ill patients by severity of kidney dysfunction: a population-based assessment [J]. Am J Kidney Dis, 2006,48(3):402-409
4 Nash K, Hafeez A, Hou S. Hospital-acquired renal insufficiency[J]. Am J Kidney Dis, 2002,39(5):930-936
5 Joyce M, Kelly C, Winter D, et al. Pravastatin, a 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor, attenuates renal injury in an experimental model of ischemia-reperfusion. Journal of surgical research. 2001; 101(1):79-84
6 McCullough PA, Adam A, Becker CR, et al. Risk prediction of contrast-induced nephropathy[J]. Am J Cardiol, 2006,98(6A):27k-36k.
7 Mchran R, Aymong ED, Nikolsky E, et al. A simple risk score for prediction of contrast-induced nephropathy after percutaneous coronary intervention: development and initial validation. J Am Coll Cardiol, 2004, 44(7):1393-1399
8 Bonventre J. Mechanism of ischemic acute renal failure. Kidney Int.1993;43:1160
9 Nouwen EJ, Verstrepen WA, Buyssen N, et al. Hyperplasia, hypertrophy, and phenotypic alterations in the distal nephron after acute proximal tubular injury in the rat. Lab Invest.1994;79:479
10 Racusen L, Firush B, Li YL, et al. Dissociation of tubular cell detachment and tubular cell death in clinical and experimental“acute tubular necrosis”. Lab Invest. 1987;56:273
11 Granata A, Andrulli S, Bigi MQ, et al. Predictive role of duplex Doppler ultrasonography in the diagnosis of acute renal obstruction in patients with unilateral renal colic Clin Nephrol. 2009 Jun;71(6):680-6
12 Jimenez C, Lopez MO, Gonzalez E, et al. Ultrasonography in kidney transplantation: values and new developments. Transplant Rev (Orlando). 2009 Oct;23(4):209-13. Epub 2009 Aug 4
13 Garcia-Covarrubias L, Martinez A, Morales-Buenrostro LE, et al. Parameters of Doppler ultrasound at five days posttransplantation as predictors of histology and renal function at one year. Transplant Proc. 2010 Jan-Feb; 42(1):262-5
14 Shimizu Y, Itoh T, Hougaku H, et al. Clinical usefulness of duplex ultrasonography for the assessment of renal arteriosclerosis in essential hypertensive patitents. Hypertens Res.2001,24(1):13-17
15 Pontremoli R, Viazzi F, Martinoli C, et al. Increased renal resistive index in patients with essential hypertension: a marker of target organ damages. Nephrol Dial Transplant.2003,14:360-365
16 Peterseen LJ, Petersen JR, Talleruphus U, et al. The pulsatility index and resistive index in renal arteries associations with long-term progression in chronic renal failure. Nephrol Dial Transplant, 2005;12:1376-1380
17 Cronin RE. Contrast-induced nephropathy: pathogenesis and prevention. Pediatr Nephrol. 2010 Feb;25(2):191-204
1 McCullough PA, Soman SS. Contrast-induced nephropathy[J]. Crit Care Clin, 2005,21(2):261-280
2 Nash K, Hafeez A, Hou S. Hospital-acquired renal insufficiency[J]. Am J Kidney Dis, 2002,39(5):930-936
3 Chew DP, Astley C, Molloy D, et al. Morbidity, mortality and ecconomic burden of renal impairment in cardiac intensive care[J]. Intern Med J, 2006,36(3):185-192
4 Bagshaw SM, Mortis G, Doig CJ, et al. One-year mortality in critically ill patients by severity of kidney dysfunction: a population-based assessment [J]. Am J Kidney Dis, 2006,48(3):402-409
5 Sarafidis PA,Statin Pleiotropy Against Renal Injury J Cardiometab Syndr. 2009;4: E4–E9
6 Zhou MS, Jaimes EA, Raij L. Atorvastatin prevents end-organ injury in salt-sensitive hypertension: role of eNOS and oxidant stress. Hypertension. 2004;44:186–190
7 Athyros VG, Mikhailidis DP, Papageorgious AA, et al. The effect of statins versus untreated dyslipidaemia on renal function in patients with coronary heart disease. A subgroup analysis of the Greek atorvastatin and coronary heart disease evaluation (GREACE) study. J Clin Pathol,2004;57:728-734
8 Khanal S, Attallah N, Simth DE, et al, Statin therapy reduces contrast-induced nephropathy: An analysis of contemporary percutaneous interventions. The American Journal of Medicine,2005;118:843-849
9 Patti G, Nusca A, Chello M, et al. Usefulness of statin pretreatment to prevent contrast-induced nephropathy and to improve long-term outcome in patients undergoing percutaneous coronary intervention. Am J Cardiol, 2008; 101:279-285
10 Zhao JL, Yang YJ, Zhang YH, et al. Effect of statins on contrast-induced nephropathy in patients with acute myocardial infarction treated with primary angioplasty. International journal of cardiology,2008;126:435-436
11 Shepherd J, Kastelein P, Bittner V, et al. Intensive lipid lowering with atorvastatin in patients with coronary heart disease and chronic kidney disease. The TNT (Treating to New Targets) Study. J Am Coll Cardiol, 2008; 51:1448-1454
12 Jia Xinwei, Fu Xianghua, Zhang Jing, et al. Comparison of usefulness of simvastatin 20 mg versus 80 mg in preventing contrast-induced nephropathy in patiants with acute coronary syndrome undergoing percutaneous coronary intervention. American journal of cardiology,2009;104(4): 519-524
13范卫泽,傅向华,姜云发等,冠脉内应用山莨菪碱对急性心肌梗塞患者经皮冠状动脉介入治疗中冠脉无复流、心功能和心室收缩同步性的影响。中华心血管病杂志,2007;35(10)908-913
14蔚永运,傅向华,刘君,急性心急梗死经皮冠脉介入治疗后无复流现象及654-2的干预,中国急救医学,2006;26(2):95-97
15蔚永运,傅向华,刘君等,冠状动脉内注射山莨菪碱对急性心急梗死介入治疗后缓再血流现象的作用,临床心血管病杂志,2006;22(1):21-24
16蔚永运,傅向华,刘君等,冠脉内注射山莨菪碱对急性心急梗死经皮介入介入术后缓再血流现象的影响,中国中西医结合杂志,2008;28(4):295-299
17刘晓城,唐望先。山莨菪碱治疗兔缺血性急性肾功能衰竭的实验研究,中国急救医学,1999;19(5):259-261
18吴广礼,温进坤,韩梅等,山莨菪碱、旋覆花素、苦碟子对过度训练大鼠肾细胞凋亡的影响,中华麻醉学杂志,2007;27(5):463-466
19潘光辉,白寒,陈彤等,山莨菪碱防治甘油所致急性肾功能衰竭的实验研究,中国病理生理杂志,1997;13(6):615-618
20唐望先,刘晓城,邵菊芳等,山莨菪碱对急性肾缺血再灌注损伤的保护机制,中华实验外科杂志,1997;14(5):304-305
21陈志勇,廖立生,张风等,山莨菪碱对毒蕈所致大鼠急性肾损伤的保护作用,肾脏病与透析肾移植杂志,1995;4(3):240-241
22刘晓城,唐望先,吕永曼等,山莨菪碱对兔急性肾缺血及再灌注损伤时肾小管超微病理变化的影响,同济医科大学学报,1998;27(5):380-382
23吴广礼,温进坤,韩梅等,山莨菪碱对过度训练大鼠急性肾损伤的保护作用,中国微循环,2006;10(4)241-244
24吴广礼,郑秋月,田牛等,樟柳碱、东莨菪碱、山莨菪碱对急性肾衰大鼠肾微血管损伤的保护作用,微循环杂志,2002;12(1):6-8
25周智广,廖二元,伍汉文等,糖尿病患者肾血浆流量的变化及山莨菪碱治疗的影响,湖南医科大学学报,1994;19(2):122-124
26吴广礼,张丽霞,张文玉等,内皮素在过度训练致大鼠急性肾损伤中的作用及山莨菪碱的干预效应,中国中西医结合杂志,2009;10(2):120-123
27吴广礼,黄旭。过度训练大鼠肾组织细胞凋亡的基因调控机制及山莨菪碱干预的影响,解放军医学杂志,2008;33(10):1209-1211
28 McCullough PA, Adam A, Becker CR, et al. Risk prediction of contrast-induced nephropathy[J]. Am J Cardiol, 2006,98(6A):27k-36k
29 Mchran R, Aymong ED, Nikolsky E, et al. A simple risk score for prediction of contrast-induced nephropathy after percutaneous coronary intervention:development and initial validation[J]. J Am Coll Cardiol, 2004, 44(7):1393-1399
30 Stacul F, Adam A, Becker CR, et al. Strategies to reduce the risk of contrast-induced nephropathy[J]. Am J Cardiol, 2006,98(6A):59k-77k
31 Joyce M, Kelly C, Winter D, et al. Pravastatin, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, attenuates renal injury in an experimental model of ischemia-reperfusion. J Surg Res. 2001;101:79–84
32 Pisani A, Uccello F, Cesaro A, et al. Effects of atorvastatin on ischemic acute renal failure in aging rats. G Ital Nefrol. 2002; 19:534–539
33 Schwartz IF, Ayalon R, Chernichovski T, et al. Arginine uptake is attenuated through modulation of cationic amino-acid transporter-1, in uremic rats. Kidney Int. 2006;69:298–303
34 Granata A, Andrulli S, Bigi MQ, et al. Predictive role of duplex Doppler ultrasonography in the diagnosis of acute renal obstruction in patients with unilateral renal colic Clin Nephrol. 2009 Jun;71(6):680-686
35 Jimenez C, Lopez MO, Gonzalez E, et al. Ultrasonography in kidney transplantation: values and new developments. Transplant Rev (Orlando).2009 Oct;23(4):209-213
36 Garcia-Covarrubias L, Martinez A, Morales-Buenrostro LE, et al. Parameters of Doppler ultrasound at five days posttransplantation as predictors of histology and renal function at one year. Transplant Proc. 2010 Jan-Feb;42(1):262-265
37 Bommart S, Cliche A, Therasse E, et al. Renal artery revascularization: predictive value of kidney length and volume weighted by resistive index. AJR Am J Roentgenol. 2010 May;194(5):1365-1372
38 Santos SN, Leite LR, Tse TS, et al. Renal resistance index predicting outcome of renal revascularization for renovascular hypertension Arq Bras Cardiol. 2010 Mar 26. pii: S0066-782X2010005000018. [Epub ahead of print]
39 Li JC, Jiang YX, Zhang SY, et al. Evaluation of renal artery stenosis with hemodynamic parameters of Doppler sonography J Vasc Surg. 2008 Aug;48(2):323-328
40 Wan L, Yang N, Hiew CY, et al. An assessment of the accuracy of renal blood flow estimation by Doppler ultrasound. Intensive Care Med. 2008 Aug;34(8):1503-10. Epub 2008 Apr 12
41 Verma A, Ranganna KM, Reddy RS, et al. Effect of rosuvastatin on C-reactive protein and renal function in patients with chronic kidney disease. Am J Cardiol. 2005;96:1290-1292
42 Ota T, Takamura T, Ando H, et al. Preventive effect of cerivastatin on diabetic nephropathy through suppression of glomerular macrophage recruitment in a rat model. Diabetologia. 2003;46:843-851
43 Usui H, Shikata K, Matsuda M, et al. HMG-CoA reductase inhibitor ameliorates diabetic nephropathy by its pleiotropic effects in rats. Nephrol Dial Transplant. 2003; 18:265-272
44 Park JK, Muller DN, Mervaala EM, et al. Cerivastatin prevents angiotensin II-induced renal injury independent of blood pressure- and cholesterol- lowering effects. Kidney Int. 2000;58:1420-430
45 Li H, Li X, Lin D, et al. Inhibition of lovastatin on proliferation and expression of proinflammatory cytokines in cultured human glomerularmesangial cells. Chin Med J. 2003;116:1366-1369
46 Massy ZA, Kim Y, Guijarro C, et al. Low-density lipoprotein-induced expression of interleukin-6, a marker of human mesangial cell inflammation: effects of oxidation and modulation by lovastatin. Biochem Biophys Res Commun. 2000;267:536-540
47 Sonmez A, Yilmaz MI, Korkmaz A, et al. Hyperbaric oxygen treatment augments the efficacy of cilazapril and simvastatin regimens in an experimental nephrotic syndrome model. Clin Exp Nephrol. 2008;12:110-118
48 Yagi S, Aihara K, Ikeda Y, et al. Pitavastatin, an HMG-CoA reductase inhibitor, exerts eNOS-independent protective actions against angiotensin II induced cardiovascular remodeling and renal insufficiency. Circ Res. 2008;102:68-76
49 Liang XM, Otani H, Zhou Q, et al. Renal protective effects of pitavastatin on spontaneously hypercholesterolaemic Imai Rats. Nephrol Dial Transplant. 2007;22:2156-2164
50 Gueler F, Rong S, Park JK, et al. Postischemic acute renal failure is reduced by short-term statin treatment in a rat model. J Am Soc Nephrol. 2002;13: 2288-2298
51 Whaley-Connell A, Habibi J, Nistala R, et al. Attenuation of NADPH oxidase activation and glomerular filtration barrier remodeling with statin treatment. Hypertension. 2008;51:474-480
52 Ott C, Schlaich MP, Schmidt BM, et al. Rosuvastatin improves basal nitric oxide activity of the renal vasculature in patients with hypercholesterolemia. Atherosclerosis. 2008;196:704-711
53 Moriyama T, Kawada N, Nagatoya K, et al. Fluvastatin suppresses oxidative stress and fbrosis in the interstitium of mouse kidneys with unilateral ureteral obstruction. Kidney Int. 2001;59:2095-2103
1 LaRosa JC, Hunninghake D, Bush D, et al. The cholesterol facts. A summary of the evidence relating dietary fats, serum cholesterol, and coronary heart disease. A joint statement by the American Heart Association and the National Heart, Lung, and Blood Institute. The Task Force on Cholesterol Issues, American Heart Association. Circulation. 1990;81(5):1721-1733
2 Castelli WP. Epidemiology of coronary heart disease: the Framingham study. Am J Med. 1984;27;76(2A):4-12
3 Endo A, Kuroda M, Tanzawa K. Competitive inhibition of3- hydroxy-
3-methylglutaryl coenzyme A reductase by ML-236A and ML-236B fungal metabolites, having hypocholesterolemic activity FEBS Lett. 1976;72(2):323-326
4 Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA. 1998;279(20):1615-1622
5 Barringer TA 3rd. WOSCOPS. West of Scotland Coronary Prevention Group. Lancet. 1997 Feb 8;349(9049):432-433
6 Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S) Lancet. 1994;19;344(8934):1383-1389
7 Flaker GC, Warnica JW, Sacks FM, et al. Pravastatin prevents clinical events in revascularized patients with average cholesterol concentrations. Cholesterol and Recurrent Events CARE Investigators. J Am Coll Cardiol. 1999;34(1):106-112
8 LaRosa JC, Grundy SM, Kastelein JJ, et al. Safety and efficacy of Atorvastatin-induced very low-density lipoprotein cholesterol levels in Patients with coronary heart disease (a post hoc analysis of the treating to new targets [TNT] study). Am J Cardiol. 2007;100(5):747-52
9 Cannon CP, Braunwald E, McCabe CH, et al. Comparison of intensive and moderate lipid lowering with statins after acute coronary syndroms. N Engl JMed, 2004, 350(15):1495-1504
10 LaRosa JC, Grundy SM, Water DD, et al. Intensive lipid lowering with atovastatin in patients with stable coronary disease. N Engl J Med, 2005, 352
11 Pedersen TR. Incremental Decrease in End Points Through Aggressive Lipid Lowering study.JAMA,2005;294:2437-2444
12 Pedersen TR, Faergeman O, Kastelein JJ, et al. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. JAMA. 2005;16; 294(19): 2437-2445
13 Shepherd J, Blauw GJ, Murphy MB,et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet. 2002 Nov 23;360(9346):1623-1630
14 Sever PS, Poulter NR, Dahl?f B,et al. Different time course for prevention of coronary and stroke events by atorvastatin in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid-Lowering Arm (ASCOT-LLA). Am J Cardiol. 2005;96(5A):39F-44F
15 Farmer JA, Gotto AM Jr, et al. The Heart Protection Study: expanding the boundaries for high-risk coronary disease prevention. Am J Cardiol. 2003 ;92(1A):3i-9i
16 Murphy SA, Cannon CP, Wiviott SD, et al. Effect of intensive lipid-lowering therapy on mortality after acute coronary syndrome (a patient-level analysis of the Aggrastat to Zocor and Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 trials). Am J Cardiol. 2007;100(7):1047-1051.
17 LaRosa JC, Grundy SM, Kastelein JJ, et al. Safety and efficacy of Atorvastatin-induced very low-density lipoprotein cholesterol levels in Patients with coronary heart disease (a post hoc analysis of the treating to new targets [TNT] study). Am J Cardiol. 2007;100(5):747-52
18 Grundy SM, Cleeman JI, Merz CNB, et al. Implications of recent clinical trials form the National Cholesterol Education Program adult treatment panel III guidelines. Circulation, 2004, 110(2):227-239
19 Haendeler J, Hoffmann J, Zeiher AM, et al. Antioxidant effects of statins via S-nitrosylation and activation of thioredoxin in endothelial cells: a novel vasculoprotective function of statins. Circulation. 2004;110:856-861
20 Liu PY, Liu YW, Lin LJ, et al. Evidence for Statin Pleiotropy in Humans. Differential Effects of Statins and Ezetimibe on Rho-Associated Coiled-Coil Containing Protein Kinase Activity, Endothelial Function, and Inflammation. Circulation. 2009;119(1):131-138
21 Sanguigni V, Pignatelli P, Lenti L, et al. Short-term treatment with atorvastatin reduces platelet CD40 ligand and thrombin generation in hypercholesterolemic patients. Circulation. 2005;111:412-419
22 19 Chello M, Goffredo C, Patti G, et al. Effects of atorvastatin on arterial endothelial function in coronary bypass surgery. Eur J Cariodothorac Surg. 2005; 28:805-810.
23 Shinohara K, Shoji T, Kimoto E, et al. Effect of atorvastatin on regional arterial stiffness in patients with type 2 diabetes mellitus. J Atheroscler Thromb. 2005,12(4):205-210
24 Raison J, Rudnichi A, Safar ME. Effects of atorvastatin on aortic pulse wave velocity in patients with hypertension and hypercholesterolaemia: a preliminary study. J Hum Hypertens. 2002,16(10):705-710
25 Rubba P. Effects of atorvastatin on the different phases of atherogenesis Drugs. 2007;67 Suppl 1:17-27
26 Choi SH, Chae A, Miller E, et al. Relationship between biomarkers of oxidized low-density lipoprotein, statin therapy, quantitative coronary angiography, and atheroma: volume observations from the REVERSAL (Reversal of Atherosclerosis with Aggressive Lipid Lowering) studyJ Am Coll Cardiol. 2008;1;52(1):24-32
27 Jensen LO, Thayssen P, Pedersen KE, et al. Regression of coronary atherosclerosis by simvastatin: a serial intravascular ultrasound study. Circulation, 2004,110(3):265-270
28 Lima JA,Desai MY, Steen H,et al. Statin-induced cholesterol lowering and plaque regression after 6 months of magnetic resonance imaging-monitoredtherapy. Circulation. 2004;110(16):2336-2341
29 Ding C, Fu XH, He ZS, et al. Cardioprotective effects of simvastatin on reversing electrical remodeling induced by myocardial ischemia-reperfusion in normocholesterolemic rabbits.Chin Med J (Engl). 2008;20;121(6):551-556
30 McCullough PA, Rocher LR. Statin therapy in renal disease: harmful or protective. Curr Atheroscler Rep 2007;9:18-24
31 Chyrchel M, Rakowski T, Rzeszutko L, et al. Effects of high-dose administered prior to coronary angioplasty on the incidence of cardiac events in patients with acute coronary syndrome. Kardiol Pol. 2006;64:1357-1362
32 Celik T, Iyisoy A, Yuksel UC, et al. The impact of admission C-reactive protein levels on the development of no-reflow phenomenon after primary PCI in patients with acute myocardial infarction: The role of inflammation. Int J Cardiol. 2009;136(1):86-88
33 Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359:2195-2207
34 Patti G, Chello M, Pasceri V, et al. Protection from procedural myocardial injury by atorvastatin is associated with lower levels of adhesion molecules after percutaneous coronary intervention: results from the ARMYDA-CAMs (Atorvastatin for Reduction of Myocardial Damage during Angioplasty-Cell Adhesion Molecules) substudy. J Am Coll Cardiol. 2006;48:1560-1566
35 Yang YJ, Qian HY, Huang J, et al. Atorvastatin treatment improves survival and effects of implanted mesenchymal stem cells in post-infarct swine hearts. Eur Heart J. 2008; 29:1578-1590
36 Atorvastatin pretreatment improves outcomes in patients with acute coronary syndromes undergoing early percutaneous coronary intervention: results of the ARMYDA-ACS randomized trial. J Am Coll Cardiol 2007; 49:1272-1278
37 Randomized trial of atorvastatin for reduction of myocardial damage during coronary intervention, Results from the ARMYDA (Atorvastatin for2004; 110: 674-678 Reduction of Myocardial Damage during Angioplasty) study. Circulation
1 Irani K. Oxidant signaling in vascular cell growth, death, and survival: a review of the roles of reactive oxygen species in smooth muscle and endothelial cell mitogenic and apoptotic signaling. Circ Res 2000;87:179-183
2 Fenster BE, Tsao S, Rockson SG et al, Endothelial dysfunction: Clinical strategies for treating oxidant stress. Am Heart J,2003;146:216-226
3 WAng HD, Xu S, Johns DG, et al. Role of NADPH oxidase in the vascular hypertrophic and oxidative stress response to Angiotensin II in mice. Circ Res, 2001;88:947-953
4 Azumi H, Inoue N, Takeshita S, et al. Expression of NADH/NADPH oxidase p22phox in human coronary arteries. Circulation, 1999;100:1494-1498
5 Cahilly C, Ballantyne CM, Lim DS et al. A variant of p22(phox) involved in generation of reactive oxygen species in the vessel wall, is associated with progression of coronary atheroscelerosis. Circ Res, 2000;86:391-385
6 Heitzer T, Brockhoff C, Mayer B,et al. Tetrahydrobiopterin improves endothelium-dependent vasodilation in chronic smokers: evidence for a dysfunctional nitric oxide synthase. Curc Res. 2000;86:E36-41
7 Mervaala EM, Cheng ZJ, Tikkanen I, et al. Endothelial dysfunction and xanthine oxidoreductase activity in rats with human renin and Angiotensinogen genes. Hypertension, 2001;37:414-418
8 Brtler R, Morris AD, Belch JJ, et al. Allopurinol mormalizes endothelial dysfunction in type 2 diabetics with mild hypertension. Hypertension, 000;35:746-751
9 Ting HH, Timimi FK, Boles KS, et al. Vitamin C improves endothelium- dependent vasodialtion in patients with non-insulin-dependent diabetes mellitus. J Clin Invest. 1996;97:22-28
10 Motoyama T, Kawano H, Kugiyama K, et al. Vitamin E administration improves impairment of endothelium-dependent vasodilation in patients with coronary spastic Angina. J Am Cardiol,1998;32:1672-1679
11 Elliott TG, Barth JD, Mancini GB. Effect of vitamin E on endothelial function in men after myocardial infarction. Am J Cardiol,1995;76:1188-1190
12 Mancini GB, Henry GC, Macaya C, et al. Angiotensin-converting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction in patients with coronary artery disease: the TREND (Trial on Reversing ENdothelial Dysfunction) Study. Circulation, 1996;94:258-265
13 Anderson TJ, Elstein E, Haber H, et al. Comparative study of ACE-inhibition, Angiotensin II antagonism, and calcium channel blockade on flow-mediated vasodilation in patients with coronary disease (BANFF study). J Am Coll Cardiol.2000;35:60-66
14 Yusuf S, Sleight P, Pogue J, et al. Effects of an Angiotensin- converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients: the Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med, 2000;342:145-153
15 Wilson SH, Simari RD, Best PJ, et al. Simvastatin preserves coronary endothelial function in hypercholesterolemia in the absence of lipid lowering, Arterioscler Thromb Vasc Biol, 2001;21:122-128
16 Wassmann S, Laufs U, Baumer AT, et al. HMG-COA reductase inhibitors improve endothelial dysfunction in normocholesterolemic hypertension viareduced production of reactive oxygen species. Hypertension, 2001;37: 1450-1457
17 Garg R, Kumbkarni Y, Aljado A, et al. Troglitazone reduces reactive oxygen apecise generation by leukocytes and lipid peroxidation and improves folw-mediated vasodilatation in obese subjects. Hypertension, 2000; 36: 430-435
18 Aljada A, Garg R, Ghanim H, et al. Nuclear factor-kappaB suppressive and inhibitor-kappaB stimulatory effects of troglitazone in obese patients with type 2 diabetes: evidence of an anti-inflammatory action? J Clin Endocrinol Metab. 2001;86:3250-3256
19 Mather KJ, Verma S, Anderson TJ, et al. Improved endothelial function with metformin in type 2 diabetes mellitus. J Am Coll Cardiol. 2001;37:1344-50.
20 Kanani PM, Sinkey CA, Browning RL, et al. Role of oxidant stress in endothelial dysfunction produced by experimental hyperhomocyst(e)inemia in humans. Circulation. 1999; 100:1161-1168
21 Raghuveer G, Sinkey CA, Clenard C, et al. Effect of vitamin E on resistance vessel endothelial dysfunction induced by methionine. Am J Cardiol. 2001; 88:285-290
22 Thambyrajah J, Landray MJ, Jones HJ, et al. A randomized double-blind placebo-controlled trial of the effect of homocysteine-lowering therapy with folic acid on endothelial function in patients with coronary artery disease. J Am Coll Cardiol. 2001;37:1858-1863
23 Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA, 1998;280:605-613
24 Brown BG, Zhao XQ, Chait A, et al. Simvastatin and niacin, antioxidant vitamins, for the prevention of coronary disease. N Engl J Med, 2001; 345:1583-1592
1 Niccoli G, Burzotta F, Galiuto L, et al. Myocardial no-reflow in humans. J Am Coll Cardiol,2009,54:281-292
2 Anderson JL, Karagounis LA, Califf RM.Metaanalysis of five reported studies on the relation of early coronary patency grades with mortality and outcomes after acute myocardial infarction. Am J Cardiol. 1996; 78(1):1-8
3 Cura FA, L'Allier PL, Kapadia SR, et al. Predictors and prognosis of suboptimal coronary blood flow after primary coronary angioplasty in patients with acute myocardial infarction. Am J Cardiol. 2001;88(2):124-128
4 Shah A, Wagner GS, Granger CB, et al. Prognostic implications of TIMI flow grade in the infarct related artery compared with continuous 12-lead ST-segment resolution analysis. Reexamining the "gold standard" for myocardial reperfusion assessment. J Am Coll Cardiol. 2000;35(3):666-672
5 Johnson TL, Topol EJ.Early, et al. Complete Infarct Vessel Patency: Arriving at a Gold Standard for Future Clinical Investigation in Myocardial Reperfusion. J Thromb Thrombolysis. 1997;4(2):259-266
6 Ito H, Okamura A, Iwakura K, Masuyama T, et al. Myocardial perfusion patterns related to thrombolysis in myocardial infarction perfusion grades after coronary angioplasty in patients with acute anterior wall myocardial infarction. Circulation. 1996;93(11):1993-1999
7 Ito H, Iwakura K, Oh H, Masuyama T, et al. Temporal changes in myocardial perfusion patterns in patients with reperfused anterior wall myocardial infarction. Their relation to myocardial viability. Circulation. 1995;91(3):656-662
8 Halkin A, Aymong E, Cox DA, et al. Relation between late patency of the infarct-related artery, left ventricular function, and clinical outcomes after primary percutaneous intervention for acute myocardial infarction (CADILLAC trial). Am J Cardiol. 2004;93(3):349-353
9 Ames A 3rd, Wright RL, Kowada M, et al. Cerebral ischemia. II. The no-reflow phenomenon. Am J Pathol. 1968;52(2):437-453
10 Krug A. Alterations in myocardial hydrogen ion concentration after temporary coronary occlusion: a sign of irreversible cell damage. Am J Cardiol. 1975;36(2):214-217
11 Kloner RA, Ganote CE, Jennings RB, et al. The "no-reflow" phenomenon after temporary coronary occlusion in the dog. J Clin Invest. 1974;54(6):1496-1508
12 DeGeare VS, Stone GW, Grines L, et al. Angiographic and clinical characteristics associated with increased in-hospital mortality in elderly patients with acute myocardial infarction undergoing percutaneous intervention (a pooled analysis of the primary angioplasty in myocardial infarction trials). Am J Cardiol. 2000;86(1):30-34
13 Resnic FS, Wainstein M, Lee MK, et al. No-reflow is an independent predictor of death and myocardial infarction after percutaneous coronary intervention. Am Heart J. 2003;145(1):42-46
14 Piana RN, Paik GY, Moscucci M, et al. Incidence and treatment of 'no-reflow' after percutaneous coronary intervention. Circulation. 1994;89(6):2514-2518
15 Abbo KM, Dooris M, Glazier S, et al. Features and outcome of no-reflow after percutaneous coronary intervention. Am J Cardiol. 1995;75(12):778-782
16 Ito H. No-reflow phenomenon in patients with acute myocardial infarction: its pathophysiology and clinical implications. Acta Med Okayama. 2009;63(4):161-168
17 Kloner RA, Ganote CE, Whalen DA Jr, et al. Effect of a transient period of ischemia on myocardial cells. II. Fine structure during the first few minutes of reflow. Am J Pathol. 1974;74(3):399-422
18 Ambrosio G, Tritto I. Reperfusion injury: experimental evidence and clinical implications. Am Heart J. 1999;138(2 Pt 2):S69-S75
19 Byrne JG, Smith WJ, Murphy MP, et al. Complete prevention of myocardial stunning, contracture, low-reflow, and edema after heart transplantation by blocking neutrophil adhesion molecules during reperfusion. J Thorac Cardiovasc Surg. 1992;104(6):1589-1596
20 Willerson JT, Scales F, Mukherjee A, et al. Abnormal myocardial fluid retention as an early manifestation of ischemic injury. Am J Pathol. 1977;87(1):159-188
21 Kunichika H, Ben-Yehuda O, Lafitte S, et al. Effects of glycoprotein IIb/IIIa inhibition on microvascular flow after coronary reperfusion. A quantitative myocardial contrast echocardiography study. J Am Coll Cardiol. 2004;43(2):276-283
22 Punch J, Rees R, Cashmer B, et al. Acute lung injury following reperfusion after ischemia in the hind limbs of rats. J Trauma. 1991;31(6):760-5; discussion 765-767
23 Grech ED, Dodd NJ, Jackson MJ, et al. Evidence for free radical generation after primary percutaneous transluminal coronary angioplasty recanalization in acute myocardial infarction. Am J Cardiol. 1996;77(2):122-127
24 Engler RL. Free radical and granulocyte-mediated injury during myocardial ischemia and reperfusion. Am J Cardiol. 1989;63(10):19E-23E
25 Baran KW, Nguyen M, McKendall GR, et al. Double-blind, randomized trial of an anti-CD18 antibody in conjunction with recombinant tissue plasminogen activator for acute myocardial infarction: limitation of myocardial infarction following thrombolysis in acute myocardial infarction (LIMIT AMI) study. Circulation. 2001;104(23):2778-2783
26 Sdringola S, Assali AR, Ghani M, et al. Risk assessment of slow or no-reflow phenomenon in aortocoronary vein graft percutaneous intervention. Catheter Cardiovasc Interv. 2001;54(3):318-324
27 Kotani J, Nanto S, Mintz GS, et al. Plaque gruel of atheromatous coronary lesion may contribute to the no-reflow phenomenon in patients with acute coronary syndrome. Circulation. 2002;106(13):1672-1677
28 Hamada S, Nishiue T, Nakamura S, et al. TIMI frame count immediately after primary coronary angioplasty as a predictor of functional recovery in patients with TIMI 3 reperfused acute myocardial infarction. J Am Coll Cardiol. 2001;38(3):666-671
29 De Luca G, Ucci G, Cassetti E, et al. Benefits from small molecule administration as compared with abciximab among patients with ST-segment elevation myocardial infarction treated with primary angioplasty: a meta-analysis. J Am Coll Cardiol, 2009,53:1668-1673
30 Van'T H A, Ten B J, Heestermans T, et al. Prehospital initiation of tirofiban in patients with ST-elevation myocardial infarction undergoing primary angioplasty (On-TIME 2): a multicentre, double-blind, randomised controlled trial. Lancet,2008,372(9638):537-546
31 Fu XH, Hao QQ, Jia XW, et al. Effect of tirofiban plus clopidogrel and aspirin on primary percutaneous coronary intervention via transradial approach in patients with acute myocardial infarction. Chin Med J (Engl). 2008;121(6):522-527
32 Sakuma T, Motoda C, Tokuyama T, et al. Exogenous adenosine triphosphate disodium administration during primary percutaneous coronary intervention reduces no-reflow and preserves left ventricular function in patients withacute anterior myocardial infarction: a study using myocardial contrast echocardiography. Int J Cardiol. 2010;140(2):200-209
33 Kopecky SL, Aviles RJ, Bell MR, et al. A randomized, double-blinded, placebo-controlled, dose-ranging study measuring the effect of an adenosine agonist on infarct size reduction in patients undergoing primary percutaneous transluminal coronary angioplasty: the ADMIRE (AmP579 Delivery for Myocardial Infarction REduction) study. Am Heart J. 2003;146(1):146-152
34 Ikeda N, Yasu T, Kubo N, et al. Nicorandil versus isosorbide dinitrate as adjunctive treatment to direct balloon angioplasty in acute myocardial infarction. Heart. 2004;90(2):181-185
35 Minamino T, Jiyoong K, Asakura, et al. Rationale and design of a large-scale trial using nicorandil as an adjunct to percutaneous coronary intervention for ST-segment elevation acute myocardial infarction: Japan-Working groups of acute myocardial infarction for the reduction of Necrotic Damage by a K-ATP channel opener (J-WIND-KATP). Circ J. 2004;68(2):101-106
36 Rupprecht HJ, vom Dahl J, Terres W, et al. Cardioprotective effects of the Na(+)/H(+) exchange inhibitor cariporide in patients with acute anterior myocardial infarction undergoing direct PTCA. Circulation. 2000;101(25):2902-2908
37 Moens AL, Claeys MJ, Timmermans JP, et al. Myocardial ischemia/reperfusion-injury, a clinical view on a complex pathophysiological process. Int J Cardiol. 2005;100(2):179-190
38 Mahaffey KW, Granger CB, Nicolau JC,et al. Effect of pexelizumab, an anti-C5 complement antibody, as adjunctive therapy to fibrinolysis in acute myocardial infarction: the COMPlement inhibition in myocardial infarction treated with thromboLYtics (COMPLY) trial. Circulation. 2003;108(10):1176-1183
39 Granger CB, Mahaffey KW, Weaver WD, et al. Pexelizumab, an anti-C5 complement antibody, as adjunctive therapy to primary percutaneous coronary intervention in acute myocardial infarction: the COMplementinhibition in Myocardial infarction treated with Angioplasty (COMMA) trial. Circulation. 2003;108(10):1184-1190
40 Dangas G, Stone GW, Weinberg MD, et al. Contemporary outcomes of rescue percutaneous coronary intervention for acute myocardial infarction: comparison with primary angioplasty and the role of distal protection devices (EMERALD trial). Am Heart J. 2008;155(6):1090-1096
41 Yip HK, Wu CJ, Chang HW, et al. Effect of the PercuSurge GuardWire device on the integrity of microvasculature and clinical outcomes during primary transradial coronary intervention in acute myocardial infarction. Am J Cardiol. 2003;92(11):1331-1335
1 McCullough PA, Soman SS. Contrast-induced nepropathy. Crit Care Clin, 2005,21(2):261-280
2 Chew DP, Astley C, Molloy D, et al. Morbidity, mortality and ecconomic burden of renal impairment in cardiac intensive care. Intern Med J, 2006,36(3):185-192
3 Bagshaw SM, Mortis G, Doig CJ, et al. One-year mortality in critically ill patients by severity of kidney dysfunction: a population-based assessment. Am J Kidney Dis, 2006,48(3):402- 409
4 Thomsen HS. Guidelines for cintrast media from the European Society of Urogenital Radiology. Am J Roentgenol, 2003,181(6):1463-1471
5 Bartholomew BA, Harjai KJ, Dukkipati S, et al. Impact of nephropathy after percutaneous coronary intervention and a method for risk stratification. Am J Cardiol ,2004,93(12):1515-1519
6 Nash K, Hafeez A, Hou S. Hospital-acquired renal insufficiency. Am J Kidney Dis, 2002,39(5):930-936
7 Rihal CS, Textor SC, Grill DE, et al. Incidence and prognostic importance ofacute renal failure after percutaneous coronary intervention. Circulation, 2002,105(19):2259-2264
8 Nikolsky E, Mchran R, Turcot DB, et al. Impact of chronic kidney disease on prognosis of patients with diadetes mellitus treated with percutaneous coroanry intervention. Am J Cardiol, 2004,94(3):300-305
9 McCullough PA, Adam A, Becker CR, et al. Risk prediction of contrast-induced nephropathy. Am J Cardiol, 2006,98(6A):27k-36k
10 Mchran R, Aymong ED, Nikolsky E, et al. A simple risk score for prediction of contrast-induced nephropathy after percutaneous coronary intervention:development and initial validation. J Am Coll Cardiol, 2004, 44(7):1393-1399
11 Nikolsky E, Mehran R, Lasic Z, et al. Low hematocrit predicts contrast-induced nephropathy after percutaneous coronary interventions. Kidney Int, 2005,67(2):706-713
12 Becker CR, Davidson C, Lameire N, et al. High-risk situations and procedures. Am J Cardiol, 2006,98(6A):37k-41k
13 Bachorzcwska-gajcwska H, Malyszko J, Sitnicwska E, et al. Neutrophil-gelatinase-associated lipocalin and renal function after percutaneous coronary interventions. Am J Nephrol, 2006,26(3):287-292
14 Mishra J, Dent C, Tarabishi R, et al. Neutrophil gelatinase-associated lipocalin(NGAL) as a biomarker for acute renal injury after cardiac surgery. Lancet, 2005,365(9466):1231-1238
15 McCullough. Contrast-induced acute kidney injury. J Am Coll Cardiol, 2008,51(22);1419-1428
16 Nikolsky E, Mchran R, Turcot DB, et al. Impact of chronic kidney disease on prognosis of patients with diabetes mellitus treated with perutaneous coronary intervention. Am J Cardiol, 2004,94(3):300-305
17 Martin JH, Fay MF, Ungerer JP. eGFR-use beyond the evidence. Med J Aust, 2009,190(4):197-199
18 Tippins RB, Torres WE, Baumgartner BR, et al. Are screening serum creatinine levels necessary prior to outpatient CT examination? Radiology,2000,216(2):481-484
19 Lameire N, Adam A, Becker CR, et al. Baseline renal function screening. Am J Cardiol, 2006,98(6A):21k-26k
20 Davidson C, Stacul F, McCullough PA, et al. Contrast medium use. Am J Cardiol, 2006,98(6A):42k-58k
21 McCullough PA, Bertrand ME, Brinker JA, et al. A meta-analysis of the renal safety of isosmolar iodixanol compared with low-osmolar cintrast media. J Am Coll Cardiol, 2006,48(4):692-699
22 Solomon R. The role of osmolality in the incidence of contrast-induced nephropathy: a systematic review of angiographic contrast media in high risk patients. Kidney Int, 2005,68(5):2256-2263
23 Jo SH, Youn TJ, Koo BK, et al. Renal toxicity evaluation and comparison between visipaque(iodixanol) and hexabrix(ioxaglate) in patients with reanl insufficiency undergoing coronary angiopraphy: the RECOVER study: a randomized controlled trial. J Am Coll Cardiol, 2006,48(5):924-930
24 Anderson JL, Adams CD, Antman EM, et al. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-elevation muocardial infarction-exceutive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guideline for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction). J Am Coll Cardiol, 2007;50:652-726
25 Solomn RJ, Natarajan MK, Doucct S, et al. Cardiac Angiography in Renally Impaired Patients(CARE) study: a randomized double-blind trial of contrast-induced nephropathy in patients with chronic kidney disease. Circulation,2007,115(25):3189-3196
26 Laskey WK, Jenkins C, Sclzer F, et al. NHLBI Dynamic Registry Investigators. Volume-to-creatinine clearence ratio: a pharmacokinetically based risk factor for prediction of early creatinine increase after percutaneous coronary intervention. J Am Cardiol, 2007,50(7):584-590
27 Mueller C, Buerkle G, Buettner HJ, et al. Prevention of contrastmedia-associated nephropathy: randomized comparison of 2 hydration regimens in 1620 patients undergoing coronary angioplasty. Arch Intern Med, 2002,162(3):329-336
28 Marenzi G, Lauri G, Campodonico J, et al. Comparison of two hemofiltration protocols for prevention of contrast-induced nephropathy in high risk patients. Am J Med, 2006,119(2):155-162
29 Stacul F, Adam A, Becker CR, et al. Strategies to reduce the risk of contrast-induced nephropathy. Am J Cardiol, 2006,98(6A):59k-77k
30 Spargias K, Alcxopoulos E, Kyrzopoulos S, et al. Ascorbic acid prevents contrast-mediated nephropathy in patients with renal dysfunction undergoing coronary angiography or intervention. Circulation, 2004,110(18):2837-2842
31 Marenzi G, Assanelli E, Marana I, et al. N-acetylcystiene and contrast-induced nephropathy in primary angioplasty. N Engl J Med, 2006,354(26):2773-2782
32 Briguori C, Airoldi F, D’Andrea D, et al. Renal insufficiency folllowing contrast media administration trial (REMEDIAL): a randomized comparison of 3 preventive strategics. Circulation, 2007,115(10):1211-1217
33 Khanal S, Attallah N, Smith DE, et al. Statin therapy reduces contrast-induced mephropathy: an analysis of contemporary percutaneous interventions. Am J Med, 2005,118(8):843-849
34 McCullough PA, Rocher LR. Statin therapy in renal disease: harmful or protective. Curr Atheroscler Rep, 2007,9(1):18-24
1 Agarwal R. Effects of statins on renal function. Am J Cardiol. 2006;97(5):748-755
2 Sandhu S, Wiebe N, Fried LF, et al. Statins for improving renal outcomes: a meta-analysis. J Am Soc Nephrol. 2006;17(7):2006-2016
3 Kshirsagar AV, Shoham DA, Bang H, et al. The effect of cholesterol reduction with cholestyramine on renal function. Am J Kidney Dis. 2005;46(5):812-819
4 Kostapanos MS, Milionis HJ, Elisaf MS. An overview oth the extra-lipid effects of rosuvastatin. J Cardiovasc Pharmacol Ther. 2008;13(3):157-174
5 Usui H, Shikata K, Matsuda M, et al. HMG-CoA reductase inhibitor ameliorates diabetic nephropathy by its pleiotropic effects in rats. Nephrol Dial Transplant. 2003; 18(2):265-272
6 Sharyo S, Yokota-Ikeda N, Mori M, et al. Pravastatin improves renal ischemia-reperfusion injury by inhibiting the mevalonate pathway. Kidney Int. 2008;74(5): 577-584
7 Li H, Li X, Lin D, et al. Inhibition of lovastatin on proliferation and expression of proinflammatory cytokines in cultured human glomerular mesangial cells. Chin Med J. 2003;116(9):1366-1369
8 Matsumoto M, Tanimoto M, Gohda T, et al. Effect of pitavastatin on type 2 diabetes mellitus nephropathy in KK-Ay/Ta mice. Metabolism. 2008;57(5):691-697
9 Fujii M, Inoguchi T, Maeda Y, et al. Pitavastatin ameliorates albuminuria and renal mesangial expansion by downregulating NOX4 in db/db mice. KidneyInt. 2007;72(4):473-480
10 Yagi S, Aihara K, Ikeda Y, et al. Pitavastatin, an HMG-CoA reductase inhibitor, exerts eNOS-independent protective actions against angiotensin II induced cardiovascular remodeling and renal insufficiency. Circ Res. 2008;102(1):68-76
11 Sonmez A, Yilmaz MI, Korkmaz A, et al. Hyperbaric oxygen treatment augments the efficacy of cilazapril and simvastatin regimens in an experimental nephrotic syndrome model. Clin Exp Nephrol. 2008; 12(2):110-118
12 Liang XM, Otani H, Zhou Q, et al. Renal protective effects of pitavastatin on spontaneously hypercholesterolaemic Imai Rats. Nephrol Dial Transplant. 2007;22(8):2156-2164
13 Whaley-Connell AT, Morris EM, Rehmer N, et al. Albumin activation of NAD(P)H oxidase activity is mediated via Rac1 in proximal tubule cells. Am J Nephrol. 2007;27(1):15-23
14 Whaley-Connell A, Habibi J, Nistala R, et al. Attenuation of NADPH oxidase activation and glomerular filtration barrier remodeling with statin treatment. Hypertension. 2008;51(2):474-480
15 Yu HY, Inoguchi T, Nakayama M, et al. Statin attenuates high glucose-induced and angiotensin II-induced MAP kinase activity through inhibition of NAD(P)H oxidase activity in cultured mesangial cells. Med Chem. 2005;1(5):461-466
16 Ott C, Schlaich MP, Schmidt BM, et al. Rosuvastatin improves basal nitric oxide activity of the renal vasculature in patients with hypercholesterolemia. Atherosclerosis. 2008;196(2):704-711
17 Yu YH, Wang Y, Dong B, et al. Fluvastatin prevents renal injury and expression of lactin-like oxidized low-density lipoprotein receptor-1 in rabbits with hypercholesterolemia. Chin Med J. 2005;118(8):621-626
18 Zhou MS, Schuman IH, Jaimes EA, et al. Renoprotection by statins is linked to a decrease in renal oxidative stress, TGF-beta, and fibronectin with concomitant increase in nitric oxide bioavailability. Am J Physiol RenalPhysiol. 2008;295(1):F53-F59
19 Kuwahara N, Sasaki S, Kobara M, et al. HMG-CoA reductase inhibition improves anti-aging klotho protein expression and arteriosclerosis in rats with chronic inhibition of nitric oxide synthesis. Int J Cardiol. 2008;123(2):84-90
20 Joyce M, Kelly C, Winter D, et al. Pravastatin, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, attenuates renal injury in an experimental model of ischemia-reperfusion. J Surg Res. 2001;101(1):79-84
21 Pisani A, Uccello F, Cesaro A, et al. Effects of atorvastatin on ischemic acute renal failure in aging rats. G Ital Nefrol. 2002; 19(5):534-539
22 Schwartz IF, Ayalon R, Chernichovski T, et al. Arginine uptake is attenuated through modulation of cationic amino-acid transporter-1, in uremic rats. Kidney Int. 2006;69(2):298-303
23 Chade AR, Zhu XY, Grande JP, et al. Simvastatin abates development of renal fibrosis in experimental renovascular disease. J Hypertens. 2008; 26(8):1651-1660
24 Vieira JM Jr, Rodrigues LT, Mantovani E, et al. Statin monotherapy attenuates renal injury in a salt-sensitive hypertension model of renal disease. Nephron Physiol. 2005;101(4):82-91
25 Yamashita T, Kawashima S, Miwa Y, et al. A 3-hydroxy-3-methylglutaryl co-enzyme A reductase inhibitor reduces hypertensive nephrosclerosis in stroke-prone spontaneously hypertensive rats. J Hypertens. 2002; 20 (12):2465-2473
26 Gianella A, Nobili E, Abbate M, et al. Rosuvastatin treatment prevents progressive kidney inflammation and fibrosis in stroke-prone rats. Am J Pathol. 2007;170(4):1165-1177
27 Kramer S, Kron S, Wang-Rosenke Y, et al. Rosuvastatin is additive to high-dose candesartan in slowing progression of experimental mesangioproliferative glomerulosclerosis. Am J Physiol Renal Physiol. 2008;294(4):F801-F811
28 Ikeuchi H, Kuroiwa T, Yamashita S, et al. Fluvastatin reduces renal fibroblast proliferation and production of type III collagen: therapeutic implications fortubulointerstitial fibrosis. Nephron Exp Nephrol. 2004;97(4):e115-122
29 Heusinger-Ribeiro J, Fischer B, Goppelt-Struebe M. Differential effects of simvastatin on mesangial cells. Kidney Int. 2004;66(1):187-195
30 Xu H, Zeng L, Peng H, et al. HMG-CoA reductase inhibitor simvastatin mitigates VEGF-induced‘‘inside-out’’signaling to extracellular matrix by preventing RhoA activation. Am J Physiol Renal Physiol. 2006; 291 (5):F995-1004
31 Danesh FR, Sadeghi MM, Amro N, et al. 3-Hydroxy-3-methylglutaryl CoA reductase inhibitors prevent high glucose-induced proliferation of mesangial cells via modulation of Rho GTissue plasminogen activator se/ p21 signaling pathway: implications for diabetic nephropathy. Proc Natl Acad Sci USA. 2002;99(12):8301-8305
32 Athyros VG, Mikholidis DP, Papageorgiou A, et al. The effect of statins versus untreated dyslipidemia on renal function in patients with coronary heart disease. A subgroup analysis of the Greek atorvastatin and coronary heart disease evaluation (GRACE) study. J Clin Pathol, 2004;57(7):728-734
33 Patti G, Nusea A, Chello M, et al. Usefulness of statin pretreatment to prevent contrast-induced mephropathy and to improve long-term outcome in patients undergoing percutaneous coronary intervention. Am J Cardiol, 2008; 101(3):279-285
34 Shepherd J, Kastelein JJP, Bitmer V, et al. Intensive lipid lowering with atorvastatin in patients with coronary heart disease and chronic kidney disease, the TNT (Treating to New Target) study. J Am Coll Cardiol. 2008; 51(15):1448-1454
35 Xinwei J, Xianghua F, Jing Z, et al. Comparison of usefulness of simvastatin
20 mg versus 80 mg in preventing contrast-induced nephropathy in patients with acute coronary coronary syndrome undergoing percutaneous coronary intervention. Am J Cardiol.2009;104(4):519-524